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Abstract 
The general objective of this project was to respond to a pressing need in clinical practice, 
which is the diagnosis of tubular dysfunction. This knowledge would not only allow the 
prediction of the early onset and progression of tubular dysfunction, but also the 
management of strategies to stop the progression of renal disease, which at present are 
non-existent. On the other hand, it would be of significant importance in the development 
of strategies to minimize tubular toxicity induced by drugs and substances used in 
diagnostic methods that pose a major challenge in clinical practice. It would also have 
added value in the preclinical tests in drug development. 
 
There is a good correlation between the degree of damage to the tubulo-interstitial 
compartment and the deterioration of renal function. Moreover, the primary role of kidney 
as a detoxification organ renders it vulnerable to develop various forms of injury. 
Motivated by the relevant detoxification activity and its main expression in kidney 
proximal tubular cells, the mercapturate pathway was chosen as a starting point of this 
mechanistic-based investigation for a reliable biomarker reflective of tubular dysfunction. 
We were particularly interested in N-acetyltransferase 8 (NAT8), the last enzyme of the 
mercapturate pathway, that acetylates cysteine-S-conjugates (Cys-S-conjugates), 
rendering their urinary elimination. Cys-S-conjugates can be more toxic than the parent 
compounds. The formation of Cys-S-conjugates have been reported in inflammatory 
diseases and a hypothesis-based review of their contribution and the contribution of 
NAT8 as a balancer of their availability was built up exemplified by a tubular view of 
diabetic nephropathy.  
 
As the kidney is highly susceptible to oxidative conditions and is exposed to relatively 
high concentrations of cysteine (Cys), which becomes easily oxidized, promoting the 
accumulation of its disulfides (in both the free and protein forms), we though that the 
measurement of Cys-S-conjugates which are disulfides could be a starting point for the 
identification of new markers of tubular dysfunction. 
 
With the general goal of non-invasively evaluate kidney tubular dysfunction, it was first 
needed to develop a method that allowed to phenotype patients as higher or lower Cys-S-
conjugates detoxifiers inspired on the activity of NAT8, which has been recognized as a 
nephroprotective factor mainly expressed in proximal tubular cells. This method 
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quantifies the mercapturates of Cys-S-conjugates that are disulfides (CysSSX). We 
measured the N-acetylcysteine moiety of these mercapturates, that we named uNAC, as 
a surrogate of detoxification of CysSSX. In Chapter I, the rationale for the mercapturates 
of CysSSX as indicators of tubular dysfunction and for method development and 
validation is presented. The developed method was validated and applied to urine from 
individuals with healthy kidney and kidney disease as well as to urine from mice and rats. 
We have shown that CysSSX are acetylated and eliminated in urine as mercapturates. 
Rats and mice showed higher levels of uNAC than man. No intra-individual variability 
was found for uNAC levels in urine samples from rats and mice. In addition, lower levels 
of uNAC were found in urine of four patients that progressed to chronic kidney disease 
(CKD) after an episode of acute kidney injury (AKI) in comparison with volunteers. 
 
In order to evaluate the potential of uNAC as an early indicator of AKI, we measured 
uNAC concentrations in two animal models of drug-induced AKI (Chapter II). Cisplatin 
(CISP) was chosen because is a tubular toxicant that undergoes the mercapturate pathway 
and gentamicin (G) also promotes tubular dysfunction, but it does not undergo this 
metabolic circuitry. For this, male Wistar rats were allocated in individual metabolic 
cages and randomly divided into three groups: (1) control group (CTL), receiving daily 
vehicle intraperitoneal for 6 days; (2) cisplatin group (CISP), receiving a single 
intraperitoneal dose of cisplatin (5 mg/kg); and (3) gentamicin group (G), receiving 
gentamicin intraperitoneal (150 mg/kg) for 6 days. The levels of uNAC decreased prior 
to the increase in pCr, particularly in CISP model (p < 0.001). This tendency was also 
observed for rats treated with G, despite only reaching significance belatedly than CISP 
(p = 0.044).  
 
Next, we were interested to know the inter-individual variability of uNAC in man and 
factors that could influence it. For that, uNAC was measured in a population of human-
immunodeficiency virus (HIV)-infected patients as a proof-of-principle (Chapter III). 
The levels of uNAC varied highly (59%) among 242 HIV-infected patients. A 
multivariable analysis showed that the levels of uNAC were positively associated with 
estimated glomerular filtration rate (eGFR) (p = 0.020) and negatively associated with 
lamivudine use (3TC) (p = 0.019) and Black race (p < 0.001). Notably, a prospective 
analysis of uNAC in 118 HIV-infected patients allowed to discriminate patients on kidney 
disease progression from those that maintained a stable renal function, that might imply 
changes in cysteine disulfides availability and dynamics in kidney disease progression. 
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Thus, the next step was to evaluate the temporal changes of cysteine disulfides dynamics 
and uNAC in models of chronic diseases that affect the kidney, aiming to evaluate if they 
are prior to kidney dysfunction and also its relation to disease development (e.g. 
hypertension, insulin resistance). For that, we selected animal models associated with 
metabolic inflammation, namely two pre-diabetic mice models induced by high fructose 
(HFruct) or hypercaloric (HFat) diet for 15 weeks (Chapter IV); and a rat model of 
hypertension and insulin resistance induced by chronic intermittent hypoxia (CIH) to a 
maximum of 60 days (Chapter V). In the three models the disease progression and 
severity diseases are mild, being appropriated to study temporal changes of kidney tubular 
dysfunction and its relation to the development of hypertension and insulin resistance. 
HFat animals presented lower uNAC right after 1 week of exposure to the diet while the 
HFruct group presented a mild increase. Nevertheless, the increment on the chronicity of 
exposure to the diets decreased uNAC until the end of the study, that was particularly 
evident for HFat model (45% lower than Chow group, p = 0.005). Moreover, Cys 
availability and protein cysteinylation (CysSSP) increased in HFruct (p = 0.046, p = 0.045 
and p = 0.017, respectively for total, free total and CysSSP); while HFat diet induced an 
overall decrease (p = 0.028, p = 0.065 and p = 0.049, respectively for total, free total and 
CysSSP fractions). Although no clear renal pathology was observed in both pre-diabetic 
groups at the end of the study, changes in urinary albumin-to-creatinine ratio (uACR) 
were earlier and more evident in the HFat, comparing with the HFruct group. HFat mice 
also presented higher renal expression of NAT8 (p = 0.001), fibrotic markers and 
enzymes of glucose and lipid metabolism. Both diets induced increases in the renal 
expression of inflammatory, epithelial to mesenchymal transition and endoplasmic 
reticulum stress markers.  
 
In the first day of exposure to CIH, there was an acute increase of almost 100% in uNAC 
in comparison with normoxic (Nx) animals. Afterwards, its levels decreased overtime, 
reaching a difference of -80% in CIH versus Nx group (p < 0.001). Kidney NAT8 gene 
expression initially decreased at days 1 (p = 0.006 for renal cortex – RC; p = 0.041 for 
renal medulla – RM) and 7 (p = 0.021 for RC and p = 0.024 for RM) of CIH exposure, 
further increasing at 21 days when hypertension is established but prior to the 
establishment of insulin resistance, and decreased at 60 days (p = 0.037 for RC and p = 
0.024 for RM), coincident with the previously reported increase in renal fibronectin 
expression. At 7 days of CIH exposure, an increase in renal total Cys (p = 0.003 for RC 
and p = 0.001 for RM) and CysSSP (p = 0.041 for RC and p = 0.028 for RM) was 
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observed, further decreasing with the chronicity of exposure to CIH (p < 0.001). An 
increase was also observed in the ratio of free Cys by CysSSX at day 7 (p = 0.008 for RC 
and p = 0.017 for RM), indicative of a more reduced state of Cys, decreasing from day 
14 to 21 (p < 0.001) and returning to values closer to control conditions by the end of the 
experiment. Nevertheless, at the end of the study, no histological alterations were 
observed neither changes in uACR, despite there was a tendency to increase in CIH 
animals.  
 
Herein, we provided evidence in order to respond to a lack of tubular dysfunction 
markers, a necessity that is mostly driven due to the need to better understand the 
pathophysiological mechanisms underlying it. Secondly, a method was developed to 
evaluate tubular dysfunction in a non-invasive manner. Lastly and although still very 
preliminary, new knowledge was herein provided based on a hypothesis that, as far as the 
author knowledge, is an innovative and never addressed issue that could pave the way for 
the identification of new mechanisms of inflammatory diseases through a tubulocentric 
perspective. 
 
The preliminary data herein reported supports uNAC as an indicator of tubular 
dysfunction progression. Our approach shows that Cys-S-conjugate’s dynamics changes 
throughout disease progression. The results support that this dynamic might be associated 
not only to adaptive mechanism, with increases in CysSSP and uNAC, but also to 
mechanisms of disease progression with the chronicity of injury, characterized by 
opposite changes on this dynamic. The translation of these results together with the 
deepening of this study might lead to the identification of new therapeutic targets to slow 
down or stop disease progression and to establish preventive strategies achieved through 
early diagnosis. Furthermore, the identification of a new marker could also help to 
evaluate the success of preventive/management strategies. 
 
Keywords: acute kidney injury; biomarkers; chronic kidney injury; cysteine-disulfides; 
inflammation; mercapturates of cysteine-disulfides; N-acetyltransferase 8; 
nephrotoxicity; oxidation; tubular dysfunction.
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Resumo 
 
O objetivo geral deste projeto visou dar resposta a uma necessidade premente na prática 
clínica, que é o diagnóstico da disfunção tubular. Este conhecimento não só permitirá o 
diagnóstico precoce desta disfunção, como também o desenvolvimento de estratégicas 
terapêuticas que permitiam travar a progressão da doença renal, que neste momento são 
inexistentes. Por outro lado, teria uma importância significativa no desenvolvimento de 
estratégias para minimizar a toxicidade tubular induzida por fármacos e por substâncias 
utilizadas nos métodos de diagnóstico, que representam um desafio major na prática 
clínica. Por último, este conhecimento teria também valor acrescentado nos testes pré-
clínicos do desenvolvimento de novos fármacos. 
 
Existe uma forte correlação entre o grau de dano no compartimento túbulo-intersticial e 
o decréscimo da função renal. Além disso, o papel principal do rim como órgão de 
destoxificação torna-o vulnerável ao desenvolvimento de várias formas de lesão. 
Motivados pela actividade destoxificante relevante e pela sua principal expressão nas 
células tubulares proximais, a via dos mercapturatos foi escolhida como ponto de partida 
para esta investigação baseada no mecanismo para a identificação de um biomarcador 
fidedigno que reflita a disfunção tubular. O nosso interesse recaiu particularmente sobre 
a N-acetiltransferase 8 (NAT8), a última enzima da via do mercapturatos, que acetila os 
S-conjugados da cisteína (Cis-S-conjugados), possibilitando a sua eliminação urinária. Os 
Cis-S-conjugados podem ser mais tóxicos do que os seus compostos de origem. A 
formação dos Cis-S-conjugados já foi reportada em doenças inflamatórias e o nosso grupo 
escreveu uma revisão baseada numa hipótese da sua contribuição e da contribuição da 
NAT8 como um balanceador da sua disponibilidade, exemplificada por uma visão 
tubulocêntrica da nefropatia diabética. 
 
Tendo em conta que o rim é altamente suscetível à oxidação e é exposto a concentrações 
relativamente altas de cisteína (Cis), que se torna facilmente oxidada promovendo a 
acumulação dos seus dissulfetos (nas suas formas livre e ligada a proteínas), 
considerámos que a quantificação dos dissulfetos poderia ser um ponto de partida para a 
identificação de novos marcadores de disfunção tubular. 
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Numa primeira etapa, foi desenvolvido um método não invasivo que permitiu fenotipar 
os doentes como menores ou maiores destoxificadores de Cis-S-conjugados, tendo por 
base a atividade da NAT8, que foi reconhecida como um fator nefroprotetor, expressa 
principalmente nas células tubulares proximais. Este método quantifica os mercapturatos 
dos Cis-S-conjugados que são dissulfetos (CisSSX). A fração de N-acetilcisteína destes 
mercapturatos foi quantificada, que denominamos de uNAC, como um equivalente da 
destoxificação dos CisSSX. No Capítulo I, é apresentado a justificação para os 
mercapturatos de CisSSX serem considerados indicadores de disfunção tubular e para o 
desenvolvimento e validação do método. O método desenvolvido foi validado e aplicado 
em urinas de indivíduos com rim saudável e com doença renal, bem como em urinas de 
murganhos e ratos. Neste capítulo foi demonstrado que os CisSSX são acetilados e 
eliminados na urina como mercapturatos. Tanto os ratos como os murganhos 
apresentaram níveis mais elevados de uNAC do que o homem. Não foi observada 
qualquer variabilidade intra-individual para os níveis de uNAC nas amostras de urina de 
ratos e murganhos. Além disso, foram observados níveis mais baixos de uNAC na urina 
de quatro doentes que progrediram para doença renal crónica (DRC) após um episódio de 
lesão renal aguda (LRA), em comparação com voluntários. 
 
Com o intuito de avaliar o potencial do uNAC como indicador precoce de LRA, as 
concentrações de uNAC foram avaliadas em dois modelos animais de LRA induzida por 
fármacos (Capítulo II). A cisplatina (CISP) foi escolhida porque é uma toxina tubular 
que é metabolizada pela via dos mercapturatos. No caso da gentamicina (G), este fármaco 
também promove disfunção tubular, mas não é substrato da via dos mercapturatos. Para 
isso, ratos Wistar machos foram colocados em gaiolas metabólicas individuais e divididos 
aleatoriamente em três grupos: (1) grupo controlo (CTL), expostos ao veículo diariamente 
via intraperitoneal durante 6 dias; (2) grupo CISP, expostos a uma única dose (via 
intraperitoneal) de CISP (5 mg/kg); e (3) grupo G, expostos diariamente a uma dose de G 
(150 mg/kg) por via intraperitoneal durante 6 dias. Os níveis de uNAC diminuíram antes 
do aumento da pCr, particularmente no modelo da CISP (p < 0.001). Esta tendência 
também foi observada em ratos tratados com G, apesar de só atingir significância mais 
tardiamente que a CISP (p = 0.044).  
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De seguida, considerámos interessante avaliar a variabilidade inter-individual do uNAC 
e os fatores que poderiam influenciar os seus níveis. Para isso, os níveis de uNAC foram 
medidos numa população de doentes infetados pelo vírus da imunodeficiência humana 
(VIH) como prova de conceito (Capítulo III). Os níveis de uNAC variaram muito (59%) 
entre 242 doentes infetados pelo VIH. Através de uma análise multivariada foi 
demonstrado que os níveis de uNAC estavam associados positivamente com a taxa de 
filtração glomerular estimada (TFGe) (p = 0.020) e negativamente associada ao uso de 
lamivudina (3TC) (p = 0.019) e à raça negra (p < 0.001). Além disto, a análise prospetiva 
do uNAC em 118 doentes infetados pelo HIV permitiu discriminar doentes com 
progressão da doença renal daqueles que mantiveram uma função renal estável, o que 
pode implicar alterações na disponibilidade e dinâmica dos dissulfetos de cisteína na 
progressão da doença renal. 
 
De seguida, fomos avaliar as alterações temporais da dinâmica dos dissulfetos de cisteína 
e do uNAC em modelos de doenças crónicas que afectam o rim, com o objectivo de 
avaliar se estas alterações precedem a disfunção renal e a sua relação com o 
desenvolvimento da doença (ex: hipertensão e resistência à insulina). Assim, foram 
selecionamos modelos animais associados à inflamação metabólica, dois modelos de 
murganho com pré-diabetes induzida por dieta rica em frutose (HFruct) e por dieta 
hipercalórica (HFat) durante 15 semanas (Capítulo IV); e um modelo de hipertensão e 
resistência à insulina induzido por hipoxia crónica intermitente (HCI) até um máximo de 
60 dias (Capítulo V). Nos três modelos, a progressão e severidade da doença são 
moderadas, o que é apropriado para estudar alterações temporais da disfunção tubular 
renal e a sua relação com o desenvolvimento de hipertensão e resistência à insulina. Os 
animais HFat apresentaram menor eliminação de uNAC imediatamente após 1 semana de 
exposição à dieta, enquanto que o grupo HFruct apresentou um ligeiro aumento. No 
entanto, a cronicidade da exposição às dietas diminuiu os níveis de uNAC até ao final do 
estudo, que foi particularmente evidente para o modelo HFat (45% menor que o grupo 
controlo – Chow; p = 0.005). Além disso, as frações de Cis aumentaram no grupo HFruct 
(p = 0.046, p = 0.045 e p = 0.017, respetivamente para as formas total, livre total e ligada 
a proteínas da Cis), enquanto que a dieta HFat provocou uma diminuição geral (p = 0.028, 
p = 0.065 e p = 0.049, respetivamente, para as formas total, livre total e ligada a proteínas 
da Cis). Embora não tenha sido observada uma patologia renal clara nos grupos pré-
diabéticos, alterações na relação albumina/creatinina na urina (uACR) foram observadas 
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mais cedo e mais evidentes no grupo HFat em comparação com o grupo HFruct. O grupo 
HFat também apresentou maior expressão renal de NAT8 (p = 0.001), de marcadores 
fibróticos e de enzimas do metabolismo da glucose e de lípidos. Ambas as dietas 
induziram aumentos na expressão renal de marcadores de inflamação, de transição 
epitelial para mesenquimal e de stress do retículo endoplasmático. 
 
No primeiro dia de exposição à HCI, houve um aumento agudo de quase 100% de uNAC 
em comparação com animais normóxicos (Nx). Posteriormente, os níveis de uNAC 
diminuíram ao longo do tempo, atingindo uma diferença de -80% no grupo HCI versus 
Nx (p < 0.001). A expressão renal da NAT8 diminuiu inicialmente nos dias 1 (p = 0.006 
para o córtex renal – CR; p = 0.041 para a medula renal – MR) e 7 (p = 0.021 para o CR 
e p = 0.024 para a MR) de exposição à HCI, aumentando aos 21 dias, quando a 
hipertensão foi estabelecida, mas antes do estabelecimento da resistência à insulina. Os 
níveis de uNAC voltaram a diminuir aos 60 dias (p = 0.037 para o CR e p = 0.024 para a 
MR), coincidente com o aumento mencionado anteriormente da expressão de fibronectina 
renal. Aos 7 dias de exposição à HCI, observou-se no rim um aumento da Cis total (p = 
0.003 para o CR e p = 0.001 para a MR) e CisSSP (p = 0.041 para o CR e p = 0.028 para 
a MR), diminuindo ainda mais com a cronicidade da exposição à HCI (p < 0.001). Foi 
também observado um aumento do rácio de Cis livre/CisSSX no dia 7 (p = 0.008 para o 
CR e p = 0.017 para a MR), indicativo de um estado mais reduzido da Cis, diminuindo 
do dia 14 para 21 (p < 0.001) e regressando a valores mais próximos das condições de 
controlo no final do ensaio. No entanto, no fim do estudo não foram observadas alterações 
histológicas nem alterações nos níveis de uACR, apesar de haver uma tendência de 
aumento nos animais exposto à HIC. 
 
Este trabalho forneceu provas para responder à falta de marcadores de disfunção tubular, 
uma necessidade que deriva maioritariamente ao facto de ser importante compreender 
melhor os mecanismos patofisológicos inerentes a esta condição. Em segundo lugar, foi 
desenvolvido um método para avaliar a disfunção tubular de forma não invasiva. Por fim, 
e apesar de serem ainda dados preliminares, este trabalho gerou conhecimentos novos 
baseados numa hipótese que, tanto quanto sabemos, é um assunto inovador e que nunca 
antes foi abordado, e que pode guiar na identificação de novos mecanismos de doenças 
inflamatórias através de uma perspetiva tubulocêntrica. 
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Os dados preliminares aqui reportados suportam o uNAC como um indicador de 
progressão de disfunção tubular. A nossa abordagem mostra que a dinâmica dos Cis-S-
conjugados está alterada ao longo da progressão da doença. Os resultados sugerem que 
esta dinâmica pode estar associada não só a mecanismos de adaptação, com aumentos na 
CisSSP e uNAC, mas também a mecanismos de progressão de doença que a cronicidade 
da lesão, caracterizado por alterações opostas nesta dinâmica. A translação destes 
resultados juntamente com o aprofundamento deste estudo pode levar à identificação de 
novos alvos terapêuticos para desacelerar ou parar a progressão da doença e para 
estabelecer estratégicas preventivas alcançadas pelo diagnóstico precoce. Além disso, a 
identificação de um novo marcador pode também ajudar a avaliar o sucesso das 
estratégias de prevenção e gestão. 
 
Palavras-chave: biomarcadores; lesão renal aguda; lesão renal crónica; disfunção 
tubular; dissulfetos de cisteína; inflamação; mercapturatos de dissulfetos de cisteína; N-
acetiltransferase 8; nefrotoxicidade; oxidação. 
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INTRODUCTION 
1. Kidney disease as one of the most important diseases of our time 
It is estimated that 5-10 million people die annually from kidney disease which should be 
considered, right next to cancer, diabetes, cardiovascular disease and chronic respiratory 
disease, as one of the most important disease of our time (Luyckx, Tonelli and Stanifer, 
2018). Acute insults to the kidney are common in hospital settings, usually developed 
from hemorrhage, sepsis, drug toxicity and use of a contrast agent (Feehally, 2016; Ozkok 
and Ozkok, 2017). On the other hand, chronic injury associated with diabetes, aging or 
hypertension, all growing concerns in the modern society, promotes progression to 
fibrosis (James, Hemmelgarn and Tonelli, 2010; Ortiz et al., 2014). Other factors 
influencing this kind of injury include infectious diseases (e.g. human immunodeficiency 
virus (HIV)-infection), environmental pollution, exposure to pesticides, analgesic abuse, 
herbal medications, use of unregulated food additives and also genetic factors (Jha et al., 
2013). 
The handicap for the prevention and management of kidney disease is the limited ability 
of the current markers of kidney function for an early diagnosis of injury progression. 
The identification of a non-invasive marker reflecting the underlying pathophysiologic 
mechanism of kidney disease will not only improve the current knowledge of kidney 
disease, but also assist on the identification of new therapeutic targets to treat and prevent 
the progression of kidney disease. A major concern in this context is the lack of markers 
of proximal tubular cell function and of drugs that are able to stop renal dysfunction. 
Kidney injury can trigger both adaptive and maladaptive responses, with the early 
adaptive response often becoming maladaptive over time, leading to a progressive decline 
in the anatomic and functional integrity of the kidney (Bonventre, 2015). 
The kidney is a highly differentiated organ, with nearly 30 different cell types that 
modulate complex physiologic processes, including endocrine function, blood pressure 
regulation, intra-glomerular hemodynamics, solute and water transport, acid-base balance 
and metabolic waste excretion (George and Neilson, 2015). The functional unit of the 
kidney is the nephron that is composed by: a) a glomerulus (that is encased by the 
Bowman’s capsule) that is able to filter the blood; b) a tubule (divided into proximal 
tubule, loop of Henle and distal tubule) that, through sequential events of reabsorption 
and secretion, progressively forms urine and c) a collecting duct that carries the urine into 
a collecting system that will ultimately lead to the elimination of urine (Reilly, Bulger 
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and Kriz, 2007; Li and Wingert, 2013; George and Neilson, 2015). The kidney has an 
outer zone, commonly known as the cortex region, and an inner zone that is divided 
between the medullary and papillary regions (Figure 1). The majority of nephrons are 
found throughout the cortex, with glomeruli and proximal tubule located in the mid-to-
outer cortex, while their tubule loops and the collecting duct system inhabit 
predominantly the inner zones of the medulla and the papilla (Li and Wingert, 2013; 
George and Neilson, 2015) (Figure 1). 
In humans, nephrogenesis (i.e., the formation of nephrons) is ceased at 36 weeks of 
gestation, with an average value of 1 million nephrons formed in each healthy kidney 
(Bertram et al., 2011). This fact has tremendous consequences, as renal disease is 
associated with a reduction on the functional nephrons (Bonventre, 2015).  
 
Figure 1 – Schematic representation of the kidney sections with details on the components of the nephron and 
their locations. The kidney is divided into cortex (outer zone), medulla and papilla (both comprising the renal inner 
zone) sections. As the functional unit of the kidney, the nephron is divided into glomerulus and a tubular and duct 
region. While both glomeruli and proximal tubule are majorly found in the cortical section, the tubule loops and the 
collecting duct are predominantly found in medullary and papillary zones. Adapted from Li and Wingert, 2013.  
ATL: ascending thin limb; CNT: connecting tubule; DCT: distal convoluted tubule; DTL: descending thin limb; G: glomerulus; LH: 
loop of Henle; MD: macula densa; PCT: proximal convoluted tubule; PST: proximal straight tubule; S1: segment 1; S2: segment 2; 
S3: segment 3; TAL: thick ascending limb. 
 
Kidney disease can either be classified into acute kidney injury (AKI) or chronic kidney 
disease (CKD). While AKI involves a rapid loss of kidney function from sudden injury 
(e.g. ischemia, toxin, sepsis) (Venkatachalam et al., 2010; Bonventre and Yang, 2011), 
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CKD is understood as a temporal progressive loss of kidney function triggered by fibrosis 
and erosion of normal tissue (El Nahas and Bello, 2005). In fact, CKD is currently viewed 
as an increasing public health concern, contributing to the rising worldwide non-
communicable disease burden (Jha et al., 2013). Furthermore, CKD could culminate with 
organ failure, known as end-stage renal disease (ESRD or stage 5 CKD) (El Nahas and 
Bello, 2005; Schedl, 2007; Venkatachalam et al., 2010; Bonventre and Yang, 2011; 
Bonventre, 2015). The progression to ESRD is a considerable socioeconomic burden, not 
only to the patients and their families but also to the healthcare system (Weiner, 2009). 
These consequences arise from the need for renal replacement therapy with dialysis and 
transplantation, with the concomitant intensive long-term care (Li and Wingert, 2013). 
The incidence of AKI has increased in the last two decades in parallel with an increase in 
ESRD (Leung, Tonelli and James, 2013), which in turn, has exceeded that expected upon 
prediction from CKD prevalence (Hsu et al., 2004). As a consequence, the current 
knowledge is now formulating the hypothesis that not only cumulative episodes of AKI 
lead to CKD but also that preexisting CKD increases the risk of AKI (Hsu et al., 2008; 
Leung, Tonelli and James, 2013). 
 
1.1. Acute kidney injury (AKI) 
AKI is a common complication among hospitalized patients. While the incidence of AKI 
in general ward has been reported to be 4.3% from community-acquired (due to volume 
depletion, adverse effects of medications and obstruction of the urinary tract) and 2.1% 
from hospital-acquired AKI (induced by sepsis, major surgical procedures, critical illness 
involving heart or liver failure and administration of intravenous iodinated contrast and 
nephrotoxic medication), this number rises to 58% in the setting of intensive care units 
(Wonnacott et al., 2014; Hoste et al., 2015; Waikar and Bonventre, 2015; Kashani et al., 
2017). Episodes of severe AKI often requires dialysis with a concomitant increase in the 
risk of development of ESRD. Clinical diagnosis of AKI encompasses an increase in 
serum creatinine (sCr) (increase of 0.3 mg/dL within 48 h or 1.5 times higher than 
baseline within 1 week), commonly associated with decreased urine volume (less than 
0.5 mL/kg/h for 6 h) (KDIGO AKI Work Group, 2012; Waikar and Bonventre, 2015). 
Hence, AKI staging is defined by sCr and urine output (KDIGO AKI Work Group, 2012). 
AKI episodes can be derived from prerenal azotemia (associated with hypovolemia, 
decreased cardiac output and medications that interfere with renal autoregulatory 
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responses such as nonsteroidal anti-inflammatory drugs and inhibitors of angiotensin II), 
intrinsic renal parenchymal disease (induced by sepsis, ischemia and nephrotoxins of both 
endogenous and exogenous sources) and postrenal obstruction (triggered by bladder 
outlet obstruction, bilateral pelvoureteral obstruction or unilateral obstruction in case of 
a solitary functioning kidney) (KDIGO AKI Work Group, 2012; Waikar and Bonventre, 
2015). 
Importantly, drug-induced AKI is a serious matter frequently faced by clinicians 
(Perazella, 2009) and is reported in about 8 to 60% if hospital-acquired AKI (Schetz et 
al., 2005). Nephrotoxic agents have the potential to promote injury in all kidney 
compartments, an effect that occurs due to the combination of patient’s risk factors and 
the innate toxicity of this compounds. Therefore, drug-induced AKI will be the 
consequence of patient-specific, kidney-related and drug-associated factors, which 
combination can determine AKI, several tubulopathies, glomerular disease and CKD 
(Perazella and Luciano, 2015). Hence, recognizing these factors should be the first step 
to reduce nephrotoxicity. The nephrotoxic potential of several different therapeutic agents 
have been documented, including antimicrobial agents, chemotherapeutics, analgesics, 
among others (Perazella, 2005). 
For instance, antibiotics such as gentamicin (G) (Kacew and Bergeron, 1990; Quiros et 
al., 2010; Ferreira et al., 2011; López-Novoa et al., 2011) and the anticancer drug 
cisplatin (CISP) (Sánchez-González et al., 2011; Sancho-Martínez et al., 2012, 2018) are 
common causes of tubular toxicity. Researchers have developed different animal models 
of AKI not only to understand the pathophysiology of the onset of AKI but also to explore 
the drug-induced toxicity. 
Still, there is an inability for approaching drug-induced kidney injury during 
pharmacological development; different urinary proteins have been proposed as kidney 
safety biomarkers but only in nonclinical studies (McDuffie, 2018). Moreover, as early 
assessment of drug-induced kidney injury by biomarker level changes is not yet available, 
histopathology changes currently remains the gold-standard for diagnosing kidney 
damage (Makris and Spanou, 2016). Emerging biomarkers should be combined with 
traditional markers and histopathology to enable early detection of damage in animal 
models. 
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1.2. Chronic kidney disease (CKD) 
CKD affects about 10-15% of the worldwide population (Levin et al., 2017) and is 
currently defined as abnormalities of kidney structure or function, present for more than 
3 months, with implications for health (KDIGO CKD Work Group, 2013). Its 
classification is based on cause, estimated glomerular filtration rate (eGFR) (eGFR < 60 
mL/min/1.73m2) and albuminuria (albumin excretion ratio  > 30 mg for 24 h urine 
collection or albumin-to-creatinine ratio – ACR > 30 mg/g of creatinine for spot first 
morning urine) categories (KDIGO CKD Work Group, 2013).  
Factors that increase the risk of CKD include small gestation birth weight, childhood 
obesity, hypertension, diabetes mellitus, autoimmune disease, advanced age, African 
ancestry, family history of kidney disease, previous episode of AKI as well as the 
presence of proteinuria, abnormal urinary sediment or structural abnormalities of the 
urinary tract (Bargman and Skorecki, 2015). Nevertheless, the five most frequent causes 
of CKD are diabetic nephropathy, glomerulonephritis, hypertension-associated CKD 
(includes vascular and ischemic kidney disease and primary glomerular disease with 
associated hypertension), autosomal dominant polycystic kidney disease and other cystic 
and tubulointerstitial nephropathies (Bargman and Skorecki, 2015). 
Stages of CKD are stratified as a way of predicting the risk of progression of CKD 
(Figure 2). While stages 1 and 2 are not usually associated with any symptoms (KDIGO 
CKD Work Group, 2013), the decline on glomerular filtration rate (GFR) progresses to 
stages 3 and 4 is linked with a more prominent clinical and laboratory complications of 
CKD. Among them, the most evident are anemia and its associated easy fatigability, 
decreased appetite leading to malnutrition, abnormalities in calcium, phosphorus, 
mineral-regulating hormones (calcitriol, parathyroid hormone and fibroblast growth 
factor 23) and sodium, potassium, water and acid-base homeostasis (KDIGO CKD Work 
Group, 2013; Bargman and Skorecki, 2015). Nevertheless, kidney failure is traditionally 
considered as the most serious outcome of CKD (KDIGO CKD Work Group, 2013). 
The pathophysiology of CKD has been linked with two distinct mechanisms of damage, 
the initial ones, which are specific to the underlying etiology (e.g. genetically determined 
abnormalities in kidney development or integrity, immune complex deposition and 
inflammation in certain types of glomerulonephritis, or toxin exposure in certain diseases 
of the renal tubules and interstitium) and the ones associated to progression, involving 
hyperfiltration and hypertrophy of viable nephrons, that are a common consequence of 
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the long-term reduction of renal mass, irrespective of its etiology (Bargman and Skorecki, 
2015).  
 
 
Figure 2 – Stages of CKD by Kidney Disease Improving Global Outcome (KDIGO). Staging of CKD is currently 
based on assessing both eGFR and 24h-albuminuria (24h urine collection) or ACR (spot first morning urine) (KDIGO 
CKD Work Group, 2013).  
ACR: albumin-to-creatinine ratio; eGFR: estimated glomerular filtration rate 
 
2. Current limitations on the detection and management of kidney 
disease 
One of the major limitations on the detection and management of kidney disease is the 
unavailability of valid markers of tubular dysfunction, which limits the development of 
new drugs able to stop or revert disease progression. Given the complexity of disease 
processes and the multiple factors that affect progression over time, there is a great need 
to understand the pathophysiological mechanisms underlying the usual development of 
renal disease. As so, for the detection and management of kidney disease progression 
there is a need for non-invasive indicators that reflect the pathophysiologic mechanisms. 
The identification of biomarkers with this profile will not only improve the current 
knowledge of the complex condition that kidney disease is, but also increase the ability 
to predict and modulate response to therapy. 
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Traditionally, the assessment of kidney function is performed through eGFR based on 
demographic factors and sCr (Levey et al., 2009) and, in a more unconventional way, 
using serum cystatin c (sCys C) alone or in combination with sCr (Inker et al., 2012). The 
renal handling of creatinine (Cr) involves glomerular filtration and tubular secretion 
(Gutiérrez et al., 2014). This last process becomes a serious issue since, as kidney 
function declines, tubular secretion of Cr increases in a proportional way to the decrease 
in its glomerular filtration, resulting in a significant overestimation of true GFR (Ferguson 
and Waikar, 2012). Moreover, as the end product of creatine, the majority of Cr is 
generated from muscle, meaning that Cr concentration is highly dependent on muscle 
mass (Perrone, Madias and Levey, 1992). Also, Cr production in patients with liver 
disease is decreased (Cocchetto, Tschanz and Bjornsson, 1983). As so, the use of sCr to 
asses kidney function in conditions associated with decreased lean body mass and an 
increased prevalence of liver disease should be performed with caution. Also, there is 
hard evidence showing that the progression of kidney disease can begin before the 
significant rise of sCr levels (Ferguson and Waikar, 2012). For instance, it has been shown 
that a rise in the levels of sCr does not occur until nearly 50% of nephrons are 
nonfunctional (Waikar, Betensky and Bonventre, 2009). 
In contrast to Cr, all nucleated cells produce cystatin c (Cys C), which is freely filtered in 
the glomerulus and catabolized by tubular cells (Tenstad et al., 1996). Cys C is not only 
affected by lean mass (Macdonald et al., 2006) but also by the inflammatory marker C-
reactive protein (Knight et al., 2004). 
The above-mentioned disadvantages of sCr and sCys C limits their use and have been 
boosting the investigation of newly accurate and precise markers of kidney dysfunction.  
For instance, kidney injury molecule-l (KIM-1), an immunoglobulin superfamily cell-
surface protein, is only upregulated on the surface of injured kidney epithelial cells 
(Ichimura et al., 1998). In this scenario, the protein functions as a phosphatidylserine 
receptor, promoting the phagocytosis of apoptotic bodies and necrotic debris, hence 
transforming these cells into semiprofessional phagocytes (Ichimura et al., 2008). As so, 
a role for KIM-1 in renal recovery and tubular regeneration has been proposed. Events of 
ischemia-reperfusion upregulates KIM-1, specifically present in proliferating 
dedifferentiated epithelial cells of the proximal tubule 48 hours after injury (Ichimura et 
al., 1998). Additionally, an increase in urinary KIM-1 was also observed after renal injury 
induce by ischemia (Han et al., 2002) and also by nephrotoxins including S-(1,1,2,2-
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tetrafluoroethyl)-L-cysteine, folic acid, and CISP (Ichimura et al., 2004). This increase 
seems to be related with the shedding of the extracellular component of KIM-1 
(immunoglobulin and muccin domains) (Bailly et al., 2002). 
Another novel biomarker is neutrophil gelatinase associated lipocalin (NGAL), that can 
be considered as both an indicator of AKI and also a therapeutic agent that protects the 
kidney from ischemia. NGAL is a bacteriostatic agent with the ability to sequestrate iron-
siderophores, preventing their uptake by bacterial pathogens (Flo et al., 2004). The 
formation of this complex between NGAL and iron-siderophores has also been proposed 
to convert renal progenitors into epithelial tubules, hence inducing tubulogenesis in the 
metanephric mass (Yang et al., 2002). Although with constitutive expression in 
neutrophils, inflammation triggers epithelial cells to express NGAL (Nielsen et al., 1996; 
Cowland et al., 2003). In fact, NGAL is highly upregulated at the transcript and proteins 
levels after ischemic or nephrotoxic kidney injury (Mishra et al., 2003; Mishra, Mori, Ma, 
Kelly, Barasch, et al., 2004). In urine, elevated NGAL is detectable as early as 3 hours 
after injury in animal models of renal ischemia-reperfusion (Mishra et al., 2003). 
Nevertheless, in the setting of cardiopulmonary bypass-associated AKI, it only took 2 
hours to observe the increase in both plasma and urine NGAL (Mishra et al., 2005). The 
potential use of NGAL as a therapeutic agent is link with its canonical function previously 
mentioned. Administration of iron-siderophore-loaded NGAL was shown to protect the 
kidney before, during or even after ischemia-reperfusion injury (Mishra, Mori, Ma, Kelly, 
Yang, et al., 2004; Mori et al., 2005). 
The proinflammatory interleukin 18 (IL-18) is also on the role for a biomarker of AKI, 
as its renal levels increase in response to different injury stimulus including ischemia-
reperfusion (Melnikov et al., 2001) as well as administration of glycerol (Homsi, Janino 
and De Faria, 2006) and CISP (Faubel et al., 2007). 
In the clinical setting, several biomarkers were studied for the early detection of AKI, 
before the falling of GFR (Vaidya et al., 2008; Soto and Devarajan, 2016). Recently, 
urinary KIM-1, Cys C and NGAL were shown to predict the nephrotoxicity of platin-
based drugs earlier than sCr (Abdelsalam et al., 2018; George, Joy and Aleksunes, 2018). 
Furthermore, KIM-1 and NGAL are good markers of acute and chronic tubular injury 
associated with aminoglycosides exposure (McWilliam et al., 2018). 
There are many more putative biomarkers of kidney dysfunction that have been described, 
and several literature reviews have been recently published in general (Kotani, Kimura 
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and Gugliucci, 2011; Alge and Arthur, 2015; Klein et al., 2016; Tan, Yap and Qian, 2016; 
Rysz et al., 2017), hence confirming the pertinence of this issue. Nevertheless, there are 
still gaps in the current knowledge of kidney disease. The translation of the results 
obtained in animal models to clinical studies is not always linear and from the wide list 
of new discovered biomarkers that are reported on a regular basis, very few of them reach 
the clinical setting (Yerramilli et al., 2016). 
In fact, we have evaluated the performance of several biomarkers that were described in 
literature (Campos, Ortiz and Soto, 2016), including klotho and paraoxonase-1, for an 
HIV-infected population and no direct associations were obtained with kidney 
dysfunction in those patients (Dias, Casimiro, et al., 2015; Dias, Maia, et al., 2015; 
Campos et al., 2016).  
In this context, it is important to have into account the value of the proximal tubule as 
relevant player in kidney injury. In fact, evidence has been recently given that the 
proximal tubule is the primary sensor and effector in the progression of CKD as well as 
AKI (Chevalier, 2016). This specific region of the nephron is packed with mitochondria 
and highly dependent on oxidative phosphorylation (Simmons, Bogusky and Humes, 
1980; Basile, Anderson and Sutton, 2012; Chevalier, 2016), which in turn makes the 
proximal tubule particularly vulnerable to oxidative injury. Specifically, recurrent tubular 
injury leads to a pattern of CKD in humans that is associated with tubular atrophy, 
interstitial chronic inflammation and fibrosis, vascular rarefaction and glomerulosclerosis 
(Bonventre, 2015). These facts suggest that looking into specific metabolic pathways of 
the proximal tubular cells could be a strategy for the prevention and management of 
kidney disease.  
Having this into account and together with the unsuccessful outcomes on the study of 
literature markers, we moved on to investigate a new marker. We developed a concept 
supported by the team experience in mechanisms of drug toxicity related to drug 
metabolism and we got into a predominant detoxification pathway of proximal tubular 
cells that was supported by association studies (Juhanson et al., 2008; Chambers et al., 
2010; Köttgen et al., 2010; Tin et al., 2013), the mercapturate pathway. 
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3. The mercapturate pathway is a hallmark of proximal tubular cell 
function 
The mercapturate pathway has been associated to kidney function and is mainly expressed 
in renal proximal tubular cells (Chambers et al., 2010; Datta et al., 2010; De Carvalho et 
al., 2011), predominantly in cortical regions (Chambers et al., 2010). The mercapturate 
pathway has been described as a metabolic detoxification circuitry for electrophilic 
species generated under inflammatory and oxidative conditions (Habig, Pabst and Jakoby, 
1974) (Figure 3).  
 
 
 
Figure 3 – The mercapturate pathway in proximal tubular cells. Upon conjugation of the electrophile with GSH 
(A), the conjugate is excreted from cells for further degradation (B). Extracellularly, glutathione-S-conjugates are 
catabolized in cysteine-glycine-S-conjugates by GGT and cysteine-S-conjugates by cysteinyl-glycine dipeptidase or 
aminopeptidase-M (C). These final conjugates are able to enter the proximal tubular cell (D) and suffer acetylation by 
NAT8 (E), being eliminated in urine. Alternatively, cysteine-S-conjugates might also undergo β-elimination through 
β-lyase activity, forming reactive intermediates with nephrotoxic features (F). Adapted from (Ramsay and Dilda, 2014). 
gGT: gamma-glutamyltransferase; CG-X: cysteine-glycine-S-conjugate; C-X: cysteine-S-conjugate; Glu: glutamate; Gly: glycine; 
GSH: glutathione; GST: glutathione-S-transferase; GS-X: glutathione-S-conjugate; MRP: multi-drug resistance association protein; 
NAC-X: mercapturate; NAT8: N-acetyltransferase 8; Pept: cysteinyl-glycine dipeptidase or aminopeptidase-M; -S-X: highly reactive 
intermediate; X – electrophile. 
 
The enzymes of the mercapturate pathway have endogenous functions in the kidney and 
may have evolved to detoxify endogenous reactive toxic intermediates rather than only 
xenobiotics (Bernstrom and Hammarstrom, 1986; Huber et al., 1990; Deol, 2015). 
Endogenous compounds undergoing the mercapturate pathway include cysteinyl-
leukotrienes (CysLTs) (Veiga-da-Cunha et al., 2010), glucose (Szwergold, 2006), 
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catecholamines (Magnay et al., 2001) and lipid peroxidation products (Ntimbane et al., 
2008; Feroe, Attanasio and Scinicariello, 2016), whereas paracetamol (Jian et al., 2009) 
and CISP (Townsend et al., 2003) are examples of xenobiotics. 
Any cell under inflammatory or oxidative conditions can produce glutathione (GSH) 
conjugates upon the intracellular conjugation of GSH with an electrophile, generating 
covalent glutathione-S-conjugates (GSH-S-conjugates), usually mediated by glutathione-
S-transferase (GST) (Ballatori et al., 2009) (Figure 3-A), which can be of both 
endogenous (e.g. disulfides: glutathione-disulfide GSSX) (Wang and Ballatori, 1998) and 
exogenous (e.g. CISP: glutathione-cisplatin conjugate GSH-CISP) (Townsend et al., 
2003) sources. However, as cells are not able to catabolize these conjugates, they are 
excreted and degraded by peripheral tissues that express gamma-glutamyltransferase 
(GGT) in the extracellular border of cell membrane (Figure 3-B). This is the first enzyme 
of the mercapturate pathway. Extracellularly, GSH-S-conjugates are catabolized in 
cysteine-glycine-S-conjugates (CysGly-S-conjugates) by GGT and cysteine-S-conjugates 
(Cys-S-conjugates) by cysteinyl-glycine dipeptidase or aminopeptidase-M, all enzymes 
that are expressed at the brush border of tubular cells (Hughey et al., 1978; Griffith, 1981; 
Hanigan, 1998) (Figure 3-C). Afterwards, Cys-S-conjugates, which can be either 
cysteine-disulfides (CysSSX, eg. cysteine-homocysteine disulfide, CysSSHCys) or not 
(e.g. cysteine-cisplatin conjugate, Cys-CISP), enter the tubular cell via various 
transporters including organic anion transport polypeptides and cystine/cysteine 
importers (Commandeur, Stijntjes and Vermeulen, 1995; Hinchman, Rebbeor and 
Ballatori, 1998; Garnier et al., 2014) (Figure 3-D). At this stage and under normal 
conditions, only CysSSX would be reduced, yielding free cysteine (Cys), which becomes 
available to perform its several physiological actions (Bannai and Tateishi, 1986). On the 
other hand, other Cys-S-conjugates including Cys-CISP are detoxified through the 
acetylation by the activity of the enzyme N-acetyltransferase 8 (NAT8) (Figure 3-E), 
forming a mercapturate generally more polar and more water soluble than the parental 
compound, that can be eliminated in urine (majorly) or bile (minor) (Ballatori et al., 2009; 
Veiga-da-Cunha et al., 2010). The later might undergo enterohepatic circulation by the 
effect of intestinal microflora (Guhlmann, Hagmann and Keppler, 1987).  
The acetylation of Cys-S-conjugates by NAT8 is the final step of the mercapturate 
pathway. Although the remaining enzymes are also expressed in liver small intestine, 
lung, brain, spleen and pancreas, enabling the formation of Cys-S-conjugates outside the 
kidney (Commandeur, Stijntjes and Vermeulen, 1995), the expression of NAT8 is almost 
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and exclusively limited to the proximal tubular cells  (Chambers et al., 2010; Veiga-da-
Cunha et al., 2010). Also, the pathway might currently have an underestimated 
importance, as shown by the recent reported nephroprotective effects of NAT8 (Juhanson 
et al., 2008; Chambers et al., 2010; Köttgen et al., 2010; Tin et al., 2013). 
The precursors of Cys-S-conjugates have a rapid extracellular metabolism through this 
pathway, resulting in shorter half-lives than their Cys-S-conjugates, which are more stable 
and readily detected in biologic fluids (Kanaoka and Boyce, 2014). Also, mercapturates 
of Cys-S-conjugates are very well known in pharmacology/toxicology field since their 
biomonitoring in urine have for long been used as biomarkers of exposure to xeno-
electrophiles (Mathias and Bhymer, 2016). 
The mercapturate pathway has also been studied as a way for target delivering prodrugs 
to drug-resistant tumors of kidney (Ramsay and Dilda, 2014). Specifically, both GST and 
GGT are highly expressed in cancer cells and represents an important factor in the 
appearance of a more aggressive and resistant phenotype. Targeting tumors with GST or 
GGT-activated drugs has been proven to be a successful strategy in driving the activation 
of cytotoxic compounds within the tumors (Sequist et al., 2009; Vergote et al., 2010; 
Horsley et al., 2013).  
Cys-S-conjugates in the proximal tubular cell might also undergo β-elimination through 
β-lyase activity, forming reactive intermediates that have been strongly related to kidney 
injury (Möller-Hartmann and Siegers, 1991; Townsend et al., 2003; Cooper and Pinto, 
2006; Lash, 2007; Cooper, Pinto, et al., 2008; Cooper, Younis, et al., 2008; Cooper et al., 
2011) (Figure 3-F). β-lyases catalyze the cleavage of Cys-S-conjugates into a potentially 
toxic thiol (sulfur)-containing fragment and dehydroalanine, which very rapidly 
hydrolyzes to ammonia and pyruvate (Commandeur, Stijntjes and Vermeulen, 1995). In 
rat, β-lyase is present mainly in cytosol and, to a lesser extent, in mitochondria. 
Differently, in man, a considerable β-lyase activity was found in microsomes. Studies 
performed in rat have shown that this activity is absent in the glomeruli and distal tubule. 
Regarding distribution in the proximal tubule, there are conflicting data on the segments 
involved (Jones et al., 1988; MacFarlane et al., 1989). The involvement of β-lyase-
mediated bioactivation of Cys-S-conjugates in nephrotoxicity has been demonstrated for 
several toxicants (Commandeur, Stijntjes and Vermeulen, 1995; Cristofori, Sauer and 
Trevisan, 2015).  
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In accordance, a nephroprotective role has been attributed to the tubular enzyme NAT8 
that promotes the urinary elimination of these compounds (Veiga-da-Cunha et al., 2010), 
counteracting β-lyase activity, avoiding their reabsorption into the bloodstream and 
promotion of systemic metabolic-inflammation. Evidence supporting that NAT8 is 
nephroprotective came majorly from association studies (Juhanson et al., 2008; Chambers 
et al., 2010; Köttgen et al., 2010; Tin et al., 2013). The study of Juhanson and colleagues 
(2008) (Juhanson et al., 2008) included 137 controls and 157 hypertensive patients with 
and without nephropathy and identified single nucleotide polymorphisms (SNPs) in the 
promoter region of NAT8 associated with systolic blood pressure and renal function 
(eGFR). In particular, minor alleles of NAT8 (of the same SNP) were found to be related 
with lower blood pressure and higher eGFR. The authors hypothesized that this effect 
was explained by the reduced susceptibility of the minor alleles to transcriptional 
suppression, hence guarantying availability of NAT8. In 2010, Chambers and co-authors 
(Chambers et al., 2010) reported an association between common genetic variations in 
NAT8 gene and Cr, Cys C, eGFR and CKD in a population of 16,626 Europeans. On the 
same year, the CKDGen consortium performed a meta-analysis of genome-wide 
association data in 67,093 Caucasian individuals and found that NAT8 was a 
susceptibility locus for reduced renal function, estimated by eGFR obtained separately 
with both Cr and Cys C and also CKD (Köttgen et al., 2010). Moreover, NAT8 was the 
only kidney locus identified that was associated with eGFR in all three different genome-
wide scans performed in 9049 European Americans (Tin et al., 2013). 
More recently, the role of NAT8 has been investigated in regenerative processes of the 
kidney tubular cell (Omata et al., 2016). Omata and co-authors (2016) found a reduction 
of NAT8 transcript levels upon exposure to transforming growth factor-1 (TGF-β1), using 
an in vitro model of dedifferentiation/re-epithelization of human proximal tubular cells. 
This cytokine promoted cell dedifferentiation, an event initiator of repair process in early 
stages of renal injury. TGF-β1 withdrawing after dedifferentiation did not prevented re-
epithelization in NAT8 knock-down cells. The authors suggested that the recovery 
process may be independent of the activity of NAT8. In addition, the difficulty in 
developing NAT8 knockout rats (Fu et al., 2014) and absence of tools to 
pharmacologically address NAT8 hinders to get hard evidence on the nephroprotective 
role of this enzyme. Nevertheless, the effect of probenecid, an inhibitor of the peritubular 
transport of organic anions, was described to impact NAT8 activity. The enzymatic activity 
of partially purified NAT8 from pig kidney cortex-derived microsomes decreased 40% and 
61% in the presence of 2 or 5 mM probenecid, respectively (Aigner et al., 1996). As so, this 
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drug, in addition to the inhibitor effect on mercapturic acid transport, might also inhibit the 
acetylation of Cys-S-conjugates. Nevertheless, this study is limited by the purification 
technique used which led to a 45% loss of enzymatic activity. Recently, we have 
investigated the effects of mesenchymal stromal cell conditioned medium (MSC-CM) on 
tubular epithelial cells exposed to TGF-β1 (dedifferentiation) and after TGF-β1 
withdrawal (re-epithelization) (Grácio, 2017; Grácio et al., 2018). We have observed that 
prolonged injury was associated with a decrease in NAT8 expression. The re-
epithelization was biphasic with a decrease of NAT8 followed by a late rescue. When 
MSC-CM was used in the absence of a harmful stimulus, it promoted re-epithelization, 
which was not related with increase in NAT8 expression. Contrastingly, MSC-CM 
addition was associated with marked recovery of NAT8 transcription under continued 
TGF-β1 exposure. To the best of our knowledge, this is the first report of the paracrine 
effects of human mesenchymal stromal cells (MSCs) on NAT8 in the kidney and the 
relevance of NAT8 to maintain regenerative potential when tubular epithelial cells 
undergo dedifferentiation (Grácio, 2017; Grácio et al., 2018). 
The above-mentioned facts support that the mercapturate pathways is a hallmark of 
proximal tubular cell function and that NAT8 activity is nephroprotective plausibly by 
avoiding systemic accumulation of Cys-S-conjugates.  
  
4. Cysteine-S-conjugates are features of inflammatory conditions 
Cys-S-conjugates have primarily vascular and hemodynamic properties (Lewis and 
Austen, 1984), being potent vasoconstrictors (Rosenthal and Pace-Asciak, 1983; Badr, 
Brenner and Ichikawa, 1987; Shastri et al., 2001) with ability to enhance the permeability 
of the postcapillary venules (Leng et al., 1988). Therefore, the elimination of these 
conjugates could have nephroprotective consequences. It has been shown that Cys-S-
conjugates are involved in glucose-stimulated insulin secretion (Guo et al., 2018), and 
have pro-inflammatory (Magnay et al., 2001), cytotoxic (Townsend et al., 2003; Stern, 
Bruno, Hennig, et al., 2005; Stern, Bruno, Horton, et al., 2005; Dvash et al., 2015) and 
immunogenic (Salauze et al., 2005) properties, all processes potentially involved in the 
development of kidney dysfunction. 
These Cys-S-conjugates seem to have significantly higher half-life than the precursors 
and are the plausible ones responsible for the biological effects (Szwergold, 2006; 
Kanaoka and Boyce, 2014). The effects of Cys-S-conjugates have been underestimated, 
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probably because the mercapturate pathway has been classically considered a 
detoxification route for xenobiotics. Although, it is known that, for instance, Cys-CISP is 
more toxic to tubular cells than CISP (Townsend et al., 2003). Another example, the Cys-
S-conjugate of paracetamol is related to its nephrotoxicity, but not to its hepatotoxicity 
(Stern, Bruno, Hennig, et al., 2005). On the other hand, treatment of cystinuria patients 
with tiopronin leads to the formation of a soluble mixed disulfide between the drug and 
Cys and was shown to reduce both the urinary excretion of cystine (the oxidized form of 
Cys, cystine, CysSSCys) and the formation of renal cystine stones due to the low 
solubility of Cys, common features of this condition (Lindell, Denneberg and Jeppsson, 
1995). 
Cys-S-conjugates can be categorized according with the formation of a sulfur-carbon (S-
C) or a disulfide (S-S) bond between the sulfhydryl group (SH) of Cys and the compound 
that is being conjugated, into thioethers (CysSCX) (Figure 4A) or CysSSX (Figure 4B), 
respectively. For simplification purposes, the thioethers will from now on be called Cys-
S-conjugates. 
 
 
Figure 4 – Cysteine-S-conjugates categorized in thioethers and cysteine disulfides. According with the type of 
bond formed between the sulfhydryl of Cys and the compound that is being conjugated, cysteine-S-conjugates can 
either be thioethers (with a sulfur-carbon bond) (A) or cysteine disulfides (with a disulfide bond) (B).  
2OH-E1-4-Cys: cysteine conjugate of 2-hydroxyestrone; CysSCX: thioether cysteine-S-conjugates; CysSSCoA: cysteine-coenzyme 
A disulfide; CysSSCys: cystine; CysSSHCys: cysteine-homocysteine disulfide; CysSSX: cysteine-disulfides; DA-5-Cys: cysteine-
dopamine conjugate; LTE: leukotriene E4.  
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4.1. Thioether cysteine-S-conjugates: relevance for kidney disease and 
other inflammatory conditions 
The formation of CysLTs is the best described example among endogenous thioether 
compounds generated through the mercapturate pathway (Wang and Ballatori, 1998; 
Veiga-da-Cunha et al., 2010). CysLTs are products of arachidonic acid metabolism and 
key mediators of inflammatory conditions (Funk, 2001; Haeggström and Funk, 2011; Di 
Gennaro and Haeggström, 2012), responsible for enhancing the conversion of arachidonic 
acid into the short-lived leukotriene A4 (LTA4) (Samuelsson et al., 1987). LTA4 is 
further conjugated with GSH to yield a GSH-S-conjugate (leukotriene C4, LTC4) that is 
expelled from cells. Extracellular LTC4 undergo a two-step catabolic process originating 
respectively the CysGly-S-conjugate (leukotriene D4, LTD4) and Cys-S-conjugate 
(leukotriene E4, LTE4) through the mercapturate pathway (Haeggström and Funk, 2011; 
Di Gennaro and Haeggström, 2012). These compounds are generally termed CysLTs, 
although these denominations fully suits only for LTE4, which has the longer half-life 
(Kanaoka and Boyce, 2014).  
The synthesis and release of CysLTs by the kidney have been described (Petric, 
Nicholson and Ford-Hutchinson, 1995; Dvash et al., 2015). The role of leukotrienes in 
kidney diseases was recently reviewed (Rubinstein and Dvash, 2018) and was 
demonstrated that they are able to reduce renal blood flow and GFR by triggering 
vasoconstriction. On the other hand, they can promote immune and non-immune-
mediated kidney damage and oxidative intracellular stress (Dvash et al., 2015). The 
selective inhibition of CysLTs is being investigated in several models of kidney disease 
(Rubinstein and Dvash, 2018), but their nephroprotection ability in man is still unknown. 
Under inflammatory conditions, the temporal changes in urinary CysLTs elimination 
were paralleled with their biosynthesis enzyme activity in renal cortical microsomes 
(Petric and Ford-Hutchinson, 1994). Urinary CysLTs levels increased in initial stages and 
decreased along kidney disease progression, supporting an early role for CysLTs in the 
development of subsequent functional changes (Petric and Ford-Hutchinson, 1994). 
CysLTs were also reported to promote angiotensin II release, increase mean arterial 
pressure, decrease cardiac output, renal blood flow and eGFR (Badr et al., 1984; Assem 
and Abdullah, 1987). Additionally, several studies showed the association of CysLTs 
biosynthesis with drug-induced nephrotoxicity (Rubinstein and Dvash, 2018). In an in 
vitro approach, aristolochic acid I-induced tubular injury was associated with CysLTs 
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release, via extracellular-signal-regulated kinase (ERK) pathway activation (Yang et al., 
2011). Additionally, diabetic kidney disease (DKD) was associated with lower urinary 
LTE4 concentrations (Rafnsson and Bäck, 2013). A multivariate analysis revealed that 
only eGFR was an independent predictor of urinary LTE4 concentrations. Currently there 
is no evidence to support if this implicates a role for circulating LTE4 in its own urinary 
excretion, a decrease in its renal formation or an increase in its elimination as a 
mercapturate (N-acetyl-LTE4) rather than in the LTE4 form.  
Even though, several aspects on CysLTs are missing such as their synthesis and 
mechanism of action in immune and non-immune-mediated kidney damage. Also, the 
receptor responsible for LTE4 effects is still to be clarified (Thompson-Souza, Gropillo 
and Neves, 2017), although evidence from one study has suggested GPR99 as a new 
receptor sensitive to LTE4 (Kanaoka, Maekawa and Austen, 2013). Moreover, the 
methodology employed for the quantification of the mercapturate pathway-derived S-
conjugates should allow the discrimination between GSH-S-conjugates, Cys-S-
conjugates and mercapturates in serum and urine and their association with kidney disease 
progression.  
Changes in the levels of several thioether endogenous Cys-S-conjugates have been 
reported in other inflammatory conditions rather than kidney disease. Table 1 
summarizes the clinical studies that evaluated the levels of specific Cys-S-conjugates, 
their associations with disease and factors that influenced them. In this literature review, 
we also included the results obtained for the GSH-S- and N-acetylcysteine- (NAC)-Cys-
S-conjugates, due to their upstream and downstream connection with Cys-S-conjugates 
in the mercapturate pathway.  
For instance, increases in LDT4 and LTE4 were observed in exhaled breath condensate 
of patients with pneumoconiosis derived from asbestos and silica exposure (Pelclova et 
al., 2012). Higher levels of CysLTs in exhaled breath condensate were detected in patients 
with more severe radiological sign of asbestosis in comparison with mild asbestosis. 
Interestingly, urine LTD4 and LTE4 correlated positively with kidney failure in silicosis 
patients (Pelclova et al., 2012). The value of quantification of CysLTs in saliva as an 
alternative diagnostic strategy in aspirin-intolerant asthma has been previously described 
(Ono et al., 2011). Although CysLTs increased in this fluid in comparison with aspirin-
tolerant asthma and healthy subjects, only the increase in urinary LTE4 in these patients 
was associated with severe aspirin-intolerant asthma (Ono et al., 2011). The role of 
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CysLTs has also been investigated in autistic children, together with 8-isoprostane 
(Qasem, Al-Ayadhi and El-Ansary, 2016), a sensitive indicator of bioactive products of 
lipid peroxidation and oxidative stress (Janicka et al., 2010). The authors proposed of 
both CysLTs and 8-isoprostane as markers of early recognition of autistic patients through 
sensory deficits phenotypes, suggesting that the quantification of this markers might 
facilitate early intervention (Qasem, Al-Ayadhi and El-Ansary, 2016). On another issue, 
the release of CysLTs in urine was assessed in patients suffering from spontaneous 
intracerebral hemorrhage, and correlated positively with hematoma volume (Winking et 
al., 1998). The effect of hematoma removal in the release of CysLTs was also assessed 
by diving the patients in two different groups of treatment, one with surgery and the other 
with conservative treatment. Differences in urinary CysLTs were only found for the 
surgically treated patients, who presented lower levels 5 days after surgery in comparison 
with the concentration detected prior to the surgery (Winking et al., 1998). An increase 
in both urine and plasma CysLTs during cardiac surgery with cardiopulmonary bypass 
was observed, and was greater in patients with moderate-to-severe chronic obstructive 
pulmonary disease than patients without the condition (de Prost et al., 2011). This 
increase may be related with the higher lung and airway production of CysLTs and 
neutrophil activation in chronic obstructive pulmonary disease patients. CysLTs were 
also found to be increased in gingival crevicular fluid in periodontitis conditions and also 
in subjects with atherosclerotic plaques, regardless of periodontal status (Bäck et al., 
2007). Moreover, Celik and collaborators assessed the effect of smoking in the exhaled 
breath condensate levels of LTE4 and LTD4 in asthmatic patients (Celik et al., 2013). 
LTE4 levels were increased in both asthmatic groups in relation to control (CTL) non-
smoking group, whereas LTD4 was only increased in asthmatic smokers, suggesting that 
CysLTs synthesis increase in smoking asthmatics. The authors also speculated on the 
importance of adding leukotriene receptor antagonists in smoking asthmatics as a blocker 
of the effects of LTD4 (Celik et al., 2013). 
On the other hand, urinary LTE4 levels were also increased in patients admitted with 
acute chest pain derived from acute myocardial infarction and unstable angina (Carry et 
al., 1992), in coronary artery disease before and after coronary artery bypass surgery 
(Allen et al., 1993). Furthermore, a recent work by Gautier-Veyret and co-authors 
reported that intermittent hypoxia (IH) is an inducer of CysLTs pathway activation and 
contributes to the obstructive sleep apnea (OSA)-induced atherogenesis (Gautier-Veyret 
et al., 2018). In this study, history of cardiovascular event, age and severity of hypoxia 
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influenced independently the levels of urine LTE4, which were increased in OSA-
cardiovascular event free patients. Urinary LTE4 was also associated with intima-media 
thickness, suggesting the activation of CysLTs pathway as a driver of vascular 
remodeling in OSA. Additionally, they showed that pharmacological blockade of 
cysteinyl leukotriene 1 receptor (CysLT1) in mice prevented IH-induced atherogenesis, 
hence representing a new therapeutic target for reducing cardiovascular risk (Gautier-
Veyret et al., 2018). Similarly, increased elimination of LTE4 in urine was identified in 
OSA in relation to obesity, and to a lesser extent, hypoxia severity (Stanke-Labesque et 
al., 2009). Episodes of acute asthma exacerbations were also associated with increases 
urinary elimination of LTE4 (Green et al., 2004). On the other hand, the increased urinary 
excretion of LTE4 has been associated with diabetes (Hardy et al., 2005; Boizel et al., 
2010), suggesting that hyperglycemia activates arachidonic acid metabolism and 
consequent CysLTs formation. Intensive glycemic control is able to reduce its elimination 
in patients with type 1 diabetes, although no changes were observed in type 2 diabetes 
(Hardy et al., 2005; Boizel et al., 2010).  
Besides CysLTs, there are also reports with altered levels of Cys-S-conjugates of 
catechols. One example is the case of 5-S-Cys-dopa, formed by the rapid binding of 
dopaquinone, a highly reactive molecule, to Cys. Oxidation of 5-S-Cys-dopa leads to 
production of pheomelanin, a yellow to reddish melanin, although a significant portion 
of 5-S-Cys-dopa leaks into the bloodstream and has been associated with the progression 
of melanoma (Wakamatsu et al., 2002). For instance, increases in serum 5-S-Cys-dopa 
have been reported in patients with melanoma and associated with poor prognosis and 
shorter survival times (Wimmer et al., 1997; Banfalvi et al., 2000; Wakamatsu et al., 
2002; Sato et al., 2003; Umemura et al., 2017). Additionally, immunochemotherapy has 
been shown to decrease 5-S-Cys-dopa levels in serum with concomitant longer survival 
times (Wimmer et al., 1997).  
Cys-S-conjugates of catechols have also been reported in neurological conditions. For 
instance, conjugates of both Cys and GSH with the catechols L-3,4-
dihydroxyphenylalanine, dopamine and 3,4-dihydroxyphenylacetic acid were found in 
postmortem brain samples of Parkinson’s disease patients (Spencer et al., 1998). 
Specifically, the authors found increased concentrations of the 5-S-Cys-conjugates of the 
three catechols in substantia nigra and substantia innominata which suggest acceleration 
of L-3,4-dihydroxyphenylalanine/dopamine oxidation occurs in Parkinson’s disease. 
Nevertheless, as all patients were under L-3,4-dihydroxyphenylalanine treatment, this 
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suggestion warrants further elucidation in patients without L-3,4-dihydroxyphenylalanine 
treatment before effectively stating that this is a primary feature of the disease (Spencer 
et al., 1998). The 5-S-Cys conjugates of these catechols had been previously studied in 
three brain sections, namely substantia nigra, putamen and caudate nucleus from 
individuals with or without neurological disorders (Fornstedt et al., 1989). In this report, 
the samples were divided according with macro- and microscopically judged degree of 
depigmentation and neuronal loss within the substantia nigra. The main findings of this 
work were that the levels of the catechols decreased with the degree of depigmentation 
and degeneration. Additionally, while no differences were found the levels of their Cys-
S-conjugates, the authors observed an increase in the ratio of Cys-catechol by 
catecholamine concentration in the more depigmented and degenerated substantia nigra 
group, except for the dopamine ratio in putamen (Fornstedt et al., 1989). The authors 
proposed that depigmentation and degeneration of dopaminergic substantia nigra neurons 
seem to correlate with enhanced rates of autooxidation, possibly due to an impaired 
antioxidant capacity. 
On the other, the levels of 5-S-Cys-dopamine were similar in cerebrospinal fluid samples 
of control individuals and synucleinopathy patients with both parkinsonian (Parkinson’s 
disease and parkinsonian multiple system atrophy) and no parkinsonian components (pure 
autonomic failure). Nevertheless, the levels of 3,4-dihydroxyphenylacetic acid were 
decreased only in Parkinson’s disease and parkinsonian multiple system atrophy, with a 
consequent increase by 2-fold in 5-S-Cys-dopamine/3,4-dihydroxyphenylacetic acid ratio 
in these patients (Goldstein et al., 2016). The authors were not able to identify factors that 
could cause this difference. However, evidence from previous works suggested that this 
might happen due to decreased antioxidant capacity (since it would shift the balance from 
catechols to catecholquinones and finally to Cys-catechol products) (Carlsson and 
Fornstedt, 1991) as well as decreased activity of aldehyde dehydrogenase (the enzyme 
responsible for the formation of 3,4-dihydroxyphenylacetic acid), which has been 
reported in both Parkinson’s disease (Goldstein et al., 2013) and parkinsonian multiple 
system atrophy (Goldstein et al., 2015) conditions. In similarity, a decrease in 
cerebrospinal fluid homovanillic acid, the ultimate metabolite of dopamine, was found in 
Parkinson’s disease patients 5 days after chronic L-3,4-dihydroxyphenylalanine therapy 
withdrawal, that was associated with an increase in the ratio of 5-S-Cys-Dopamine/ 
homovanillic acid (Cheng et al., 1996). The authors hypothesized that the translocation 
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of GSH or Cys into neuromelanin-pigmented dopaminergic cell bodies in the substantia 
nigra might represent an early event in the pathogenesis of Parkinson’s disease.  
Catechol estrogens, namely 2- and 4-hydroxyestrone (or estradiol) can also conjugate 
with GSH, Cys and N-acetylcysteine (NAC) and their urinary levels were found to be 
increased in healthy subjects relatively to patients with breast cancer (Gaikwad et al., 
2008; Gaikwad, Yang, Pruthi, et al., 2009), non-Hodgkin lymphoma (Gaikwad, Yang, 
Weisenburger, et al., 2009) and Parkinson’s disease (Gaikwad et al., 2011). Additionally, 
the ratio of depurinating estrogen deoxyribonucleic acid (DNA) adducts by estrogen 
metabolites and conjugates (where the conjugates with GSH, Cys and NAC were 
included) is higher in cases of thyroid and ovarian cancer in comparison with healthy 
individuals (Zahid et al., 2013, 2014). 
Interestingly, glucose can also generate cysteine-S-conjugates that are far more stable 
than glucose-GSH. In specific, higher urinary levels of glucose-Cys were detected in 
patients with diabetes (Szwergold, 2006).  
Hence, endogenous thioether Cys-S-conjugates are associated with innumerous and 
different inflammatory chronic conditions. Nevertheless, these compounds have in 
common the detoxification by the proximal tubular cells. That might motivate a 
tubulocentric perspective for multiple inflammatory conditions, which has been 
performed in the current year (Gonçalves-Dias et al., 2019). 
 
4.2. Cysteine-disulfide conjugates and disulfide stress: the kidney as a 
primordial organ for Cys accumulation and oxidation 
The Cys-residue of the strong antioxidant GSH is the most abundant small-molecule thiol 
in cells whereas extracellularly, Cys is predominantly found in its free oxidized form 
(cystine) (Rossi et al., 2009). In liver, the majority of Cys is rapidly incorporated into 
GSH which is then exported (Lu, 2009). GSH is hence distributed by the blood to cells 
that have high GGT activity, such as kidney proximal tubular cells (De Carvalho et al., 
2011), that catabolize GSH to Cys (Dröge et al., 1991; Pitts, 1995) for its release in the 
peripheral circulation (Stipanuk et al., 2002). For this reason, some peripheral tissues may 
be exposed to relatively high concentrations of Cys such as the kidney. 
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The key regulatory enzymes of Cys metabolism are cysteine dioxygenase (CDO), that 
converts Cys into cysteine-sulfinate and 3) gamma-glutamylcysteine synthetase (GCS) 
that competes with CDO for the use of Cys as substrate for the formation of GSH (Bella, 
Hahn and Stipanuk, 1999; Stipanuk et al., 2002, 2006). Additionally, Cys availability is 
also dependent on other pathways including coenzyme A (coA) synthesis and hydrogen 
sulfide production (Stipanuk et al., 2006). 
Nevertheless, hepatic CDO plays a dominant role in the regulation of Cys levels, with a 
rapidly drop on its turnover upon the increase of intracellular Cys levels (Bagley and 
Stipanuk, 1995; Bella et al., 1999; Bella, Hahn and Stipanuk, 1999; Stipanuk et al., 2002, 
2006). In fact, the maintenance of low levels of Cys in the body is critical due to the toxic 
effects elicited by excess Cys is plasma. Increased plasma levels of Cys were reported in 
inflammatory conditions such as rheumatoid arthritis (Bradley et al., 1994), systemic 
lupus erythematosus (Gordon et al., 1992), cardiovascular disease (Özkan, Özkan and 
Şimşek, 2002; De Chiara et al., 2012), metabolic syndrome (Mohorko et al., 2015), in 
both diabetic and non-diabetic patients with CKD (Suzuki et al., 2014; Pastore et al., 
2015) as well as in the neurological disorders Parkinson’s disease, Alzheimer’s disease 
and motor neuron disease (Heafield et al., 1990). The value of these results is, however, 
limited due to the quantification of the total fraction of Cys rather than its different forms, 
since the predominant fraction of Cys in plasma is its oxidized form (Rossi et al., 2009) 
and changes on this proportion could trigger toxic effects. In rats, the expression and 
activity of CDO in the kidney is less than half of the hepatic one (Tsuboyama et al., 1996). 
This could be one of the reasons why the ratio of Cys to GSH increases 4 times in the 
kidney while it decreases 2 to 3 fold in the liver from the newborn to the adult period in 
rats (States, Foreman and Segal, 1987). However, contrarily to the data obtained in rats, 
CDO was not detected in human kidney (Tsuboyama-Kasaoka et al., 1999).  
Both Cys and GSH have important roles in maintaining the homeostasis of the 
metabolizing cells. Cys per se is essential for growth and development due to its 
involvement in protein synthesis, transsulfuration and transmethylation pathways 
(Hirakawa and Baker, 1985; Finkelstein, Martin and Harris, 1986) and is an important 
constituent of most proteins, establishing disulfide bridges that determine protein’s 
tertiary structure. Further, it is the sulfhydryl group of Cys that allows GSH to perform 
its reducing function. In fact, Cys is less likely to remain reduced in an oxidative 
environment than GSH (Jones et al., 2000; Grunwell et al., 2015) and the reaction of Cys 
with reactive compounds forming Cys-S-conjugates has been reported to be far more 
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stable and faster than the reaction with GSH (Szwergold, 2006) and with higher half-lives 
than its precursors (Kanaoka and Boyce, 2014).  
On the other hand, the kidney is exposed to relatively high concentrations of Cys (Dröge 
et al., 1991; Pitts, 1995; Stipanuk et al., 2002) and is a primordial organ for oxidation due 
to its high metabolic rate and strong dependence on oxidative phosphorylation to produce 
energy (Simmons, Bogusky and Humes, 1980; Basile, Anderson and Sutton, 2012; 
Chevalier, 2016). Nearly 80 meq Na/g kidney/day are reabsorbed by the intact 
mammalian kidney across the renal tubules, accounting approximately 70% of oxygen 
utilization by the kidney (Lewy et al., 1973). Hence, meeting this demand requires the 
tubular cells to generate a significant amount of adenosine triphosphate (ATP), whose 
preferential energy substrate are non-esterified free fatty acids, mainly palmitate, and to 
a lesser degree, lactate, pyruvate and citrate (Lewy et al., 1973). In fact, the proximal 
tubule does not utilize glucose, but is the only part of the kidney with the appropriate 
enzymes for gluconeogenesis (Mather and Pollock, 2011). 
It is well established the degree of damage to the tubulointerstitial compartment correlated 
with the deterioration of renal function (Tramonti and Kanwar, 2013; Tonolo and 
Cherchi, 2014). On this regard and having into account the above-mentioned facts linking 
the kidney and Cys, the regulation of Cys availability might be an important factor to 
consider in kidney disease. Diet content (mainly), protein breakdown and GSH recycling, 
that occurs mainly in renal tubule through the mercapturate pathway contribute to Cys 
availability, as well as Cys metabolism that is high in liver and adipose tissue (Lu, 1999). 
As so, the metabolism of Cys is pivotal in keeping its levels below the threshold of 
toxicity (Stipanuk et al., 2006). Of note, the mean normal levels of total Cys in plasma is 
about 190 to 250 µM (Özkan, Özkan and Şimşek, 2002; Davis et al., 2006; Rossi et al., 
2009) and Cys in plasma exists mainly in oxidized form (Ashfaq et al., 2006). 
In fact, the promotion of toxicity by Cys is related to the formation of its auto-oxidative 
products, namely CysSSX (Vina et al., 1983; Munday, 1989; Poole, 2015), playing 
important roles in redox cycling and/or regulation of enzymes and transcription factors 
involved in cell signaling processes (Forman, Maiorino and Ursini, 2010; Poole, 2015).  
The formation of CysSSX occurs through a disulfide bond between Cys with other low 
molecular weight (LMW) thiol-containing molecule, including GSH, Cys, coenzyme A 
(CoA) or homocysteine (HCys) yielding cysteine-glutathione disulfide (CysSSG), 
CysSSCys, cysteine-coenzyme A disulfide (CysSSCoA) and CysSSHCys, respectively 
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(Wang and Ballatori, 1998; Moreno et al., 2014; Coelho et al., 2018). We have previously 
shown an increase in the formation of CysSSX at the kidney at early stages of disease in 
an animal model of systemic hypertension (Coelho et al., 2018), characterized by 
increased oxidative and inflammatory status (Abuyassin et al., 2018). Moreover increased 
formation of LMW disulfides namely CysSSCys and homocystine (HCysSSHcys) 
together with increased protein cysteinylation (CysSSP) and glutamylcysteinylation 
(GluCysSSP) (i.e. the oxidation of Cys residues in protein with, respectively, free Cys 
and glutamate-cysteine – GluCys) has been described as a redox signaling mechanism 
associated with acute organ inflammation (Moreno et al., 2014). This mechanism was 
named disulfide stress and represents a new paradigm in inflammatory/oxidative 
conditions, as it is independent of the classical view of GSH redox status. Furthermore, 
targets of this disulfide stress (i.e. oxidation of Cys residues) have important roles in DNA 
repair, cell proliferation, apoptosis, endoplasmic reticulum (ER) stress and inflammatory 
response (Moreno et al., 2014). This could be seen as a double-edged sword since in one 
hand, oxidation of the Cys residues might result in functional inactivation of enzymes 
(e.g. ribonuclease inhibitor, APE1, PP2A) while in other hand it could induce an adaptive 
response to oxidative stress through the activation of both the unfolded protein response, 
by the oxidation of protein isomerase disulfide (Parakh and Atkin, 2015) and the 
antioxidant response element, through oxidation of Keap1 with consequent activation of 
Nrf2 (Taguchi, Motohashi and Yamamoto, 2011; Levonen et al., 2014; Poole, 2015). 
Interestingly, no changes in GSH oxidation or protein glutathionylation were observed in 
a model of acute organ injury. This is in accordance with the fact that the redox state of 
GSH in plasma is not equilibrated with the pool of Cys (which is far larger in plasma than 
GSH), eliciting different responses to chemical toxicants and physiologic stimuli, 
suggesting that oxidative stress may be better defined as a disruption of redox signaling 
and control rather than the redox state of GSH (Jones, 2006). Moreover, it seems that 
disulfide stress might be a good mechanism for regulation of proteins (through activation 
of the unfolded protein response and the antioxidant response element), while the 
formation of LWM disulfides might induce an opposite reaction. For instance, CysSSCys 
can accumulate in lysosomes, which promotes mitochondrial depolarization and the 
induction of redox‐sensitive genes (Sumayao et al., 2016). Additionally, a recent review 
evaluating the relative solute retention of several compounds in uremia through the ratio 
of the mean of all reported uremic concentrations  measured (M) in patients to the normal 
concentration (N) measured in healthy controls, revealed that plasma Cys (that is mainly 
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in its oxidized form, cystine) was among the 18 solutes with the ratio M/N, ranging 
between one and two (positioned in number 8 of 18) (Duranton et al., 2012).  
Under oxidative stress conditions, CysSSX might be directly formed in proximal tubular 
cells, independently of GSH levels (Jones et al., 2000; Grunwell et al., 2015). Also, 
CysSSX might reach tubular cells upon the catabolism of GSSX generated plausibly by 
any cell, through the mercapturate pathway, by the mechanism above-mentioned 
(sequential hydrolysis by GGT and cysteinyl-glycine dipeptidase or aminopeptidase-M) 
and finally transported into the tubular cell. As so, under chronic injury, the kidney might 
be exposed to high and potentially toxic concentrations of CysSSX, that together with the 
increased susceptibility of the kidney for oxidation (Simmons, Bogusky and Humes, 
1980; Basile, Anderson and Sutton, 2012; Chevalier, 2016) might perpetuate the effects 
of CysSSX accumulation, promoting injury of proximal tubular cells.  
In fact, increased levels of plasma CysSSCys have been reported in conditions associated 
with kidney dysfunction. For instance, higher levels of CysSSCys were detected in 
patients under hemodialysis (HD) (Wlodek et al., 2001; Suzuki et al., 2018). A recent 
study showed that increased concentrations of CysSSCys were associated with older age, 
longer HD duration, HD-associated hypotension and higher body mass index (BMI), 
demonstrating that higher CysSSCys levels predicted the cardiovascular-related and all-
cause mortality in these patients (Suzuki et al., 2018). Additionally, patients with 
coronary artery disease also presented higher levels of CysSSCys, that, among other 
factors, were associated with impaired renal function as demonstrated by a lower eGFR 
(Patel et al., 2016). On the other hand, although no changes were observed in CysSSCys 
in a population of patients with different stages of CKD, the redox potential of Cys 
increased with disease progression towards a more oxidized state of Cys (Rodrigues et 
al., 2012). 
Regarding the levels of CysSSX in studies with animal models, rats exposed to chronic 
intermittent hypoxia, mimicking co-morbidities of OSA, presented an increased in renal 
concentrations of CysSSX in an early phase of disease (Coelho et al., 2018). In another 
model, a drop in plasma and renal levels of total Cys was observed 24 hours right after 
injection of CISP in rats, although the individual levels of Cys and CysSSCys could not 
be evaluated (Ezaki et al., 2017). 
Similarly to the thioether Cys-S-conjugates, changes in CysSSX have also been reported 
in other inflammatory conditions, although the reports are only regarding plasma samples 
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(Table 1). Specifically, the levels of CysSSCys were increased in plasma samples from 
coronary artery disease patients, representing greater oxidant burden on this setting (Patel 
et al., 2016). The increase in CysSSCys was accompanied by a reduction of GSH, 
indicating a low intracellular reducing capacity. Furthermore, a high ratio of 
CysSSCys/GSH was observed and was associated with a 2-fold increase in risk of 
mortality over a mean of 5 years, regardless of age and other risk factors such as 
inflammation. Factors contributing for the increase in CysSSCys were older age, female 
sex, higher BMI, lower eGFR as well as the presence of hypertension and diabetes (Patel 
et al., 2016). In fact, other reports have shown that increased plasma CysSSCys is 
associated with ageing (Ashfaq et al., 2006; Giustarini et al., 2006), diabetes (Ashfaq et 
al., 2008) as well as hypertension and higher BMI (Ashfaq et al., 2008; Dhawan et al., 
2011). In an otherwise healthy population, CysSSCys was also positively associated with 
Framingham risk score (used to estimate the 10-year cardiovascular risk of an individual). 
Moreover, a higher level of oxidized metabolites, namely CysSSCys and CysSSG was 
associated with worse endothelial function (Ashfaq et al., 2008). In critically ill children, 
decreased vitamin D was associated with a more oxidative status of Cys (Alvarez et al., 
2018). Additionally, impaired microvascular function and increase necrotic core was 
related with a higher ratio of CysSSCys/GSH, reflective of higher oxidative stress, in 
patients with coronary atherosclerotic heart disease (Dhawan et al., 2011). Higher intima-
media thickness correlated with a higher profile of plasma levels of CysSSCys and also 
higher redox potential of GSH (more oxidized), although after adjusting for traditional 
risk factors and inflammation, only the latter remained a predictor of intima-media 
thickness in a manner that was both independent of and additive to the Framingham risk 
score (Ashfaq et al., 2006). Oxidation of Cys, shown by an increase in CysSSCys and the 
redox potential of Cys (more oxidized) was associated with decrease responsiveness to 
the systemic glucocorticoid triamcinolone in children with difficult-to-treat asthma 
(Stephenson et al., 2015).  
The effect of antioxidant supplementation on plasma CysSSCys levels has also been 
studied. In a randomized, double-blind placebo-controlled clinical trial of patients with 
history of sporadic colorectal adenoma, supplementation with an antioxidant 
micronutrient combination lead to a reduction in plasmatic levels of CysSSCys, an effect 
that was further pronounced in nonsmoking patients (Hopkins et al., 2010). However, 
standard or modified (containing micronutrients and minimal lipids alone) parenteral 
nutrition had no effect on the levels of CysSSCys or the redox potential of both GSH and 
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Cys, that increased over time in patients undergoing bone marrow transplantation 
following chemotherapy (Jonas et al., 2000). 
In summary, the study of CysSSX seems to be still poorly explored in relation of what is 
known for other Cys-S-conjugates. Nevertheless, evidence shows that increased levels of 
CysSSX are associated with both kidney dysfunction and other inflammatory conditions.  
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Table 1 – Endogenous cysteine-S-conjugates (thioethers and disulfides) in inflammatory conditions. 
Conjugates Study  aim/rationale 
Biological sample and 
patients’ characteristics 
Method, ranges 
or cut-offs 
Results 
Metabolite levels, association with disease Reference 
CysLTs 
Evaluate the impact of systemic 
diseases, pharmaceuticals and 
diet on CysLTs in EBC and 
correlation of respiratory 
disorders with plasma and urine 
CysLTs. 
EBC, plasma and urine 
samples from 82 patients with 
pneumoconiosis – 45 from 
asbestos exposure (mean age 
70 yo; 53% men) and 37 from 
silica exposure (mean age 69 
yo; 97% men); and 27 CTLs; 
subjects with systemic 
disorders were present in all 
groups. 
LC-ESI-MS/MS 
• ­ LTD4 and LTE4 in pneumoconiosis versus CTL group in EBC; 
• ­ urine LTD4 and plasma LTE4 in asbestosis versus CTL group; 
• ­ CysLTs in severe asbestosis versus mild asbestosis in EBC; 
• In CTL group, plasma LTE4 was correlated with nephrolithiasis (+) 
and fibrates; 
• In asbestosis group, plasma LTC4 was correlated with steroids; 
• In silicosis group, urine LTD4 was correlated with kidney failure 
(+), urine LTE4 with kidney failure (+) and salicylates, and plasma 
LTE4 with vitamin C and E. 
(Pelclova et 
al., 2012) 
Clarify the types of CysLTs in 
saliva and evaluate them in AIA 
patients; 
Compare the levels of CysLTs 
between saliva and urine. 
Saliva and urine samples from 
26 non-smoking asthmatic 
patients: 15 AIA (mean age 51 
yo; 40% men) and 11 ATA 
(mean age 55 yo; 36% men); 
and 10 CTLs; AIA patients 
were also divided in mild (n=6) 
and mild (n=9) asthma. 
Purification by 
HPLC followed 
by EIA (LLOD: 
13 pg/mL). 
• LTC4 (30%), LTD4 (32%) and LTE4 (38%) were detectable in 
saliva in similar amounts; 
• ­ CysLTs in saliva of AIA versus other groups; 
• CysLTs correlated with LTB4 in saliva in all groups (+); 
• ­ LTE4 in urine of AIA versus other groups; 
• No association between urine LTE4 and CysLTs in saliva; 
• ­ LTE4 in urine of severe AIA patients. 
(Ono et al., 
2011) 
Determine the correlation of 8-
isoprostane, CysLTs, age and 
autism severity scales to clarify 
the role of oxidative stress and 
inflammation in the 
etiopathology of autism. 
Plasma samples from 44 
autistic children (mean age 7 
yo) and 40 CTLs (mean age 7 
yo). Autistic cases were all 
simple and tested negative for 
the fragile X gene mutations. 
ELISA 
• ­ CysLTs and 8-isoprostane in autistic versus CTL group; 
• CysLTs correlated with 8-isoprostane (+); 
• SSP test correlated with CysLTs and 8-isoprostane (-). 
(Qasem, Al-
Ayadhi and 
El-Ansary, 
2016) 
Quantify CysLTs in urine of 
spontaneous ICH patients; 
compare the release of CysLTs 
with the edema volume; assess 
the effect of hematoma removal 
in the release of CysLTs. 
Urine samples from 17 
spontaneous ICH patients 
(mean age 58 yo; 53% men): 
12 treated surgically and 5 
treated conservatively. 
Samples were collected before 
treatment and during 5 days of 
treatment. 
HPLC 
• CysLTs were correlated with hematoma volume (+); 
• ¯ CysLTs 5 days after surgery in comparison with before surgery; 
• No differences with conservative treatment 
(Winking et 
al., 1998) 
Study CysLTs changes during 
and after cardiac surgery with 
CPB and the differences between 
patients with and without COPD. 
Plasma and urine samples from 
patients undergoing cardiac 
surgery with CPB: 9 with 
moderate-to-severe COPD 
(mean age 69 yo; 78% men) 
and 10 non-smoker CTLs 
(mean age 64 yo; 60% men). 
ELISA 
• ­ CysLTs in urine with time, in both groups, but more evident in 
COPD patients; 
• ­ CysLTs in plasma of COPD patients between baseline and 
admission to ICU. 
(de Prost et 
al., 2011) 
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Samples were collected after 
intubation (baseline), at the end 
of CPB, after CPB and 2h after 
admission in ICU. 
Detect the formation of CysLTs 
and atherosclerosis in subjects 
with and without periodontitis. 
GCF samples of 19 subjects 
with periodontitis (mean age 
55 yo; 63% men; 13 with 
atherosclerotic plaques) and 16 
CTLs (mean age 53 yo; 44% 
men; 5 with atherosclerotic 
plaques). 
EIA 
• > subjects with atherosclerotic plaques in periodontitis versus CTL; 
• ­ CysLTs than LTB4 in GCF; 
• ­ CysLTs in periodontitis subjects with high PLI; 
• ­ CysLTs in subjects with atherosclerotic plaques, even when 
dividing between periodontitis and CTL subjects. 
(Bäck et al., 
2007) 
Evaluate the effect of smoking in 
LDT4 and LTE4 levels in 
asthma 
EBC samples from 59 
asthmatic patients – 30 
smokers (mean age 34 yo; 50% 
men) and 29 non-smokers 
(mean age 34 yo; 48% men); 
and 29 CTLs (mean age 34 yo; 
48% men; non-smokers). 
ELISA 
• ­ LTD4 in asthmatic smokers versus other groups; 
• ­ LTE4 in asthmatic versus CTL group; 
• LTE4 correlates with the ratio of forced expiratory volume in one 
second by forced vital capacity (measure of airway obstruction) in 
asthmatic smokers (-). 
(Celik et al., 
2013) 
LTE4 
Assess in vivo release of LTE4 
during and after an ischemic 
episode. 
Urine samples from 16 AMI 
(mean age 51 yo; 88% men) 
and 14 UA patients (mean age 
52 yo; 21% men); and 8 
clinical (88% mean) and 10 
normal (50% men) CTLs. 
Samples were collected upon 
admission with acute chest 
pain and 3 days after. 
HPLC followed 
by RIA 
• ­ LTE4 in MIA and UA at admission versus CTL groups; 
• ­ LTE4 on admission than 3 days after in AMI and UA groups; 
(Carry et al., 
1992) 
Study the relation between the 
systemic CysLTs synthesis and 
stable CAD and changes after 
bypass surgery 
Urine samples from 13 CAD 
patients (mean age 59 yo; 
100% men) and 12 CTLs 
(mean age 44 yo; 100% men; 
no previous history of CAD). 
For CAD patients, samples 
were collected in the 
preoperative and for up to 7 
days after. 
Solid-phase 
extraction, 
HPLC 
purification and 
RIA 
• ­ LTE4 in preoperative CAD versus CTL group; 
• ­ LTE4 2 days after surgery versus preoperative in CAD group; 
(Allen et al., 
1993) 
Identify the determinants on the 
activation of CysLTs pathway 
and the role of CysLTs in OSA-
related atherosclerosis 
Urine samples from 170 OSA 
patients (mean age 57 yo; 81 % 
men) – 136 CVE free and 34 
with previous CVE; and 20+9 
CTLs (mean age 52 yo; 52% 
men). 
LC-MS 
• Whole cohort: LTE4 was independently influenced by age, min 
SaO2 and history of CVE and was correlated with IMT (+); 
• ­ LTE4 in OSA CVE free patients versus CTL group and was 
independently related to min SaO2 and traditional risk factors of the 
10-year cardiovascular risk score. 
(Gautier-
Veyret et al., 
2018) 
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Monitor urine LTE4 in OSA; to 
determine the influence of 
obesity and other confounders 
on; to examine the mechanisms 
involved through transcriptional 
profiling of CysLTs pathway in; 
and to investigate the effect of 
continuous positive air pressure 
(CPAP) on LTE4. 
Urine samples from 40 
nonobese OSA patients (mean 
age 49 yo; 85% men) and 25 
CTLs (mean age 45 yo; 72% 
men). A group of 72 OSA 
patients (mean age 51 yo; 81% 
men) was included to study 
confounder factors of LTE4. 
All were nonsmokers. 
LC-MS; LLOD: 
10 pg/mL 
• ­ LTE4 in nonobese OSA versus CTL group; 
• In nonobese OSA patients, LTE4 was correlated with % of time 
spent with SaO2<90% (+); 
• In the 72 OSA patients, BMI and % of time spent with SaO2<90% 
were identified as independent predictors of LTE4; 
• CPAP ¯ LTE4 by 22% only in OSA patients with normal BMI. 
(Stanke-
Labesque et 
al., 2009) 
Analyze CysLTs activation in 
asthma during treatment in the 
ED and 2 weeks after; determine 
whether the degree of airflow 
limitation is correlated with 
activation of CysLTs pathway. 
Urine samples from 184 
patients with acute asthma at 
the ED (mean age 35 yo). 
Samples were collected at the 
ED and 2 weeks after. 
HPLC followed 
by RIA. 
• ­ LTE4 during asthma exacerbations versus 2 weeks later; 
• LTE4 was correlated with FEV1 (+) over the 2-week interval. 
(Green et al., 
2004) 
Evaluate urinary excretion of 
LTE4 in patients with T1D and 
the influence of glycemic control 
in this excretion 
Urine samples from 34 T1D 
patients – 20 with GMC 
(median age 39 yo; 55% men) 
and 14 with PMC (median age 
41 yo; 50% men) and 28 CTLs 
(median age 39 yo; 43% men), 
all nonsmokers. 
LC-MS 
• ­ LTE4 in T1D versus CTL group; 
• ­ LTE4 in T1D patients with PMC versus CTL group; 
 
(Hardy et al., 
2005) 
Investigate the effect on LTE4 
and 11-dehydro-TXB2 of a 3-
month improvement of glycemic 
control by intensive insulin 
treatment in diabetes. 
Urine samples from 20 T1D 
(mean age 37 yo; 35% men) 
and 19 T2DM patients (mean 
age 58 yo; 68% men), all 
nonsmokers. 
LC-MS; 
detection range: 
10-100 pg/mL 
• ¯ LTE4 after intensive insulin treatment (-32%) in T1D but not in 
T2DM groups. 
(Boizel et al., 
2010) 
5-S-CD 
Retrospective evaluation of the 
usefulness of serum 5-S-CD as a 
biomarker for prognosis and 
early detection of relapse of 
MM. 
Serum samples of 120 patients 
with MM (mean age 64 yo; 
41% men). 
HPLC;  
Normal range: 
1.5-8 nmol/L but 
the cut-off has 
been established 
to be 10 nmol/L. 
• ­ 5-S-CD in advanced stages (III and IV) versus early stages (0–II) 
patients; 
• In patients with advanced stages, 5-S-CD>15.0 nmol/L correlated 
with a poor prognosis; 
• 5-S-CD>10 nmol/L in 11/14 patients with disease progression 
during follow up.  
(Umemura et 
al., 2017) 
Case report for diagnosis of 
rectal malignant melanoma with 
5-S-CD. 
Serum sample from woman 
with 84 yo diagnosed with 
rectal MM. 
Method was not 
specified;  
Normal range: 
1.5-8 nmol/L. 
• Before tumor resection: 5-S-CD levels were 26 nmol/L; 
• 3 months after surgery: 5-S-CD levels were 12.6 nmol/L 3 (still>10 
nmol/L) and CT scan confirmed multiple liver and lung metastasis.  
(Sato et al., 
2003) 
Usefulness of serum 5-S-CD in 
following melanoma progression 
and prognosis. 
Serum samples from 218 
melanoma patients (mean age 
55 yo; 51% men). 
HPLC-EC; 
Upper limit of 
normal range: 10 
nmol/L  
• 5-S-CD>10 nmol/L in stage IV patients; 
• Elevation of 5-S-CD preceded or occurred at the same time of 
clinical detection of visceral metastasis in, respectively, 33% and 
37% of cases; 
• ­ 5-S-CD was associated with shorter survival time. 
(Wakamatsu 
et al., 2002) 
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Serum 5-S-CD-levels as a useful 
marker for monitoring tumor 
progression and regression due 
to immunochemotherapy cycles 
in metastasizing MM and its 
value for prognosis and therapy 
response. 
Serum samples from 11 
patients with metastatic MM 
(mean age 47 yo; 64% men). 
HPLC-EC; 
Upper limit of 
normal range: 
3.2 ng/mL (10 
nmol/L);  
Variations of 0.2 
ng/mL were 
taken ¯ or ­ 
• Before and after therapy, mean 5-S-CD were 4.3 ng/mL and 94.3 
ng/mL, respectively; 
• ¯ and ­ in 5-S-CD was observed in, respectively 68% and 32% of 
therapy cycles; 
• Declines in 5-S-CD in > 68% of therapy cycles had longer survival 
time. 
(Wimmer et 
al., 1997) 
Levels of 5-S-CD in different 
stages of malignant melanoma, 
and its value on the extent of 
metastasis.  
Serum sample from 252 
patients with MM (51% men). 
HPLC;  
Upper limit of 
normal range: 10 
nmol/L. 
• ­ 5-S-CD in symptomatic versus asymptomatic patients; 
• ­ 5-S-CD in stage III versus stage I and II patients; 
• ­ 5-S-CD in stage III versus primary tumor, lymph node and lung 
metastasis symptoms; 
• ­ 5-S-CD correlated with tumor burden. 
(Banfalvi et 
al., 2000) 
5-S-Cys and  
5-S-GSH 
conjugates of 
DA,  
L-DOPA and 
DOPAC 
Quantification of 5-S-Cys- and 
5-S-GSH-catechol conjugates in 
brain tissue and changes on their 
levels in PD. 
Postmortem brain samples 
from 6 PD patients with PD 
(mean age 77 yo, L-DOPA 
therapy) and 6 CTLs (mean age 
81 yo); Brains were dissected 
into 11 regions. 
HPLC-EC 
• Detectable conjugates in most brain regions, with higher levels in 
SN and PUT; 
• ¯ 5-S-glutathionyl- versus 5-S-cysteinyl-conjugates; 
• ¯ conjugates in PD with the exception of 5-S-cysteinyl-conjugates 
that were ­ in SN and SI. 
(Spencer et 
al., 1998) 
5-S-Cys  
conjugates of 
DA,  
L-DOPA and 
DOPAC 
 
Investigate the connection 
between SN’s degenerative 
changes and the occurrence of 5-
S-Cys-catechol conjugates and 
their ratio with the 
catecholamines. 
Postmortem brain samples 
(SN, PUT and CN sections) 
from 17 individuals (72-90 yo; 
41% men); Samples were 
divided according to degree of 
depigmentation and neuronal 
loss within SN. 
HPLC-EC 
• ¯ DA, DOPAC and DOPA in depigmented group in SN; 
• No differences for Cys-DA among groups;  
• ­ 5-S-Cys-catechol conjugates/catecholamine ratio in the more 
depigmented and degenerated SN group, except for the DA ratio in 
PUT. 
(Fornstedt et 
al., 1989) 
5-S-Cys-DA 
Assess the value of increased 
Cys-DA/DOPAC ratio CSF as a 
specific biomarker of 
parkinsonism.  
CSF samples from 24 PD 
patients (mean age 61 yo, 58% 
men); 32 MSA-P (mean age 60 
yo; 66% men); 18 PAF (mean 
age 63 yo; 67% men) and 32 
CTLs (mean age 53 yo; 53% 
men). Patients were not under 
levodopa or monoamine 
oxidase inhibitor treatment. 
HPLC-EC 
• ¯ DOPAC in PD and MSA-P versus PAF and CTL groups; 
• Cys-DA levels were similar among groups; 
• Cys-DA/DOPAC >2-fold in PD and MSA-P than PAF and CTL 
groups; 
• Cys-DA/DOPAC was correlated with putamen/occipital ratios (-) 
and washout fractions of 18F-fluorodopa-derived radioactivity (+). 
(Goldstein et 
al., 2016) 
Evaluate the levels of Cys-DA, 
homovanillic acid (HVA) and 
their ratio in CSF samples of PD 
patients. 
CSF samples from 20 PD 
patients (mean age 69 yo, 85% 
men) and 16 CTLs (mean age 
60 yo years, 63 % men); 
Samples under and 5 days after 
L-DOPA withdrawal. 
HPLC-EC 
• ¯ HVA in PD patients after L-DOPA withdrawal versus CTLs; 
• No differences for Cys-DA among groups;  
• ­ Cys-DA/HVA ratio in PD after L-DOPA withdrawal versus CTLs.  
(Cheng et al., 
1996) 
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Cys, GSH and 
NAC 
conjugates of 
2-OHE1(E2) 
and  
4-OHE1(E2) 
To test if estrogen metabolites, 
conjugates and depurinating 
DNA adducts differ between 
healthy women and women with 
breast cancer or at high risk for 
breast cancer. 
Urine samples from 12 women 
with high-risk for breast cancer 
(mean age 52 yo), 17 with 
breast cancer (mean age 54 yo) 
and 46 CTLs (mean age 50 yo).  
UPLC/MS-MS 
detection 
• ­ Cys, GSH and NAC conjugates of 2-OHE1(E2) in CTL versus 
other groups. 
(Gaikwad et 
al., 2008) 
Analyze the urinary levels of 
estrogen metabolites, conjugates 
and depurinating DNA adducts 
and their association with breast 
cancer. 
Urine samples from 40 women 
with high risk for breast cancer 
(median age 57 yo) and 40 with 
newly diagnosed with breast 
cancer (median age 58 yo) and 
CTLs (median age 45 yo), all 
without estrogen-containing 
treatment. 
UPLC/MS-MS 
detection 
• ­ Cys, GSH and NAC conjugates of 2-OHE1(E2) and 4-OHE1(E2) in 
CTL versus other groups. 
(Gaikwad, 
Yang, Pruthi, 
et al., 2009) 
Determine if the estrogen 
depurinating DNA adducts are 
involved in the etiology of NHL. 
Urine samples from 15 NHL 
patients (median age 59 yo; 
100% men) and 30 CTLs 
(median age 60; 100% men). 
UPLC/MS-MS 
detection 
• ­ Cys, GSH and NAC conjugates of 4-OHE1(E2) in CTL versus 
NHL group. 
(Gaikwad, 
Yang, 
Weisenburger, 
et al., 2009) 
Assess if high levels of estrogen 
DNA adducts are associated with 
PD. 
Urine samples from 20 PD 
patients (mean age 62 yo; 75% 
men; all under levodopa) and 
40 CTLs (mean age 63 yo; 
75% men) 
UPLC/MS-MS 
detection 
• ­ Cys, GSH and NAC conjugates of 4-OHE1(E2) in CTL versus PD 
group. 
(Gaikwad et 
al., 2011) 
Investigate the role of estrogen 
metabolism in thyroid cancer 
Urine samples from 40 women 
with thyroid cancer (mean age 
47 yo) and 40 CTL women 
(mean age 47 yo). 
UPLC/MS-MS; 
the ratio of 
depurinating 
estrogen DNA 
adducts by 
metabolites and 
conjugates was 
obtained. 
• ­ ratio in thyroid cancer than CTL group. (Zahid et al., 2013) 
Investigate the role of estrogen 
metabolism in ovarian cancer 
Urine samples from 33 women 
with ovarian cancer (mean age 
58 yo) and 34 CTL women 
(mean age 58 yo). 
UPLC/MS-MS; 
the ratio of 
depurinating 
estrogen DNA 
adducts by 
metabolites and 
conjugates was 
obtained. 
• ­ ratio in ovarian cancer than CTL group. (Zahid et al., 2014) 
Glucose-Cys 
Assess if a-thiolamines such as 
Cys is a good candidate to fulfill 
the role of general trans- 
glycating agent 
Urine samples from 5 patients 
with diabetes and 2 
normoglycemic subjects 
SIM • ­ Glucose-Cys in diabetes than normoglycemic subjects. (Szwergold, 2006) 
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CysSSCys 
Examine the association of 
emerging aminothiol markers of 
non-free radical mediated 
oxidative stress with clinical 
outcomes. 
Plasma samples from 1411 
subjects prior to undergoing 
coronary angiography for 
investigation or management 
of CAD (mean age 63 yo; 66% 
men). 
HPLC-FD 
• A multivariable model showed that older age, female sex, ­ BMI, ¯ 
eGFR, presence of diabetes and HTN were independently associated 
with ­ CysSSCys; 
• ­ CysSSCys was associated with risk of death; 
• ­ CysSSCys/GSH leads to a 2-fold increase in risk of mortality over 
a mean of 5 years, regardless of age and other risk factors such as 
inflammation. 
(Patel et al., 
2016) 
Assess whether there is a shift of 
the thiol/disulfide balance during 
aging 
Plasma samples from 41 
healthy individuals (age 
between 21 and 92 yo; 41% 
men) 
HPLC-FD • Aging was correlated with ­ CysSSCys.  (Giustarini et al., 2006) 
Effects of an antioxidant 
micronutrient combination on 
oxidative and inflammatory 
biomarkers in sporadic 
colorectal adenoma. 
Pilot, randomized, double-
blind, placebo-controlled 
clinical trial. Plasma samples 
from 47 patients with in 
patients with a history of 
sporadic colorectal adenoma: 
23 under placebo (median age 
59 yo; 52% men) and 24 under 
antioxidant treatment (median 
age 61 yo; 50% men). 
HPLC 
• ¯ CysSSCys in the antioxidant (-39%) versus placebo group; 
• In the antioxidant group, ¯ CysSSCys was more pronounced in 
nonsmokers (-35%) versus smokers (-12%). 
(Hopkins et 
al., 2010) 
CysSSCys and 
CysSSG 
Assess oxidative stress in the 
bloodstream as a reliable 
predictor of endothelial function 
in healthy adults. 
Plasma samples from 124 
healthy nonsmokers subjects 
without any known 
cardiovascular risk factors 
(mean age 44 yo; 40% men). In 
A subset of individuals with 
HTN, diabetes or BMI≥30 was 
analyzed (n=41).  
HPLC-FD 
• CysSSCys was correlated with age (+), BMI (+), HTN (+) and 
Framingham risk score; 
• ­ CysSSCys in patients with HTN, diabetes or BMI≥30 versus the 
remaining individuals; 
• CysSSG was correlated with TG (-), HDL (+), HTN (+); 
• Endothelium-dependent vasodilation correlated with CysSSCys (-) 
and CysSSG (-). 
(Ashfaq et al., 
2008) 
CysSSCys and 
GSSG 
Investigate the relationship 
between vitD status and GSH 
and Cys redox and immunity in 
critically ill children. 
Plasma samples of 50 critically 
ill children (mean age 12 yo; 
56% men) that were stratified 
by vitD levels: <20 ng/dl 
(n=29); 20-30 ng/dL (n=8) and 
≥30 ng/dL (n=13). 
HPLC 
• ¯ vitD associated with ¯ CysSH/CysSSCys and ­ 
EhCysSH/CysSSCys; 
• ­ vitD associated with ¯ GSSG. 
(Alvarez et al., 
2018) 
Determine if higher oxidative 
stress is associated with impaired 
coronary microvascular function 
and plaque necrotic core content 
Plasma samples from 47 
patients undergoing cardiac 
catheterization (mean age 58 
yo; 64% men). 
HPLC 
• ­ CysSSCys/GSH associated with impaired microvascular function 
and greater necrotic core; 
• ­ CysSSCys in patients with ­ BMI and HTN. 
(Dhawan et 
al., 2011) 
Characterize systemic Cys 
oxidation and its association 
with inflammatory and clinical 
features in children with asthma 
Plasma and PBMCs samples 
from 99 children with asthma 
(median age 12 yo; 67% men) 
and 15 CTLs (median age 10 
HPLC 
• ¯ CysSH and ­ CysSSCys and EhCysSH/CysSSCys in plasma of 
asthmatic versus CTL group; 
• ­ GSSG in PBMCs of asthmatic versus CTL group; 
(Stephenson et 
al., 2015) 
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yo; 20% men). Response to 
triamcinolone treatment was 
assessed in 57 children. 
• The lowest CysSH and highest EhCysSH/CysSSCys were found in 
children with severe asthma; 
• ­ EhCysSH/CysSSCys and ¯ CysSH in triamcinolone non-
responders at both the baseline and the 2-week after treatment visits. 
Investigate the relationship 
between biomarkers of oxidative 
stress and early atherosclerosis. 
Plasma samples from 114 
healthy nonsmokers subjects 
without known clinical 
atherosclerosis (mean age 44 
yo; 41% men). 
HPLC-FD 
• ­ IMT correlated with both CysSSCys (+) and EhGSH/GSSG (+); 
• Age correlated with GSH/GSSG (+) and CysSSCys (+); 
• Multivariable analysis showed that only EhGSH/GSSG was an 
independent predictor of IMT. 
(Ashfaq et al., 
2006) 
Determine the effect of high-
dose chemotherapy in 
circulating antioxidants in 
patients undergoing BMT and if 
administration of standard PN 
(sPN) maintains systemic 
antioxidant concentrations 
compared with modified PN 
(mPN) containing 
micronutrients and minimal 
lipids alone. 
Double-blind, controlled, 
randomized clinical trial. 
Plasma samples from 24 BMT 
patients (mean age 40 yo; 58% 
men). Patients were divided 
into treatment with sPN (mean 
age 41 yo; 36% men) and mPN 
(mean age 38 yo; 69% men). 
Samples were collected before 
chemotherapy and BMT 
(baseline) and 1, 3, 7, 10 and 
14 days after BMT. 
HPLC-FD • ­ EhGSH/GSSG, EhCys/CysSSCys and CysSSCys over time, 
regardless of PN treatment type. 
(Jonas et al., 
2000) 
­: higher; ¯: lower; (-): negative correlation; (+): positive correlation; 2-OHE1(E2), 2-hydroxyestrone (estradiol); 4-OHE1(E2), 4-hydroxyestrone (estradiol); 5-S-CD: 5-S-Cysteinyl-dopa; 5-S-Cys-DA: 5-S-Cysteinyl-dopamine; AIA: aspirin-intolerant 
asthma; AMI: acute myocardial infarction; ATA: aspirin-tolerant asthma; BMI: body mass index; BMT: bone marrow transplantation; CAD: coronary artery disease; CoA-SSG: coenzyme A-glutathione disulfide; COPD: chronic obstructive pulmonary 
disease; CPAP: continuous positive air pressure; CPB: cardiopulmonary bypass; CRP: C-reactive protein; CTL: controls; CSF: cerebrospinal fluid; CVD: cardiovascular disease; CVE: cardiovascular event; Cys: cysteine; CysSH: free cysteine; CysLTs: 
cysteinyl-leukotrienes; CysSSCys: cystine; CysSSG: cysteine-glutathione disulfide; DA: dopamine; CN: caudate nucleus; DOPAC; 3,4-dihydroxyphenylacetic acid EBC: exhaled breath condensate; ED: emergency department; eGFR: estimated 
glomerular filtration rate; Eh: redox potential; EIA: enzyme immunoassay; ELISA: enzyme-linked immunosorbent assay; FEV1: forced expiratory volume in 1 second; GCF: gingival crevicular fluid; GCM: good metabolic control; GSH: glutathione; 
GSSG: oxidized glutathione; HD: hemodialysis; HDL: high-density lipoprotein; HPLC: high-performance liquid chromatography; HPLC-EC: high-performance liquid chromatography with electrochemical detection; HPLC-FD: high-performance 
liquid chromatography with fluorescence detection; HTN: hypertension; HVA: homovanillic acid; ICH: intracerebral hemorrhage; ICU: intensive care unit; IMT: intima-media thickness; L-DOPA; L-3,4-dihydroxyphenylalanine; LC-ESI-MS/MS: 
liquid chromatography − electrospray ionization − tandem mass spectrometry; LC-MS: liquid chromatography-tandem mass spectrometry ; LLOD: lower limit of detection; LTB4: leukotriene B4; LTC4: leukotriene C4; LTD4: leukotriene D4; LTE4: 
leukotriene E4; min SaO2: minimal oxygen saturation; MM: malignant melanoma; MSA-P: parkinsonian multiple system atrophy; NAC_ N-acetylcysteine; NHL: non-Hodgkin lymphoma; OSA: obstructive sleep apnea; PAF: pure autonomic failure; 
PBMCs: peripheral blood mononuclear cells; PCM: poor metabolic control; PD: Parkinson’s disease; PLI: dental plaque index; PN: parenteral nutrition; PUT: putamen; RIA: radioimmunoassay; SI: substantia innominata; SIM: selective ion monitoring; 
SN: substantia nigra; SSP: short sensory profile; T1D: type 1 diabetes; T2DM: type 2 diabetes mellitus; TG: triglycerides; UA: unstable angina; UPLC/MS-MS: ultraperformance liquid chromatography – tandem mass spectrometry; vit: vitamin D; yo: 
years old. 
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5. Urinary mercapturates for biomonitoring in kidney disease 
Based on the previously exposed association of NAT8 and kidney function (Juhanson et 
al., 2008), urinary mercapturates may be used as a hallmark of proximal tubular cells 
capability to detoxify Cys-S-conjugates. As mentioned, this enzyme is highly and almost 
exclusively expressed in proximal tubular cells (Chambers et al., 2010). In addition, 
mercapturates are measured in urine, rendering them feasible for biomonitoring purposes 
(Mathias and Bhymer, 2016; Dias et al., 2017). In fact, urinary mercapturates of several 
xenobiotics have been used for biomonitoring of environmental and occupational 
exposure (Mathias and Bhymer, 2016). Thereby, the generation of mercapturates is 
considered a feature of proximal tubular cells (Hughey et al., 1978; Lash, 2007).  
As mentioned, there are dozens of endogenous compounds undergoing the mercapturate 
pathway (Wang and Ballatori, 1998). There has been an association between 
mercapturates of endogenous compounds and kidney disease. The urinary elimination of 
the mercapturate N-acetyl-LTE4 is increased in inflammatory conditions (Petric and 
Ford-Hutchinson, 1994) and with cyclosporine A treatment (Butterly et al., 2000). 
Moreover, severe nephrotoxicity induced by a high dose of iron nitrilotriacetate increased 
the concentration of mercapturates derived from 4-hydroxynonenal in both plasma and 
kidneys of rats right after 5 hours of administration (Mally et al., 2007). This effect was 
not observed in low doses of iron nitrilotriacetate neither with the administration of 
potassium bromate. Four-hydroxynonenal is a lipid peroxidation product and normal 
constituent of mammalian cell membranes, considered a highly potent reactive species 
that promotes propagation and amplification of the effects elicited by free radicals 
(Ntimbane et al., 2008). 
In fact, several potentially toxic metabolites originated from both endogenous (e.g. 
leukotrienes, prostaglandins, hepoxilin, nitric oxide, hydroxyalkenals, ascorbic acid, 
dihydroxyphenylalanine, dopamine, maleic acid) and exogenous (e.g. drugs, natural 
toxins, environmental pollutants) sources are eliminated from the body after their 
conversion to the corresponding mercapturate (Boyland and Chasseaud, 1969; 
Chasseaud, 1979; Dekant, Vamvakas and Anders, 1989; Stevens and Jones, 1989; 
Hinchman et al., 1991; Hinchman and Ballatori, 1994; Dawn and Ballatori, 1998; 
Hinchman, Rebbeor and Ballatori, 1998; Wang and Ballatori, 1998).  
Changes in the mercapturates of endogenous Cys-S-conjugates have also been reported 
in other inflammatory conditions. For instance, acrolein is a dietary, environmental 
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pollutant and lipid metabolism-derived electrophile associated to diabetic dysmetabolism 
and two of its urinary mercapturates were associated with diabetes and insulin resistance 
(Feroe, Attanasio and Scinicariello, 2016). Urinary acrolein mercapturates are increased 
in diabetic patients and are related to glycemic control parameters, but not with lipid 
metabolism nor albumin to creatinine ratio (Daimon et al., 2003), whereas in Alzheimer’s 
disease patients, its levels were found to be decreased (Tsou et al., 2018). 
Additionally, urinary mercapturates of 4-hydroxynonenal are decreased in patients with 
impaired glucose tolerance (Ntimbane et al., 2008). On the other hand, mercapturates of 
4-hydroxynonenal and 4-oxo-2-nonenal, another lipid peroxidation product, are elevated 
in urine of smokers and decrease significantly following smoking cessation, further 
showing the relevance of mercapturates as markers of in vivo oxidative stress. (Kuiper et 
al., 2010) 
In rats, treatment with bromotrichloromethane, an inducer of lipid peroxidation, increased 
the amount of urinary 1,4-hydroxynonene mercapturic acid, a mercapturate derived from 
4-hydroxynonenal, compared to its normal basal levels (Peiro et al., 2005; Guéraud et al., 
2006). Similarly, increased urinary elimination of several mercapturates derived from 4-
hydroxynonenal and 4-oxo-2-nonenal was observed after treatment of rats with carbon 
tetrachloride, an established animal model of acute oxidative stress (Kuiper et al., 2008). 
The transport of mercapturates for elimination is still a debating issue, but evidence shows 
that the probenecid-sensitive organic anion transport (OAT) system might be involved 
(Inoue, Okajima and Morino, 1981; Burckhardt and Burckhardt, 2003; Burckhardt, 
2012). For instance, intravenous administration of S-benzyl-N-acetyl-L[U-14C] cysteine 
(10 µmol/Kg) in rats lead to a very rapidly decrease in plasma level radioactivity with 
concomitant increase in the renal one. However, after 2 minutes, these levels decreased 
rapidly and a consequent increase of radioactive in the urine was observed (Inoue, 
Okajima and Morino, 1981). More than 98% of the radioactivity in urine was accounted 
for by the intact form of the mercapturate. Both renal accumulation and excretion into 
urine were inhibited by intravenously administration of probenecid (350 µmol/Kg).  
In 2001, Pombrio and colleagues tested the hypothesis that renal clearance of 
mercapturates is partially mediated by the kidney OAT-1 (Pombrio et al., 2001). The 
OAT-1 is highly expressed in the kidney, particularly localized in the basolateral 
membrane of the S2 segment of the renal proximal tubule (Sweet, Miller and Pritchard, 
1999; Tojo et al., 1999), where mercapturates are secreted within the nephron (Stevens 
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and Jones, 1989). Using several N-acetyl-Cys-S-conjugates, the authors proved that these 
compounds are substrates of OAT-1. Once taken up into renal proximal tubular cells, 
mercapturic acids may then be secreted into tubular fluid for excretion in urine. However, 
the exact mechanism of transport across the apical membrane is still to be elucidated. In 
fact, this should have been a top priority in these studies, as evidence shows that the 
majority of the mercapturates of Cys-S-conjugates are formed in vivo within the proximal 
tubular cell due to the almost exclusively expression of NAT8 (Chambers et al., 2010; 
Veiga-da-Cunha et al., 2010). As so, the formed mercapturates require a transporter for 
its urinary elimination at the apical membrane.  
Summarizing, there is evidence on the biomonitoring of mercapturates of endogenous 
compounds in man and its relation to kidney disease and other inflammatory conditions. 
Although there are dozens of endogenous compounds undergoing the mercapturate 
pathway (Wang and Ballatori, 1998), information is still missing such as the contribution 
of each particular mercapturate in kidney disease. The inability of proximal tubular cells 
to detoxify Cys-S-conjugates, through NAT8 activity, might perpetuate injury. This 
dysfunction in proximal tubular cell activity can be monitored through the quantification 
of mercapturates of Cys-S-conjugates in urine. A better understanding of the impairment 
on the mercapturate pathway triggering kidney dysfunction may help to find out new 
therapeutic approaches and strategies for early prediction and biomonitoring of disease. 
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RATIONALE & HYPOTHESIS 
The general aim was to discover a bioindicator of progression of kidney disease. This is 
relevant because kidney disease impacts global morbidity and mortality by increasing the 
risk associated with major killers including diabetes, hypertension and HIV-infection 
(Kassebaum et al., 2016; Wang et al., 2016). Moreover, the renal injury acquired in the 
hospital setting by contrast agents, drugs and sepsis (Feehally, 2016; Ozkok and Ozkok, 
2017) is also a serious health problem and a heavy weight in the global burden of kidney 
disease. Importantly, as the proximal tubule is considered to be the primary sensor and 
effector in the progression of both AKI and CKD, the study of specific pathways of 
proximal tubular cells might shed a light on the critical issue that kidney disease 
represents today. 
For that and based on the literature, we merged genes that were reported to be highly 
expressed in kidney proximal tubular cells, associated to kidney function through 
genome-wide association studies and related to detoxification pathways. It is known that 
genes contributing to normal fetal renal programming and kidney function in adult life 
have been signalized in the etiology of kidney disease (Zandi-Nejad, Luyckx and Brenner, 
2006). This motivated a targeted-screening of genes involved in renal metabolic pathways 
(Samani, 2003; Chambers et al., 2010) that allowed the identification NAT8 (Juhanson 
et al., 2008).The knowledge on NAT8 actions has been hampered by its late association 
to both disease (Juhanson et al., 2008) and the mercapturate pathway (Juhanson et al., 
2008; Chambers et al., 2010; Veiga-da-Cunha et al., 2010). Moreover, there are no 
available pharmacological tools to manipulate NAT8 levels that together with reported 
difficulties in generating a viable NAT8 knock-out model in rat (Fu et al., 2014) further 
contribute for this gap on the knowledge. However, it is now recognized that NAT8 is 
almost exclusively expressed in kidney proximal tubular cells (Ozaki et al., 1998; 
Chambers et al., 2010) and has been implicated in: 
§ protection against elevated systolic blood pressure and kidney failure in 
hypertensive patients (Juhanson et al., 2008); 
§ development and maintenance of kidney’s structure, function (Ozaki et al., 
1998) and detoxification pathways (Lock et al., 2006; Veiga-da-Cunha et al., 
2010; Deol and Josephy, 2017); 
§ adaptive response after electrophilic-stress-related injury of renal tubular cell  
(Fu et al., 2014) and hepatocyte (Liu and Pravia, 2010; Omata et al., 2016) 
characterized by an increase on the expression of the enzyme. 
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A hypothesis-oriented investigation is herein presented, underlying that NAT8 activity is 
related to kidney disease in inflammatory conditions because it controls the balance of 
Cys-S-conjugates. Upon oxidative/inflammatory injury exposure, Cys-S-conjugates are 
generated as part of an adaptive response and their concentration are controlled by NAT8 
activity mainly in kidney proximal tubular cells. The exposure to environmental noxious 
factors (nephrotoxicants) that undergo the mercapturate pathway or endogenous Cys-S-
conjugates generated upon injury might lead to a misbalance of the detoxification of these 
conjugates and promote kidney disease progression. As a consequence, Cys-S-conjugates 
will be retained in the course of renal dysfunction and impact multiple organ and systems. 
This occurs in a temporal and dose dependent manner. Urinary products of NAT8 activity 
in proximal tubular cells (the mercapturates of Cys-S-conjugates) might be indicators of 
kidney tubule function. This is a never addressed concept that has a rationale strongly 
supported by literature data: 
§ the clearance of Cys-S-conjugates is controlled by NAT8 activity which protects 
against elevated systolic blood pressure and kidney failure in hypertensive 
patients (Juhanson et al., 2008); 
§ there are dozens of endogenous Cys-S-conjugates described with relation to 
common features of inflammatory conditions including oxidative stress, 
inflammation and activation of sympathetic nervous system. Examples include 
Cys-S-conjugates of catecholamines, prostaglandins, leukotrienes or steroids 
(Wang and Ballatori, 1998; Gonçalves-Dias et al., 2019); 
§ Cys-S-conjugates are stable metabolites that can be measured in biological fluids 
and can slowly accumulate over time (Kanaoka and Boyce, 2014); 
§ Cys-S-conjugates have been associated to several actions including 
vasoconstriction (Rosenthal and Pace-Asciak, 1983; Badr, Brenner and 
Ichikawa, 1987; Shastri et al., 2001), cytotoxicity (Townsend et al., 2003; Stern, 
Bruno, Hennig, et al., 2005; Stern, Bruno, Horton, et al., 2005; Dvash et al., 
2015), inflammation and immunogenicity (Salauze et al., 2005). 
 
Endogenous Cys-S-conjugates that accumulate can circulate because the Cys-S-conjugate 
has higher half-life than the prior compounds and they are associated with different 
inflammatory chronic conditions (as reviewed in Table 1). Nevertheless, these 
compounds have in common the detoxification by the proximal tubular cells as 
mercapturates that might motivate tubulocentric perspectives for multiple inflammatory 
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conditions, such the one recently reported by us regarding diabetic kidney disease 
(Gonçalves-Dias et al., 2019). A short preview of the article is herein presented, with the 
mechanistic hypothesis shown in Figure 5. 
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Abstract 
Background: The recent growing evidence that the proximal tubule underlies the early 
pathogenesis of DKD is unveiling novel and promising perspectives. This 
pathophysiological concept links tubulointerstitial oxidative stress, inflammation, 
hypoxia, and fibrosis with the progression of DKD. In this new angle for DKD, the 
prevailing molecular mechanisms on proximal tubular cells emerge as an innovative 
opportunity for prevention and management of DKD as well as to improve diabetic 
dysmetabolism. 
Summary: The mercapturate pathway is a classical metabolic detoxification route for 
xenobiotics that is emerging as an integrative circuitry detrimental to resolve tubular 
inflammation caused by endogenous electrophilic species. Herein we review why and 
how it might underlie DKD.  
Key Messages: The mercapturate pathway is a hallmark of proximal tubular cell function, 
and cysteine-S-conjugates might represent targets for early intervention in DKD. 
Moreover, the biomonitoring of urinary mercapturates from metabolic inflammation 
products might be relevant for the implementation of preventive/management strategies 
in DKD. 
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Summary and Perspectives in Mercapturate Involvement in DKD 
The inability of proximal tubular cells to detoxify Cys-S-conjugates, through NAT8 
activity, might perpetuate metabolic inflammation and dysmetabolism and supports that 
the mercapturate pathway underlies the tubulocentric perspective of DKD. This 
dysfunction in proximal tubular cell activity can be monitored through the quantification 
of mercapturates of Cys-S-conjugates in urine. 
A better understanding of the mercapturate pathway impairment triggering early DKD is 
necessary. Such knowledge may help to find out new therapeutic approaches and 
strategies for early prediction and biomonitoring of DKD.  
 
Figure 5 – Mechanistic hypothesis of MAP role in the tubulocentric view of diabetic kidney disease (DKD) billed 
up on literature review herein presented. (a) GSH-S-conjugates (GSH-X) of electrophiles increase in inflammatory 
conditions in both immune and nonimmune cells, (b) being excreted into the bloodstream and have a short half-life due 
to its rapid (c) metabolization at the external apical membrane of proximal tubular cells. The generated cysteine-S-
conjugate (Cys-X) may have one of 3 fates. (d) They may be detoxified by N-acetyltransferase 8 (NAT8), generating 
mercapturates that are eliminated in urine, (e) they may be bioactivated to highly cytotoxic species or (f) they may be 
reabsorbed into the bloodstream, (g) perpetuating metabolic inflammatory processes and DKD progression (Gonçalves-
Dias et al., 2019).  
Cys-X: cysteine-S-conjugate; DKD: diabetic kidney disease; GSH-X: glutathione-S-conjugate; HNE: 4-hydroxynonenal; NAT8: N-
acetyltransferase 8. 
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GENERAL and SPECIFIC AIMS 
The general aim was to discover a bioindicator of progression of tubular kidney disease 
and contribute to the knowledge of NAT8 function in the mechanisms underlying kidney 
tubular dysfunction with different etiologies.  
The current work is focused on the evaluation of renal handling of the endogenous Cys-
S-conjugates that are disulfides (CysSSX).  
Specifically, this work intended to: 
§ develop and validate a phenotyping method for NAT8 activity (Chapter I); 
§ quantify the renal tubular detoxification of CysSSX in animal models of drug-
induced AKI, comparing drugs that undergo the mercapturate pathway (CISP) 
and those that do not (G) (Chapter II); 
§ investigate the effect of antiretroviral drugs on the excretion of mercapturates of 
CysSSX in HIV-infection and other factors of variability for CysSSX 
detoxification as well as prospectively evaluate changes in the detoxification of 
CysSSX with the progression of kidney disease (Chapter III); 
§ investigate Cys availability and dynamics and the temporal variation of 
mercapturates of CysSSX in two animal models of pre-diabetes (Chapter IV) 
and a model of hypertension (Chapter V). 
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CHAPTER I 
A mechanistic-based approach to non-invasively quantify the kidney ability to 
detoxify cysteine-disulfides 
 
I.1. Rationale & Objectives 
The first specific objective of our work was to develop a method that would allow us to 
phenotype the activity of NAT8. We focused on CysSSX as evidence shows that, 
similarly to the Cys-S-conjugates which are thioethers rather than disulfides (CysSCX), 
CysSSX might be detoxified by the action of NAT8 (Deol and Josephy, 2017). Thus, we 
hypothesized that the quantification of mercapturates of CysSSX will be indicative of the 
capability of kidney to detoxify CysSSX and NAT8 activity. The contribution of CysSSX 
for disulfide stress signaling and its effects in kidney are still to be unveiled, but it might 
contribute to an adaptive response to an acute insult (Moreno et al., 2014; Coelho et al., 
2018). Our general aim was to find out a strategy to non-invasively measure tubular 
disulfide stress in kidney. Thereby, we developed a method to quantify mercapturates of 
CysSSX (N-acetyl-CysSSX) in urine samples (Figure I.1) and we applied it to evaluate 
the capability of kidney to detoxify CysSSX in rodents, volunteers and patients after an 
episode of AKI.
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Figure I.1 – Rationale for method development. Cysteine-disulfides (CysSSX) are detoxified by N-acetyltransferase 8 (NAT8) forming mercapturates (N-acetyl-CysSSX) that are eliminated in 
urine. The developed method was able to quantify urinary mercapturates of cysteine-disulfides, using uNAC as a surrogate. The method takes advantage of a reducing agent that selectively reduces 
disulfide bonds followed by derivatization with a selective fluorescent reagent for thiol groups. uNAC can then be monitored through fluorescence detection in a high-performance liquid 
chromatography system (HPLC-FD). This strategy allowed the quantification of both reduced cysteine and oxidized cysteine-disulfides. For the measurement of the free NAC, the same protocol 
is followed, although with no addition of the reducing agent, allowing the derivatization of only the naturally free NAC.  
CoA: coenzyme A; Cys: cysteine; CysSSX: cysteine-disulfides; HCys: homocysteine; HPLC-FD: high-performance liquid chromatography with fluorescence detection; NAC: N-acetylcysteine; N-acetyl-CysSSX: 
mercapturates of cysteine-disulfides; NAT8: N-acetyltransferase 8; uNAC: urinary surrogate of mercapturates from cysteine-disulfides.
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I.2. Methods 
I.2.1. Method development  
The formation of  CysSSX occurs through a disulfide bond between Cys with other LMW 
thiol-containing molecule, including GSH, Cys, CoA or HCys yielding CysSSG, 
CysSSCys, CysSSCoA and CysSSHCys, respectively (Wang and Ballatori, 1998; 
Moreno et al., 2014; Coelho et al., 2018). 
Our strategy, aimed to evaluate the capability of kidney to detoxify CysSSX and to 
address renal disulfide stress, was based on three basic premises: a) insult-triggered 
disulfide stress in kidney increases CysSSX formation (Coelho et al., 2018); b) Cys-S-
conjugates are acetylated by NAT8 activity and are eliminated in urine as mercapturates 
(Veiga-da-Cunha et al., 2010; Deol and Josephy, 2017); and c) NAT8 is almost 
exclusively expressed in kidney and is related to kidney function (Juhanson et al., 2008; 
Chambers et al., 2010; Veiga-da-Cunha et al., 2010). This encouraged us to develop a 
method to quantify urinary mercapturates of CysSSX (N-acetyl-CysSSX) (Figure I.1).  
For that, we used a reducing agent, tris(2-carboxyethylphosphine) (TCEP), that allows 
the selective reduction of disulfide bonds, converting the oxidized form to the 
corresponding reduced thiol, i.e. N-acetylcysteine (Figure I.1) (Burns et al., 1991). We 
named as uNAC the N-acetylcysteine moiety formed upon reduction of urinary N-acetyl-
CysSSX and we used it as a surrogate of N-acetyl-CysSSX (Figure I.1). By using a 
fluorescent reagent selective for thiol groups, 7-fluorobenzofurazan-4-sulfonic acid 
ammonium salt (SBD-F) (Imai, Toyo’oka and Watanabe, 1983), uNAC can be quantified 
through fluorescence detection (FD), affording high sensitivity to the method (Grilo et 
al., 2017). The coupled chromatographic step allows the separation of uNAC from the 
other endogenous thiols such as cysteine-glycine (CysGly), GSH, Cys, CoA, cysteamine 
and HCys (sections I.2.2.3. and I.2.2.4.).  
We have evaluated the ability of the method to distinguish uNAC from NAC in urine 
(section I.2.3.7.). Moreover, we ascertain that the uNAC that is being quantified is a 
surrogate of N-acetyl-CysSSX that is excreted from renal tubular cells and not from other 
cells further undergoing glomerular filtration. To this end, we quantified the levels of 
uNAC in serum samples from volunteers, following the protocols described in sections 
I.2.2.3. and I.2.2.4. (Figure I.1). The levels of free NAC were also quantified, employing 
the protocol described in section I.2.3.7. (Figure I.1). Actually, if uNAC formed at the 
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hepatocytes is excreted in bile and not in plasma with subsequent filtration by the 
glomerulus, the levels of uNAC would not be detectable in serum samples.  
Serum samples were collected from volunteers with normal kidney function, as confirmed 
by a glomerular filtration rate higher than 90 mL/min/1.73m2.  
 
I.2.2 Method description  
I.2.2.1. Chemicals 
High-performance liquid chromatography (HPLC)-grade solvents were purchased from 
VWR (Belgium). All reagents were purchased from Sigma-Aldrich (USA), except for 
trichloroacetic acid (TCA), which was purchased from Roth (Germany). 
 
I.2.2.2. Stock and calibration solutions 
Calibration solutions (CS) were prepared from successive dilutions in phosphate buffered 
saline (PBS 1x) to obtain eight different concentrations of NAC, namely, 2.1875, 6.25, 
12.5, 18.75, 25, 150, 400 and 600 µM.  
 
I.2.2.3. Reduction and derivatization 
An initial volume of 50 µL of each CS, quality control solution (QC) or sample were 
treated with TCEP (100 g/L, 5 µL) in reverse osmosis water for reduction of disulfide 
bonds. After an incubation period of 30 min at room temperature (RT), proteins were 
precipitated by mixing with 45 µL of TCA (100 g/L) in 1 mM ethylenediaminetetraacetic 
acid (EDTA). The mixture was then centrifuged (13,000 g, 10 min, 4 ˚C) and the 
supernatant collected into a new tube containing 5 µL of 1.55 M sodium hydroxide, 62.5 
µL of 125 mM sodium tetraborate buffer (pH 9.5) with 4 mM EDTA, and 25 µL of SBD-
F (1 g/L) prepared in the same buffer. The final mixture was vortexed and incubated in 
the dark, at 60 °C for 1 h, to complete derivatization of free sulfhydryl groups. 
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I.2.2.4. Chromatographic conditions  
The solutions prepared as described in section 2.2.3. were analyzed by HPLC-FD on a 
Shimadzu LC-10AD VP (Shimadzu Scientific Instruments Inc) system, using a reversed-
phase C18 LiChroCART 250x4 column (LiChrospher 100 RP-18, 5µm, VWR, USA), at 
29 °C, as previously described (Nolin, McMenamin and Himmelfarb, 2007; Grilo et al., 
2017). The detector was set at excitation and emission wavelengths of 385 and 515 nm, 
respectively. The mobile phase consisted of 100 mM acetate buffer (pH 4.5) and methanol 
(MeOH) [99:1 (v/v)]. The analytes were separated in an isocratic elution mode, at a flow 
rate of 0.8 mL/min for 20 min.  
 
I.2.3. Method validation  
The validation criteria were defined according to standard procedures for bioanalytical 
methods (European Medicines Agency, 2012). For this purpose, the criteria assessed 
included linearity, lower limit of quantification (LLOQ), higher limit of quantification 
(HLOQ), and four QC samples were prepared to obtain concentrations independently 
from CS. Selectivity, carry-over effect, accuracy, intra- and inter-assay precision and 
stability after freezing cycles were also evaluated.  
 
I.2.3.1. Selectivity and carry-over effect. 
Blank samples of PBS, MeOH or mobile phase were prepared as described in section 
2.2.3. The carry-over effect was studied by preparing and injecting into the HPLC system 
three blank samples of PBS after the analysis of the highest CS sample.    
 
I.2.3.2 Linearity 
Three calibration curves were prepared from different stock solutions. Each calibration 
curve contained eight CSs ranging from 2.1875 to 600 µM of NAC (namely, 2.1875, 6.25, 
12.5, 18.75, 25, 150, 400 and 600 µM). Linearity was assessed by plotting the curves by 
linear regression of the chromatographic peak area (mAU*min) as a function of NAC 
concentration (µM). The average back-calculated concentrations were also assessed. The 
slopes and Y-intercept of the curves were compared in order to access reproducibility. 
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I.2.3.3. Lower and higher limits of quantification 
The LLOQ was defined as the lowest concentration of NAC that could be quantified with 
acceptable accuracy and precision. For this, six samples with a concentration of 2.1875 
µM were analyzed for the accuracy and the intra- and inter-assay precisions. Additionally, 
the same was performed for the validation of the HLOQ.  
 
I.2.3.4. Accuracy 
Accuracy was defined as the closeness to the theoretical concentration of the QC samples. 
To study the accuracy of the method, six samples from the LLOQ and the HLOQ, as well 
as four QC samples with concentrations within the established concentration range (QC1 
= 3.125 µM; QC2 = 9.375 µM; QC3 = 50 µM and QC4 = 300 µM) were analyzed. The 
accuracy of the method was calculated as the ratio between the measured and theoretical 
concentrations, expressed in percentage.   
 
I.2.3.5. Intra- and inter-assay precision 
The precision of the method was defined as the closeness between multiple measures. 
Intra- and inter-assay precision were assessed by analysis of six samples of LLOQ, HLOQ 
and QC. While intra-assay precision was assessed by the coefficient of variation (CV) 
obtained from analytical runs on the same day, the inter-assay precision was evaluated 
using the CV obtained on different days. The calculation of the precision was performed 
assuming that its value would ideally be 100%, subtracting the obtained CV.  
 
I.2.3.6. Stability and storage conditions 
Stability tests were carried out to ensure that the concentration of uNAC is not affected 
during sample preparation, sample analysis or even during storage. To this end, urine 
samples from volunteers were collected to a) readily quantify uNAC; b) store at RT for 2 
h and for 6 h; c) store at 4 °C for 2 h and for 6 h; and d) store at -80 °C and unfreeze. The 
stability was also investigated in samples stored at -80 °C for 1, 6 and 12 months after 
collection. 
Chapter I 
 59 
I.2.3.7. Quantification of uNAC vs. free NAC 
The ability to differentiate uNAC from free NAC in urine was also evaluated (Figure 
I.1). Thiols might be present in urine in different fractions, the protein-bound and the 
unbound/free fractions, which includes disulfides and free reduced forms (Grilo et al., 
2017; Sutton et al., 2018).  
To measure each fraction, we adapted the protocol previously described (Grilo et al., 
2017) (Figure I.1). The sum of all fractions corresponds to the total urinary NAC content, 
herein called uNAC. To quantify free NAC that do not require the reducing step, as it is 
present in its reduced sulfhydryl form, freshly collected urine samples from volunteers, 
referred in section 2.1, were firs submitted to protein precipitation with TCA, followed 
by centrifugation (13,000 g, 10 min, at 4 °C). Then, samples were incubated with reverse 
osmosis water for 30 min at RT. The use of reverse osmosis water instead of the reducing 
agent TCEP allows the posterior derivatization exclusively of the naturally free NAC 
(Figure I.1), following the protocol described in section I.2.2.3. For quantification of 
uNAC, a surrogate of mercapturates derived from CysSSX, samples from the same 
volunteers were analyzed by performing the protocol described in I.2.2.3. 
 
I.2.4. Method applicability 
I.2.4.1. uNAC in urine of rats and mice  
Experiments were performed using male Wistar Crl:WI (Han) and male C57BL/6 mice 
obtained from the NOVA Medical School rodent facility. Animals were housed in 
polycarbonate cages with wire lids and maintained under standard laboratory conditions 
as follows: artificial 12 h light/dark cycles at RT. Animals were maintained on a standard 
laboratory diet (SDS diets RM1 for rats and RM3 for mice, Special Diets Services) and 
reverse osmosis water, both ab libitum. While the RM1 diet has 2.2 g/Kg of methionine 
and 2.4 g/Kg of CysSSCys, the RM3 diet has 3.6 g/Kg of methionine and 3.5 g/Kg of 
CysSSCys. Urine samples were collected at different time-points. Animals were specific-
pathogen-free according to Federation for Laboratory Animal Science Associations 
(FELASA) recommendations (Mähler et al., 2014). All applicable institutional and 
governmental regulations concerning the ethical use of animals were followed, according 
to the NIH Principles of Laboratory Animal Care (NIH Publication 85 23, revised 1985), 
the European guidelines for the protection of animals used for scientific purposes 
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(European Union Directive 2016/63/EU) and the Portuguese Law nº 113/2013. The 
experimental procedures received prior approval by the Institutional Ethics Committee of 
the NOVA Medical School for animal care and use in research (protocol nº 
15/2017/CEFCM) for rats and Portuguese Directorate-General for Food and Veterinary 
that regulates the animal care and use in research (protocol nº 0421/000/000/2017) for 
mice. 
The levels of uNAC were obtained using the procedure described in section I.2.2.3 and 
I.2.2.4. 
 
I.2.4.2. uNAC in patients with kidney disease 
To obtain a proof-of-principle of the impact of kidney dysfunction in uNAC, its levels 
were quantified in urine samples from patients after an episode of AKI employing the 
same procedure described in sections I.2.2.3. and I.2.2.4. The levels of uNAC were then 
compared with the levels obtained in urine samples from volunteers (quantified in section 
I.2.3.7.). 
 
I.2.5. Statistical analysis 
Statistical analysis was performed using GraphPad Prism® version 5.0 (GraphPad 
Software Inc., San Diego, CA, USA). Data are presented in percentage, mean ± standard 
error of the mean (SEM) or mean ± standard deviation (SD) or median ± interquartile 
range (IQR), whenever applicable. Variability among data is expressed in CV. The F-test 
was used to explore differences between the slopes and elevations of the calibration 
curves and to ascertain the influence of the concentrations on the chromatographic signal 
area. Comparisons among groups were performed using paired t-test, unpaired t-test or 
one-way ANOVA, whenever applicable. Significance was set at p < 0.05. 
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I.3. Results & Discussion 
I.3.1. Method development 
To establish if uNAC can be used as a surrogate of CysSSX excreted by kidney tubular 
cells, by the action of NAT8, serum samples from five volunteers (median [IQR] age of 
39 [28-54] years old, 60% men, all Caucasian) were submitted to the protocol, described 
in sections I.2.2.3. and I.2.3.7. for quantification of uNAC and free NAC, respectively. 
Neither uNAC nor free NAC were found in all serum samples tested (Figure I.2). This 
suggests that uNAC is a marker of N-acetylation of CysSSX in the kidney. It is known 
that cysteine-S-conjugates are acetylated by NAT8 which is predominantly expressed in 
human kidney tubular cells, being also present in substantially lower levels in hepatocytes 
(Chambers et al., 2010). The absence of uNAC in serum might indicate that either the 
mercapturates from the liver are formed in small amounts and/or they are excreted into 
the bile and thus not found in circulation. As such, uNAC present in urine, i.e. the N-
acetyl-CysSSX, are not derived from the glomerular filtrate but rather from tubular cells 
where the expression of NAT8 is the highest (Chambers et al., 2010).  
 
Figure I.2 – Representative chromatograms of NAC (black arrow). No uNAC or free NAC were detected in serum 
samples. In black, a chromatogram for calibration solution; In pink, uNAC (oxidized + reduced + protein-bound 
fractions) and in blue, free NAC fraction in a serum sample of a volunteer. 
 
The methodology used is able to measure the total fraction of mercapturates from CysSSX 
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cysteinylation by NAT8 has never been described in literature. Nonetheless, as CysSSP, 
i.e. the formation of a disulfide bond between a free Cys and a Cys residue in proteins, 
was described in kidney (Coelho et al., 2018), these conjugates will be plausible 
substrates of NAT8. Nevertheless, since urine from healthy kidneys is not enriched in 
proteins, we have not addressed this topic in this work. This can be easily performed by 
promoting protein precipitation prior to the reducing step and should be evaluated in 
models of kidney disease.  
Free NAC was also not expected to be observed, taking into consideration previous 
reports showing that free NAC levels are only detectable in serum or plasma samples after 
oral administration of the drug N-acetylcysteine (Tsikas et al., 1998). 
In fact, the acetylation of Cys in the kidney seems to be the only process whereby 
endogenous NAC is produced. This explains the fact that NAC can only be found in urine 
but not in plasma (Hannested and Sörbo, 1979). Therefore, the obtained results support 
that the approach herein employed is able to distinguish N-acetyl-CysSSX formed in 
tubular cells from those formed in hepatocytes, by measuring uNAC in urine. 
 
I.3.2. Method description 
I.3.2.1. Optimization of reduction and derivatization steps 
The general approach for the quantification of thiols initially requires the generation of 
free thiols from disulfides, a process accomplished by the use of a reducing agent such as 
TCEP (Burns et al., 1991). This step is required for quantification of the total and of the 
oxidized fractions of thiols (free and protein-bound, as this is the only way for the 
sulfhydryl groups to be available for subsequent derivatization). Other authors have taken 
advantage of the properties conferred by TCEP (Kuśmierek and Bald, 2008), while the 
quantification was performed in a reversed-phase ion-pair liquid chromatography with 
ultraviolet (UV) absorption at 355 nm. Herein, we employed FD to minimize the 
interferences from other biological substances characteristic of absorption methods, 
especially in the UV range (Peng et al., 2012). 
On the other hand, thiols have physicochemical properties, including high polarity and 
water-solubility, that renders their extraction from biological matrices nearly impossible 
without a derivatization process (Kuśmierek et al., 2009). As thiols are not spontaneously 
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fluorescent (Jakubowski and Głowacki, 2011), this step needs to be performed with a 
fluorescent probe that selectively reacts with the free sulfhydryl group of the thiol in order 
to generate a derivative that is strongly fluorescent, hence enabling a highly sensitive and 
precise measurement (Imai, Toyo’oka and Watanabe, 1983; Kuśmierek et al., 2009).  
Taking advantage of a previously reported method (Grilo et al., 2017), we added NAC to 
the analytical run and were able to reduce the initial volumes of samples, CS and reagents 
to half of those previously employed without any changes in the chromatographic peak 
area. 
 
I.3.2.2. Optimization of chromatographic conditions 
The development of this methodology required the optimization of several 
chromatographic conditions namely a) mobile phase – isocratic elution using different 
concentrations of acetate buffer with MeOH in several proportions; b) stationary phase – 
two C18 columns of different lengths were tested (LiChroCART 125-4 and C18 
LiChroCART 250x4) with different temperatures (from 23 to 35 °C) and c) flow rate – 
0.6 and 0.8 mL/min were tested. As far as we know, this is the first method specifically 
developed with the goal of quantifying the mercapturates of CysSSX. 
Using an isocratic elution with 1% MeOH in 100 mM acetate buffer (pH 4.5) on a C18 
LiChroCART 250x4 column at 29 °C, the chromatographic peak of NAC eluted at 16.5 
min, totally separated from the retention time of the remaining thiols (Cys: 5.9 min, HCys: 
8.1 min; CysGly: 10.0 min; cysteamine: 10.5 min CoA: 11.8 min and GSH: 13.1 min).  
A few methods have been developed for pharmacokinetics studies of the drug N-
acetylcysteine that would also allow the quantification of uNAC, even though laborious, 
require high amounts of sample and employ other reducing and labelling agents 
(Hannested and Sörbo, 1979; Ventura et al., 1999; Kuśmierek and Bald, 2008). However, 
it is important to highlight that these methods were not developed to investigate N-acetyl-
CysSSX nor its potential as non-invasive indicators of renal injury. One of the plausible 
reasons to explain the absence of studies investigating the meaning of altered levels of N-
acetyl-CysSSX in urine might be the lack of information regarding NAT8 and disulfide 
stress, that is recent as is their relation with renal function (Juhanson et al., 2008; 
Chambers et al., 2010; Veiga-da-Cunha et al., 2010; Moreno et al., 2014; Coelho et al., 
2018).  
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The novelty of our approach is based on the association between disulfide stress and 
increased CysSSX with NAT8 activity and their detoxification as mercapturates. This is, 
in fact, the first report aiming at the quantification of uNAC as a surrogate of the urinary 
mercapturates derived from CysSSX and that provides first-hand evidence that its 
formation occurs in the kidney. 
 
I.3.3. Method validation 
I.3.3.1. Selectivity and carry-over effect 
The injection of blank samples of PBS, MeOH or mobile phase (100 mM acetate buffer 
(pH 4.5) and MeOH [99:1 (v/v)]) showed no interference with uNAC. Additionally, the 
injection of three blank samples after the higher CS (600 µM) showed no carry-over 
effect.  
 
I.3.3.2. Linearity 
Linearity was assessed using three calibration curves containing eight CSs ranging from 
2.1875 to 600 µM of NAC. Linear regression proved to be the most suitable model for 
fitting the experimental data (Runs Test, p > 0.05). The concentration of the standard 
samples significantly influenced the chromatographic signal area (F test p < 0.001). 
Additionally, no differences were found between the slopes and elevations of the 
calibration curves. The correlation coefficients, r2, of the calibration curves were >0.99, 
showing a good adjustment of all calibration curves. The 95% confidence interval for the 
intercept contained zero, indicating that the concentration of the CSs was the only factor 
with significant influence on the chromatographic peak area.  
The observed back-calculated values were close to the expected ones at each tested 
concentration. The CVs were lower than 13% for higher and lower limits and 12% for the 
remaining standards. 
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I.3.3.3. Lower and higher limits of quantification 
The LLOQ was set at 2.1875 µM, and the CV of multiple measurements was 5%. 
Although concentrations lower than 2.1875 µM were also tested, the chromatographic 
peaks were not distinguishable from background noise. This LLOQ allows the 
quantification of NAC at urinary levels reported (Mårtensson and Hermansson, 1984). 
The HLOQ was defined at 600 µM, with CV of several measures lower than 12%. The 
accuracy and intra- and inter-assay precisions of LLOQ and HLOQ are presented in Table 
I.1. 
Table I.1 – Mean accuracy, intra- and inter-assay precision of the method. 
Sample 
(µM) 
Accuracy 
(%) 
Intra-assay 
precision (%) 
Inter-assay 
precision (%) 
LLOQ 
(2.1875) 96 96 95 
QC1 
(3.125) 98 95 96 
QC2 
(9.375) 104 97 95 
QC3 
(50) 105 98 98 
QC4 
(300) 110 96 98 
HLOQ 
(600) 102 97 88 
HLOQ: higher limit of quantification; LLOQ: lower limit of quantification; QC: quality control solution 
 
I.3.3.4. Accuracy 
The accuracy ranged from 87 to 114% for LLOQ and HLOQ and from 102 to 112% for 
QC samples (Table I.1).  
 
I.3.3.5. Intra- and inter-assay precision  
The intra-assay precision was 96% and 97% for LLOQ and HLOQ, respectively, and 95-
98% for the remaining QCs. As for the inter-assay precision, the obtained values were 88 
and 95% for the LLOQ and HLOQ and 95-98% for the QCs (Table I.1). The obtained 
results further support the use of this method to quantify with accuracy and precision the 
levels of uNAC in biological samples. 
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I.3.3.6. Stability and storage conditions 
The variations in uNAC levels in urine samples subjected to different storage conditions 
are presented in Table I.2. No significant differences were found in uNAC concentrations 
obtained for all samples from the same volunteer under the several tested conditions.  
Table I. 2– Stability of uNAC in urine samples from volunteers subjected to different storage conditions. 
 Condition 
Temperature RT 4 °C -80 °C 
Time 2 h 6 h 2 h 6 h 24 h 1 m 6 m 12 m 
uNAC a (%) 104 ± 5 107 ± 5 98 ± 4 113 ± 3 109 ± 4 117 ± 5 106 ± 6 97 ± 6 
a Mean ± SEM; uNAC expressed as % of values quantified readily after collection; h: hour; m: month; RT: room 
temperature; uNAC: urinary surrogate of mercapturates from cysteine-disulfides 
 
The presented results are particularly important for clinical studies, where the logistics of 
sample procurement, its storage, lifecycle and delivery to the laboratory are often difficult 
to manage. Similarly to mercapturates of endogenous CysSSX, the levels of several 
mercapturates derived from both endogenous (e.g. acrolein, 4-hydroxy-2-nonenal) and 
exogenous substances (e.g. flupirtine, 1-vinyl-2-pyrrolidones, thioTEPA, acrylamide, 
acrylonitrile, benzene, 1,3-butadiene, crotonaldehyde, ethylene, ethylene oxide, N,N-
dimethylformamide, vinyl chloride, propylene oxide, styrene, toluene, propylene oxide) 
were found to be fairly stable when subjected to different storage conditions or several 
freeze-thaw cycles (Alary et al., 1998; Van Maanen and Beijnen, 1999; Schettgen, Musiol 
and Kraus, 2008; Cosnier et al., 2012; Pluym et al., 2015; Scheuch et al., 2015; Bertram, 
Schettgen and Kraus, 2016).    
 
I.3.3.7. Quantification of uNAC vs. free NAC 
Urinary levels of uNAC (58 [44-69] µM) were higher than free NAC (9 [8-13] µM) 
(Paired t-test, p = 0.001). The levels of free NAC represent 13-24% of uNAC (Table I.3).  
Table I.3 – Quantification of uNAC vs. free NAC in urine samples from volunteers. 
Sample Age Sex uNAC 
(µM) 
free NAC 
(µM) 
free NAC 
(% of uNAC) 
1 27 F 67 12 18 
2 29 M 70 14 20 
3 68 M 33 8 24 
4 39 F 58 9 16 
5 39 M 54 7 13 
F: female; M: male; uNAC: urinary surrogate of mercapturates from cysteine-disulfides; NAC: N-acetylcysteine 
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The presence of endogenous free NAC in urine samples was already reported in 
volunteers (Hannested and Sörbo, 1979). Free NAC levels in urine varied from 3 to 7 µM 
and represented 18-26% of uNAC, results that are in accordance with our findings. In 
fact, the acetylation of Cys in the kidney seems to be the only process whereby 
endogenous free NAC is present in urine (Hannested and Sörbo, 1979), although this 
represent a small contribution to uNAC. The presence of free NAC in urine has been also 
described as a result of oral administration of NAC (Shih and Schulman, 1969). 
Our results support the hypothesis that CysSSX might undergo acetylation by NAT8, 
forming mercapturates that are eliminated in urine. uNAC can hence be used as a 
surrogate of these mercapturates and the difference between free NAC and uNAC results 
from this acetylation step.  
 
I.3.4. Method applicability 
I.3.4.1. uNAC in urine of rats and mice  
The levels of uNAC were quantified in urine samples from rat (n=13 male rats, 12 weeks 
of age, mean ± SD body weight, BW, 303 ± 28 g) and mouse (n=13 male mice, 5 weeks 
of age, 19 ± 2 g BW). There were no temporal differences in uNAC levels for both species 
(Figure I.3). uNAC levels found in both rat and mouse samples are higher than the ones 
quantified in human samples. These results might indicate that there are species 
differences regarding the elimination of uNAC and hence the mercapturate pathway. In 
fact, rat livers dosed with l-chloro-2,4-dinitrobenzen excreted lower amounts of its 
mercapturate and higher quantity of the GSH-conjugate in bile whereas the opposite was 
found in guinea pig livers (Hinchman et al., 1991). On the other hand, the metabolism of 
acrylamide in humans is apparently more prone for GSH conjugation rather than 
conversion to glycidamide when compared with rats and mice (Li et al., 2016). 
Differences on the expression of the enzymes of the mercapturate pathway have also been 
reported. For instance, rats and mice have very low hepatic but very high renal activities 
of GGT in comparison with guinea pig, pig, macaque monkey and man (Hinchman and 
Ballatori, 1990). Species differences were also found for dipeptidases activity, although 
in a lower magnitude than the one observed for GGT (Hinchman and Ballatori, 1990). 
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Figure I.3 – Temporal variation of uNAC in urine samples from rats (A) and mice (B).  The intra-individual 
variability in uNAC levels was low in control conditions for both species (n= 5 to 13 per week).  
uNAC: urinary surrogate of mercapturates from cysteine-disulfides. 
 
I.3.4.2. uNAC in patients with kidney disease 
uNAC levels were quantified in four patients after an episode of AKI. Anthropometric 
and clinical data are presented in Table I.4. Lower levels of uNAC were found in urine 
of patients after an episode of AKI (23 [16-41] µM) in comparison with volunteers (58 
[44-69] µM) (Unpaired t-test, p = 0.016). All AKI patients progressed to chronic kidney 
disease. These findings support that uNAC might represent an added value for the 
diagnosis and monitoring of kidney tubular injury. Nevertheless, an increase in uNAC in 
this setting was expected as an adaptive mechanism. However, these results require 
further elucidation, as the samples were not collected neither right after the episode nor 
at the same time for the 4 patients.  
 
I.4. Conclusions 
The developed and validated HPLC-FD method is able to quantify the levels of 
mercapturates derived from endogenous CysSSX, herein called uNAC. This method 
might be applied in clinical studies aiming to investigate NAT8 and disulfide stress in 
kidney tubular dysfunction in man as well as in animal models of kidney tubular disease.    
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Table I.4 – Anthropometric and clinical data from patients with an episode of AKI. 
Patients A B C D 
Age (years) 74 85 56 23 
Sex M F F M 
Race NB B NB NB 
Co-morbidities DM, CVD CVD - CVD 
AKI etiology CRSd NSAIDs RPGN (Wegener) 
MHT, 
TMA 
AKI SCr (mg/dL) 2.3 3 3.13 4.5 
AKI eGFRa 
(mL/min/1.73m2) 27 16 16 17 
AKI grade 2 1 3 3 
Urine sampling time 
(days after AKI) 17 2 17 6 
SCr (mg/dL) 2.95 2.19 3.12 4.31 
eGFR 
(mL/min/1.73m2) 20 23 16 18 
uNAC (µM) 45 17 15 28 
a calculated with CKD-EPI equation using serum creatinine; AKI: acute kidney injury; B: black; CRSd: cardiorenal 
syndrome; CVD: cardiovascular disease; DM: diabetes mellitus; eGFR: estimated glomerular filtration rate; F: female; 
M: male; MHT: malignant hypertension; NB: non-Black; NSAIDs: non-steroidal anti-inflammatory drugs; RPGN: 
rapidly progressive glomerulonephritis; SCr: serum creatinine; TMA: thrombotic microangiopathy; uNAC: urinary 
surrogate of mercapturates from cysteine-disulfides. 
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CHAPTER II 
Changes in mercapturates of cysteine-disulfides associate to acute kidney injury 
induced by cisplatin and gentamicin 
 
II.1. Rationale & Objectives 
The kidney is a major target for chemical and drug toxicities. One of the most important 
functions of the kidney is the clearance of endogenous waste products, but also the 
metabolism and excretion of exogenous agents (George and Neilson, 2015). This primary 
role for removing exogenous drugs and toxins makes the kidney vulnerable to develop 
various forms of injury. AKI is characterized by a rapid decline in kidney function over 
a period of hours or days. It was demonstrated that AKI determines worse kidney and 
patient outcomes (Soto et al., 2016). The major cause of intrinsic AKI is acute tubular 
necrosis that results mainly from ischemic or nephrotoxic injury.  
Herein, we used a targeted mechanistic-based approach, centered on the mercapturate 
pathway as a metabolic controller of CysSSX in kidney tubular cells. Encouraged by the 
increased formation of disulfides that was described in acute organ failure (Moreno et al., 
2014) and knowing that kidney tubular cells are likely to be exposed to high 
concentrations of CysSSX, we hypothesized that their detoxification would involve the 
formation of mercapturates that would be a protective factor in AKI. Supported by a 
literature review we defined the scheme presented in Figure II.1 and we aimed at 
quantifying the temporal changes of three urinary metabolites: mercapturates of CysSSX 
(uNAC, marker of detoxification of Cys-S-conjugates that are disulfides plausibly 
through NAT8 activity), total cysteine (uCys) (measure of CysSSX filtration and 
reabsorption) and total cysteine-glycine (uCysGly) (measure of GSH turnover) in animal 
models of AKI-induced by tubular nephrotoxins.  
It must be highlighted that both drugs are deleterious for the tubule, but CISP undergoes 
the mercapturate pathway and G does not, and this justifies the choice of our models. Cys 
in its reduced state is essential as the rate-limiting synthesis factor of the antioxidant GSH 
(Rathbun and Murray, 1991). Oxidized glutathione, i.e., GSH-S-conjugates, which can be 
of both endogenous (eg. disulfides, GSSX) (Wang and Ballatori, 1998) and exogenous 
(eg. CISP, GSH-CISP) (Nunes and Serpa, 2018) sources, might be released mainly by 
liver and degraded by peripheral tissues that express GGT in the extracellular border of 
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cell membrane (De Carvalho et al., 2011). This is the first enzyme of the mercapturate 
pathway, a metabolic circuit that is mainly expressed in kidney tubular cells (Chambers 
et al., 2010). Extracellularly, GSH-S-conjugates are catabolized in CysGly-S-conjugates 
by GGT and Cys-S-conjugates by cysteinyl-glycine dipeptidase or aminopeptidase-M, all 
enzymes that are expressed at the brush border of tubular cells (Hughey et al., 1978; 
Griffith, 1981; Hanigan, 1998). This Cys-S-conjugate, which can be disulfides (CysSSX, 
eg. CysSSHCys) or not (Cys-CISP), enter the tubular cell. At this stage and under normal 
conditions, Cys would be reduced, being available to perform its several physiological 
actions (Bannai and Tateishi, 1986).  
Drug-induced toxicity models were herein used as proof-of-concept, but the study of 
nephrotoxicity is pertinent as it is a problematic burden for health and economy 
worldwide, affecting 25% of the 100 most used drugs in intensive care units (Taber and 
Mueller, 2006). In addition, it is one of the major causes leading to candidate drop during 
the drug discovery process of otherwise pharmacologically relevant molecules 
(Loghman-Adham et al., 2012).  
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Figure II.1 – Formation of CysSSX and their elimination in proximal tubular cells through the mercapturate 
pathway. CysSSX increase in tubular cell. (A) Oxidative injury triggers the direct formation of CysSSX in proximal 
tubular cells in a process that is independent of GSH levels. (B) CysSSX might also be delivered to proximal tubular 
cells through the catabolism of GSSX generated intracellularly by any cell. These GSSX are then converted into 
CysSSX by enzymes expressed at the brush border membrane through the mercapturate pathway. This conversion of 
GSSX in CysSSX occurs mainly and almost exclusively in kidney tubular cells (C). CysSSX decrease in tubular cell 
– The intracellular detoxification of CysSSX seems to be dependent on their acetylation plausibly by NAT8 (D), 
forming mercapturates that are readily eliminated in urine (E). The formation of these mercapturates can be monitored 
through the quantification of uNAC, that is the N-acetyl moiety common to all mercapturates from CysSSX (F). 
* urinary quantifications performed in this work; CysGlySSX: cystine-glycine-dissulfides; CysSH: cysteine; CysSSX: cysteine-
disulfides; GSH: glutathione; GSSX: glutathione-disulfides; N-acetyl-CysSSX: mercapturates of cysteine-disulfides; NAT8: N-
acetyltransferase 8; uNAC: urinary surrogate of the mercapturates from cysteine-disulfides; XSH: thiol. 
 
II.2. Animals & Methods 
II.2.1. Animals and experimental protocol 
Urine samples from AKI animal models (Ferreira et al., 2011) were kindly provided by 
Dr. Francisco J. López-Hernández from Institute of Biomedical Research of Salamanca 
(IBSAL) & University of Salamanca (USAL), Department of Physiology and 
Pharmacology, Salamanca, Spain (Figure II.2). Animals were treated in accordance with 
the Declaration of Helsinki Principles and the Guiding Principles in the Care and Use of 
Animals stated in the international regulations and in the following European and national 
institutions: Conseil de l’Europe (published in the Official Daily N. L358/1-358/6, 18 
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December 1986), Spanish Government (published in Boletín Oficial del Estado N. 67, pp 
8509-8512, 18 March 1988, and Boletín Oficial del Estado N. 256, pp 31349-31362, 28 
October 1990). Male Wistar rats (200–250 g, n = 6 per group) were allocated under 
controlled environmental conditions in individual metabolic cages, for 24 h urine samples 
collection. Rats were randomly divided into three groups: (1) CTL group (CTL), 
receiving daily vehicle (0.9% NaCl) intraperitoneal for 6 days; (2) gentamicin group (G), 
receiving gentamicin intraperitoneal (150 mg/kg body weight per day) for 6 days; and (3) 
cisplatin group (CISP), receiving a single intraperitoneal dose of cisplatin (5 mg/kg body 
weight per day). At the end of the experiment kidneys were perfused by the aorta with 
saline (0.9% NaCl) and immediately dissected. One kidney was fixed in buffered 3.7% 
p-formaldehyde for histological studies. Blood samples were also obtained in heparinized 
capillaries at different time points by a small incision in the tail tip. Plasma was obtained 
and kept at - 80 ºC until use as well as urine after being cleared by centrifugation. 
 
Figure II.2 – Experimental design. Wistar rats (n = 6 animals per group) were allocated under controlled 
environmental conditions in individual metabolic cages, for 24 h urine samples collection. Rats were randomly divided 
into three groups: (1) control group (CTL), receiving daily vehicle (NaCl 0.9%) intraperitoneal for 6 days; (2) 
gentamicin group (G), receiving gentamicin intraperitoneal (150 mg/kg body weight per day) for 6 days; and (3) 
cisplatin group (CISP), receiving a single intraperitoneal dose of cisplatin (5 mg/kg body weight per day). 
CISP: cisplatin; CTL: control; G: gentamicin. 
 
II.2.2. Histological studies  
Paraffin blocks were obtained and 5 µm tissue sections were stained with hematoxylin 
and eosin (H&E). Photographs were taken using an Olympus BX51 microscope 
connected to an Olympus DP70 color digital camera (Olympus, Barcelona, Spain). 
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II.2.3. Biochemical measurements 
Plasma Cr (pCr) levels were measured using an automated analyzer Reflotron (Roche 
Diagnostics, Barcelona, Spain).  
The levels of uNAC, uCys (as a measure of CysSSX filtration and reabsorption) and 
uCysGly (as a measure of GSH turnover) were quantified in urine by HPLC-FD (Chapter 
I) (Grilo et al., 2017; Coelho et al., 2018). 
 
II.2.4. Statistical analysis 
Statistical analysis was performed using GraphPad Prism® version 7.0 (GraphPad 
Software Inc., San Diego, CA, USA). Data are presented as mean ± SEM. Whenever 
applicable, data was analyzed through One-way ANOVA with Dunnett’s multiple 
comparisons test or Two-way ANOVA with Bonferroni’s multiple comparisons test. 
Statistical significance for all tests was set at the level of p < 0.05. 
 
II.3. Results 
II.3.1 Characterization of AKI-induced by G and CISP 
Severe AKI was associated with high mortality (50%) in the G group, and surviving 
animals coursed with a small but significant weight loss and polyuria, whereas no 
mortality was observed in the CISP model. Given that, in most cases and types of AKI, 
most of the damage is located in the outer cortical and medullary areas, these two regions 
have been analyzed and photographed (Figure II.3). The histological analysis by H&E 
stain revealed a clear tubular necrosis in both AKI models, with loss of the integrity, 
detachment and vacuolization of epithelial cells and widespread tubular obstruction with 
hyaline casts. No gross modification of the glomeruli was evident.  
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Figure II.3 – Histological analysis of renal sections. Representative images (400x magnification) of kidney sections, 
cortex and outer medulla, stained with H&E from CTL, CISP and G groups. CISP and G induced massive tubular 
necrosis. * Hyaline tubular casts; # detachment epithelial tubular cells; + vacuolization in tubular cells. All symbols 
represent phenomena of acute tubular necrosis. 
 
II.3.2. Biochemical measurements 
II.3.2.1. Quantification of pCr 
pCr levels were quantified as a temporal marker of renal changes, remaining unchanged 
in the CTL group (0.55 ± 0.05 mg/dL) and increasing after 4 days of CISP treatment (2.55 
± 0.56 mg/dL, p < 0.001, Figure II.4A) and after 5 days of G treatment (3.3 ± 0.4 mg/dL, 
p < 0.001, Figure II.4B). 
 
Figure II.4 – pCr levels. pCr levels increased after 4 days of CISP administration (A) and after 5 days of treatment 
with G (B) (n = 6 animals per group). 
*** Two-way ANOVA with Bonferroni’s multiple comparison test, versus CTL group; CISP: cisplatin group; CTL: control group; 
G: gentamicin; pCr: plasma creatinine; *** p < 0.001 
 
 
CONTROL GENTAMICINCISPLATIN
CO
RT
EX
OU
TE
R 
M
ED
UL
LA *
*
*
*
*
* *
*
*
* # ##
# ##
#
#
#
#
#
#
#
#
##
#
#
#
#
+
+
+
+
+ +
+
+
+
+
+
+
+
+
*+
*
*
+
Basal Day 2 Day 4
0
1
2
3
4
pC
r (
m
g/
dL
)
CTL CISP
***
A
Basal Day 4 Day 5
0
1
2
3
4
pC
r (
m
g/
dL
)
B
CTL G
***
Chapter II 
 
 79 
II.3.2.2. uNAC assessment 
To investigate tubular detoxification of CysSSX in both AKI-models, the levels of uNAC 
were quantified in urine as a surrogate of the mercapturates of CysSSX. Temporal 
changes of uNAC in the CISP model were prior to the increase in pCr. Comparing with 
basal state (163 ± 6 µM), the levels of uNAC decreased 2 days after administration of 
CISP (64 ± 10 µM), further decreasing at day 4 (47 ± 3 µM, p < 0.001, Figure II.5A). 
This tendency was also observed for rats treated with G, despite with lower levels of basal 
uNAC excretion (basal state 97 ± 14 µM) and only reaching significance at day 5 (37 ± 7 
µM, p = 0.044, Figure II.5B).  
 
Figure II.5 – Temporal variation of uNAC levels. A decrease in the levels of uNAC was found 2 days after CISP 
treatment, worsening at day 4 (A). A similar trend was observed in rats treated with G although only after 5 days of 
treatment (B) (n = 6 animals per group). 
* or *** One-way ANOVA with Dunnett’s multiple comparison test, versus Basal state; uNAC: urinary surrogate of the mercapturates 
from cysteine-disulfides; * p < 0.05; *** p < 0.001. 
 
II.3.2.3. Determination of uCys and uCysGly 
To further understand the contribution of CysSSX filtration and reabsorption, we 
quantified the temporal variation of uCys. The onset of changes in uCys was coincident 
with the alterations observed for pCr, although in a higher magnitude for CISP (319 ± 24 
µM versus 56 ± 3 µM obtained in basal state, p < 0.001, Figure II.6A) than for the G 
group (53 ± 11 µM versus 27 ± 3 µM obtained in basal state, p = 0.039, Figure II.6B).  
 
Figure II.6 – Variation of uCys throughout study time as a measure of CysSSX filtration and reabsorption. An 
increase in the levels of uCys was observed A. 4 days after CISP administration and B. on day 5 of G treatment (n = 6 
animals per group). 
* or *** One-way ANOVA with Dunnett’s multiple comparison test, versus Basal state; uCys: urinary cysteine as a measure of 
CysSSX filtration and reabsorption; * p < 0.05; *** p < 0.001 
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On the other hand, the effect of GSH turnover might also account for changes in renal 
tubule. For this reason, uCysGly was also quantified. While a decrease in the levels of 
uCysGly was observed for the CISP group at day 2 (18 ± 2 µM) and day 4 (9 ± 2 µM) in 
relation to basal state (33 ± 3 µM) (p < 0.001, Figure II.7A), no changes were observed 
for the G group (Figure II.7B).  
 
Figure II.7 – Temporal changes of uCysGly as a measure of GSH turnover. A decrease in the levels of uCysGly 
was found 2 days after CISP administration, further decreasing at day 4 (A). Treatment with G had no effect on uCysGly 
(B) (n = 6 animals per group). 
* One-way ANOVA with Dunnett’s multiple comparison test, versus Basal state; uCysGly: urinary cysteine as a measure GSH 
turnover; *** p < 0.001 
 
The main results obtained for both models are depicted at Table II.1. 
Table II.1 – Summary of the temporal renal changes observed. 
 CISP  (5 mg/Kg) 
G  
(150 mg/Kg) 
Day 2 ¯ uNAC 
¯ uCysGly  
Day 4 ­ plasma Cr 
­ uCys  
Day 5 - ­ plasma Cr 
­ uCys and ¯ uNAC 
CISP: cisplatin; Cr: creatinine; G: gentamicin; uCys: urinary cysteine as a measure of CysSSX filtration and reabsorption; uCysGly: 
urinary cysteine as a measure GSH turnover; uNAC: urinary surrogate of the mercapturates from cysteine-disulfides. 
 
II.4. Discussion 
Herein, we have shown that uNAC decreases according to decreased kidney function 
mediated by nephrotoxicity of CISP and G. In both models, uNAC decreased before the 
increase of pCr and might suggest that changes on the detoxification of CysSSX might 
underlie AKI-episodes induced by both CISP and G drugs. Consequently, uNAC might 
represent an early biomarker of drug induced-AKI, particularly for drugs undergoing the 
mercapturate pathway, such as CISP.  
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The rationale for this hypothesis-driven study was the fact that as kidney is enriched in 
Cys (Dröge et al., 1991; Pitts, 1995) and a primordial organ for oxidation (Simmons, 
Bogusky and Humes, 1980; Basile, Anderson and Sutton, 2012; Chevalier, 2016), high 
concentrations of CysSSX are toxic (Vina et al., 1983; Munday, 1989; Coelho et al., 
2018), the renal handling of CysSSX could add relevant data on the mechanism 
underlying kidney injury. In fact, an increased formation of CysSSX has been previously 
reported in a model of acute organ injury (Moreno et al., 2014). Thus, our approach was 
to investigate the detoxification of CysSSX in animal models of drug-induced AKI. For 
this, we selected two drugs, CISP and G, whose wide used is limited by the frequent 
development of AKI episodes (Madias and Harrington, 1978; Goldstein and Mayor, 
1983; López-Novoa et al., 2011; Vicente-Vicente et al., 2017). The nephrotoxicity 
elicited by both drugs affects mainly the proximal tubular cells (Markowitz and Perazella, 
2005; Ferreira et al., 2011) which seems to be mediated through oxidative reactions 
(Pedraza-Chaverrı́ et al., 2000; Al-Majed et al., 2002; Karahan et al., 2005; Aydinoz et 
al., 2007; Randjelovic et al., 2012; Ozkok and Edelstein, 2014; Hosohata, 2016; Vicente-
Vicente et al., 2017; Soni et al., 2018). CISP and G have also been associated with renal 
ER stress (Peyrou, Hanna and Cribb, 2007; López-Novoa et al., 2011; Kong et al., 2013; 
Xu, Wang and Li, 2014; Jaikumkao et al., 2016; Randjelovic et al., 2017; Yan et al., 
2018), which is an important aspect to have into account since NAT8 is predominantly 
expressed in the microsomes of proximal tubular cells (Chambers et al., 2010; Veiga-da-
Cunha et al., 2010). Furthermore, the accumulation of the oxidized form of Cys in 
lysosomes promotes mitochondrial injury with consequent proximal tubular cell 
dysfunction (Sumayao et al., 2016). 
 
CISP and G are widely used and frequently associated with AKI complications (Goldstein 
and Mayor, 1983; López-Novoa et al., 2011; Perazella and Luciano, 2015). Clinically, 
high doses of G have been shown to produce nephrotoxicity in 10 to 20% of cases (Kacew 
and Bergeron, 1990; Walker, Barri and Shah., 1999; Vicente-Vicente et al., 2017) and in 
up to 58% in the ICU setting (Oliveira et al., 2009). G’s kidney toxicity is characterized 
mostly by tubular damage, although glomerular and vascular alterations are also detected 
in a dose-dependent manner (López-Novoa et al., 2011). 
The administration of G induced a marked acute renal failure with an associated mortality 
of nearly 50% after 6 days of treatment (Ferreira et al., 2011). Rats from this group 
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presented lower weight and Cr clearance, higher levels of plasma urea, proteinuria, higher 
excretion of N-acetyl-β-D-glucosaminidase (NAG), KIM-1 and bone morphogenetic 
protein 7 (BMP-7), and higher urinary flow (Ferreira et al., 2011). Regarding the CISP 
model, rats develop an overt renal failure demonstrated by increase in plasma urea, higher 
excretion of NAG and decrease in creatinine clearance.  
The authors identified increases in regenerating islet-derived protein III β (reg IIIb) and 
gelsolin (both the full-length, fl-gelsolin, and the fragment of 43 kDa, t-gelsolin) in the 
gentamicin-induced AKI model, differentiating the nephrotoxicity evoked by this drug in 
relation to CISP. While reg IIIb was overexpressed in the kidneys and eliminated in the 
urine, urinary gelsolin was delivered to the kidneys by glomerular filtration (Ferreira et 
al., 2011). The temporal profile of renal damage was further elucidated. Table II.2 
summarizes the temporal variations of renal markers of the animal models (Ferreira et al., 
2011). For simplification purposes, the table shows only the time at each marker starts its 
increase. Regarding the gentamicin group, significant renal damage occurs after 4 days 
of treatment. While reg IIIb appears in the urine at this time, urinary t-gelsolin appears on 
day 1 and its increase is permanent along with the treatment. As for CISP, renal 
dysfunction is also observed at day 4 but only t-gelsolin increases in the urine of these 
rats at day 2. 
Table II.2 – Temporal variations of renal changes previously reported for the models employed. 
 G  (150 mg/Kg) 
CISP  
(5 mg/Kg) 
Day1 ­ urine t-gelsolin  
Day2  ­ urine t-gelsolin 
Day3 
Cytoplasmatic vacuolation of  
tubule epithelial cells  
Day4 
­ in plasma Cr; 
­ in urine: reg IIIb, proteinuria, 
NAG, KIM-1, NGAL and PAI-1 
­ in plasma Cr; 
­ in urine: KIM-1 and NAG 
Day5  - 
Day6 ­ urine fl-gelsolin - 
CISP: cisplatin; Cr: creatinine; fl-gelsolin: full-length gelsolin; G: gentamicin; KIM-1: kidney injury molecule 1; NAG: N-acetyl-β-
D-glucosaminidase; NGAL: neutrophil gelatinase associated lipocalin; PAI-1: plasminogen activator inhibitor 1; reg IIIb: regenerating 
islet-derived protein III β; t-gelsolin: 43 kDa fragment of gelsolin.  
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CISP is an anti-cancer drug broadly used for treatment of different cancers. Its 
nephrotoxic effects are frequent and represents the major limitation in CISP-based 
chemotherapy. Several mechanisms contribute to kidney dysfunction elicited by CISP, 
including direct tubular toxicity in the form of apoptosis and necrosis that is mediated 
through inflammation, reactive oxygen species, calcium overload, phospholipase 
activation, GSH depletion, inhibition of mitochondrial respiratory chain function, 
opening of mitochondrial permeability of transition pore and ATP depletion (Arany and 
Safirstein, 2003; Pabla and Dong, 2008; Sánchez-González et al., 2011; Sancho-Martínez 
et al., 2012, 2018; Dasari and Tchounwou, 2014; Karasawa and Steyger, 2015; Vicente-
Vicente et al., 2015).  
All these factors might suggest an interaction between the nephrotoxicity-induced by 
CISP and G and the detoxification of CysSSX in proximal tubular cells. Although both 
drugs are also hydrophilic (Hilmer et al., 2011; England et al., 2015), they have different 
mechanisms of elimination that might in a certain way explain the differences found 
regarding the detoxification of CysSSX. G is excreted unchanged by the kidneys mainly 
through glomerular filtration and eliminated in urine with no significant metabolism 
reported (Sande, 1985; Hilmer et al., 2011). On the other hand, the renal clearance of 
CISP is performed by both glomerular filtration and tubular secretion (Miller et al., 2010). 
Once inside the tubular cell, the metabolism of CISP is related with the mercapturate 
pathway. However, this interaction is an exception to the common assumption that this 
route is a mechanism of detoxification (Mathias and Bhymer, 2016). In fact, the 
conjugation of CISP with GSH seems to be the first step on the conversion of CISP into 
a potent nephrotoxin (Townsend et al., 2003). Similarly to other GSH-S-conjugates, 
GSH-CISP is excreted into the lumen where undergoes hydrolysis by the brush border 
enzyme GGT (Griffith, 1981; Hanigan, 1998), forming the CysGly conjugate of CISP 
(CysGly-CISP) that is further metabolized by cysteinyl-glycine dipeptidase or 
aminopeptidase-M, also expressed at the brush border (Hughey et al., 1978). The final 
Cys-CISP is transported into the proximal tubular cells where it is bioactivated through 
β-lyase activity, forming a reactive thiol that has nephrotoxic effects (Mistry, Lee and 
McBrien, 1989; Townsend et al., 2003). In fact, the formation of toxic intermediates 
through this pathway has been strongly related to kidney injury (Dekant, Vamvakas and 
Anders, 1989; Mistry, Lee and McBrien, 1989; Möller-Hartmann and Siegers, 1991; 
Townsend et al., 2003; Lash, 2007; Jung et al., 2008; Soo et al., 2018). This β-elimination 
route competes with the acetylation of Cys-S-conjugates by NAT8, producing 
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mercapturates (Veiga-da-Cunha et al., 2010), that have polar, water-soluble and anionic 
features, rendering their elimination in urine (Hinchman and Ballatori, 1994; Veiga-da-
Cunha et al., 2010). Of note, mercapturates might also be metabolized by β-lyase, forming 
reactive intermediates that might evoke toxic effects similar to the ones described for the 
parent compound (Wolfgang et al., 1989; Townsend et al., 2003). However, this process 
is dependent on the prior deacetylation of the mercapturate (Dekant, Vamvakas and 
Anders, 1989; Wolfgang et al., 1989). 
A relevant role in CISP toxicity has been attributed to GGT, the first and limiting step of 
GSH-S-conjugates degradation, producing CysGly-S-conjugates and dictating the low 
half-life of GSH-S-conjugates. This step is essential for Cys recycling from the 
extracellular space and to provide the cell with Cys for intracellular de novo synthesis of 
GSH. A strong evidence that GGT is an important factor underlying CISP nephrotoxicity 
came from studies with GGT knock-out mice, where CISP (15 mg/Kg) was nephrotoxic 
in wild-type but not in GGT-deficient mice (Hanigan et al., 2001). Furthermore, similar 
results were obtained when renal GGT activity was blocked with acivicin in rats (Hanigan 
et al., 1994). However, despite this in vivo proof favouring the role of GGT in CISP 
toxicity, results from in vitro models are contradictory. On one hand, similar results to 
the one previously mentioned were obtained using the more selective GGT inhibitor 
OU749 while the addition of exogenous GGT lead to an increase in CISP cytotoxicity 
(Fliedl et al., 2014). On the other hand, other studies describe GGT as the main 
detoxification mechanism, where GSH-CISP and CysGly-CISP renders a non-toxic 
profile (Daubeuf et al., 2002, 2003; Paolicchi et al., 2003). Further, a study performed by 
Wainford and co-authors (2008) showed that while inhibition of GGT in rats prevented 
CISP nephrotoxicity, cellular toxicity was still observed in both rat and human proximal 
tubular cell cultures (Wainford et al., 2008). These results further support that GSH-CISP 
and other GSH-S-conjugates that are disulfides might be formed in other tissues and reach 
the proximal tubular cells. 
 
Nevertheless, the intravenous administration of substantially higher concentrations of 
reduced GSH compared to the CISP dose (about 83-fold higher) seems to protect against 
CISP-induced nephrotoxicity (Cozzaglio et al., 1990). As the major physiologic substrate 
of GGT (Hanigan and Pitot, 1985), the high concentration of GSH might inhibit the 
enzyme’s activity, reducing the metabolism of GSH-CISP. In fact, a glutathione-disulfide 
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mimetic (NOV-002, oxidized glutathione with cisplatinum at an approximate 1000:1 
ratio) acts as a competitive substrate for GGT and its administration to mice after 
treatment with CISP protected the kidneys from CISP-induced proximal tubule damage, 
including dilation of tubules and the presence of protein casts (Jenderny et al., 2010).  
The toxicity of this concentration needs to be elucidated in more complex organisms such 
as rats and humans, but it has been shown that high levels of reduced GSH inhibits growth 
and promote cell death in yeast strains (Kumar et al., 2011). Nevertheless, the inhibition 
of GGT activity allows the inhibition of Cys-CISP reaching the tubular cell. This would 
avoid the accumulation of toxic metabolites through β-lyase activity in these cells. 
However, the activity of NAT8 would be redirected to the detoxification of Cys-CISP 
formed directly in tubular cells rather than acting on CysSSX that would continue to reach 
or be formed in the cells. 
From these studies, one can assume that the dose of GSH disulfide required to inhibit the 
enzyme and avoid Cys-CISP induced toxicity is very high and that GGT might prefer 
GSH-CISP than other GSH-S-conjugates. This might also explain the reduction in urinary 
excretion of CysGly in the CISP model and increase in uCys, which was described to be 
increased in mixed disulfide forms in urine of both animals treated with GGT inhibitors 
and of a patient with severe GGT deficiency (Griffith and Meister, 1980). This could 
justify the absence of decrease found in the G group that do not form GSH conjugates. 
Moreover, Cys-CISP might also inhibit the entrance of CysSSX in cells, supporting its 
increase in urine. This increase in uCys was also observed in the G model, although in a 
lower magnitude. Nevertheless, the increase of uCys coincided with the increase in pCr 
in both models.  
 
The premature decrease in the levels of uNAC in the CISP model was not observed in 
rats treated with G. In fact, changes in uNAC happened at the onset of the increase in pCr. 
As mentioned, G is actively eliminated in its unchanged form by glomerular filtration 
(Sande, 1985; Hilmer et al., 2011) and seems to have no influence from the mercapturate 
pathway. However, after glomerular filtration, a small portion of the drug (3 to 5%) is 
reabsorbed by proximal tubular cells (Pattyn et al., 1988; Verpooten et al., 1989). This 
site-specific accumulation of G is related with the high expression at the proximal tubule 
of the megalin and cubilin complex, known to transport G and other aminoglycosides by 
endocytosis (Schmitz et al., 2002; Sassen et al., 2006). Afterwards, G accumulates mainly 
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in lysosomes, Golgi apparatus and ER (Silverblatt and Kuehn, 1979; Silverblatt, 1982). 
G binds to membrane phospholipids, changing their turnover and metabolism, causing 
lysosomal phospholipidosis, i.e., the accumulation of undigested phospholipids in 
lysosomes, that correlates tightly with the levels of G nephrotoxicity (Laurent, Kishore 
and Tulkens, 1990; Nonclercq et al., 1992). Furthermore, extensive mitochondrial 
swelling and damage is also observed (Giuliano et al., 1984; Mingeot-Leclercq and 
Tulkens, 1999).  
However, it is at the ER level that G could impair the activity of NAT8, and hence, the 
detoxification of CysSSX. In fact, at the ER, G inhibits protein synthesis, disrupts 
translation accuracy and protein posttranslational modifications (Horibe et al., 2004). Of 
note, NAT8 has been associated with the ability to acetylate correctly folded proteins, 
allowing the progression of these polypeptides through the secretory pathway and 
complete maturation, whereas non-acetylated proteins are disposed off (Ding et al., 
2014). 
The effects of G above-mentioned leads to ER stress and activation of the unfolded 
protein response that, if continuously stimulated, induces apoptosis by caspase 12 and 
calpain (Peyrou, Hanna and Cribb, 2007). As so, NAT8 activity could be inhibited by G, 
which could explain the impairment on the detoxification of CysSSX, although in a less 
magnitude and belatedly in comparison with CISP treatment. This difference might be 
related with the fact that the interaction of CISP with NAT8 could happen not only at the 
mercapturate pathway but also due to the ER stress induced by this drug (Peyrou, Hanna 
and Cribb, 2007; Kong et al., 2013; Xu, Wang and Li, 2014; Yan et al., 2018). 
Changes in uCysGly were not observed in the G group. Data regarding the levels of renal 
GSH in G-induced nephrotoxicity models are conflicting, with reports showing a decrease 
(Ateşşahin et al., 2003; Parlakpinar et al., 2005; Silan et al., 2007; Derakhshanfar, 
Bidadkosh and Hashempour Sadeghian, 2009) or unchanged (Karahan et al., 2005) 
levels. Nevertheless, the nephrotoxicity of G was attenuated when N-acetylcysteine and 
methionine were administered as precursors of GSH (Ali et al., 2009; Derakhshanfar, 
Bidadkosh and Hashempour Sadeghian, 2009). The observed effect might also be related 
with its metal chelating properties (as iron chelators ameliorated oxidative stress induced 
by gentamicin) (Ali, 2003). The more strongly proposed mechanism underlying the 
nephroprotection conferred by N-acetylcysteine and methionine may be related to the 
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decrease in oxidative stress in renal cortex (Unnikrishnan and Rao, 1990; Priuska and 
Schacht, 1995). 
These data seem to be a paradox, as both N-acetylcysteine and methionine would 
contribute to the increase in Cys, which in oxidative conditions could lead to the 
formation of CysSSX. Cys is a nonessential amino acid because it can be available from 
methionine via the transsulfuration pathway, which largely occurs at the liver of healthy 
organisms. N-acetylcysteine is a reasonable alternative to Cys because it is more stable, 
less toxic, and more readily soluble than Cys. In rat, N-acetylcysteine was superior to 
methionine as a source of Cys (Neuhäuser et al., 1986; Pajares and Perez-Sala, 2017). N-
acetylcysteine is converted in Cys through deacetylation by several acylases, an enzyme 
activity that is predominantly present in kidney and, to a lesser extent, in liver (Yamauchi 
et al., 2002) and higher in rodents that in man. Although, this was not apparent in healthy 
volunteers who received N-acetylcysteine by intravenous infusion, since no increase in 
the plasma concentration of Cys was observed (Magnusson et al., 1989). Cys in plasma, 
contrary to cells where it is GSH, is the predominant thiol and exists in oxidized form, 
particularly in a pool linked to proteins, CysSSP (disulfides with Cys residues in proteins) 
(Han et al., 1997; Oliveira and Laurindo, 2018), that might protect Cys residues from 
irreversible oxidation at least until there is a mild threshold of oxidative stress (Dalle-
Donne et al., 2007; Hochgräfe et al., 2007; Auclair, Johnson, et al., 2013).  
It has been shown that in plasma, N-acetylcysteine reacts with CysSSCys and produce 
mercapturates of cysteine (NAC-Cys), N-acetylcysteine symmetric disulfide (NAC-
NAC) and Cys (Whillier et al., 2009). As so, N-acetylcysteine is able to reduce CysSSX, 
forming mercapturates that are directly eliminated (NAC-Cys and NAC-NAC) and so 
reducing the toxic potential of CysSSX accumulation. 
Nevertheless, Small and collaborators (2018) have recently show that progression to 
chronic kidney pathologies after AKI-induced by ischemia/reperfusion can be enhanced 
by N-acetylcysteine therapy, possibly by dampening endogenous antioxidant responses 
(by eliminating redox-sensitive endogenous cytoprotective Nrf2 signaling) and 
enhancing persistent kidney mitochondrial and metabolic dysfunction (Small et al., 
2018). Linking this evidence to our hypothesis, the supplementation with N-
acetylcysteine therapy might promote the elimination in early formation of CysSSX that 
increase as an adaptive response – disulfide stress. This might lead to an increase in 
intracellular levels of Cys and GSH, which in it turn, could be further oxidized with 
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continuous injury, promoting the formation and accumulation of more CysSSX and of 
other endogenous Cys-S-conjugates increased in inflammatory/oxidative conditions 
(Alkhamees et al., 2017). This will lead to an overload of NAT8 activity that might be 
more evident in drugs undergoing the mercapturate pathway or in patients with higher 
risk (e.g. lower NAT8 activity, chronic inflammatory conditions, among others). 
 
The combination of the results obtained for the CISP model suggest that the impairment 
on the detoxification of CysSSX formed in proximal tubular cells is coincident with 
changes in GSH turnover and precede the increase in CysSSX levels in urine and pCr. 
This was, however, not observed for the G treatment. The impairment on CysSSX 
detoxification and increase in CysSSX urinary levels seem to be concomitantly with the 
increase in pCr. We were not able to obtain samples from day 1, which could determine 
if the variation on uNAC precedes the changes on GSH turnover. According to our 
hypothesis, when proximal tubular cells are exposed to oxidative injury, Cys is readily 
oxidized and changes on uNAC would happen before the ones related with GSH status. 
As a consequence, there is a reduction on the Cys available to form GSH and an 
accumulation of toxic Cys products. GSH would then oxidize in the form of disulfide, 
conjugating with CISP which are effluxed from cells, or with several endogenous 
molecules as catecholamines and inflammatory chemical mediators (Wang and Ballatori, 
1998; Gonçalves-Dias et al., 2019). Afterwards, they are catabolized to CysSSX and Cys-
CISP or other Cys-S-conjugates that would compete for NAT8’s activity, leading to an 
overload of the enzyme’s capacity. The impairment of the detoxification of CysSSX 
might also be promoted by inhibition of NAT8’s activity, of other enzymes of the 
mercapturate pathway and of the transporters involved on urinary elimination of the 
mercapturates. In all these scenarios, CysSSX either formed in tubular cell or the ones 
reaching them will accumulate and might promote the activation of pathways associated 
with toxicity in proximal tubular cells. 
 
As for the G group, the impairment on CysSSX detoxification and increase in CysSSX 
urinary levels seem to be concomitantly with the increase in pCr. The interaction of G 
and the mercapturate pathway has not been reported, although it might affect NAT8’s 
activity due to its ability to induce ER stress (Horibe et al., 2004). The unavailability of 
samples from days prior to day 4 and 5 limits the possibility to investigate if changes in 
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uNAC could also be identified at earlier stages, although the results obtained at day 4 
points the other direction.  
The effects of Cys-S-conjugates have been underestimated, probably because the 
mercapturate pathway has been classically considered a detoxification route for 
xenobiotics. Cys-S-conjugates have primarily vascular and hemodynamic properties 
(Lewis and Austen, 1984), being potent vasoconstrictors (Rosenthal and Pace-Asciak, 
1983; Badr, Brenner and Ichikawa, 1987; Shastri et al., 2001) with ability to enhance the 
permeability of the postcapillary venules (Leng et al., 1988). Moreover, they are involved 
in glucose-stimulated insulin secretion (Guo et al., 2018), and have pro-inflammatory 
(Magnay et al., 2001), cytotoxic (Townsend et al., 2003; Stern, Bruno, Hennig, et al., 
2005; Stern, Bruno, Horton, et al., 2005; Dvash et al., 2015) and immunogenic (Salauze 
et al., 2005) properties. As mentioned, Cys-CISP conjugate is more toxic to tubular cells 
than CISP (Townsend et al., 2003). Another example, the Cys-S-conjugate of 
paracetamol is related to its nephrotoxicity, but not hepatotoxicity (Stern, Bruno, Hennig, 
et al., 2005). Additionally, the accumulation of CysSSCys in lysosomes leads to proximal 
tubular dysfunction (renal Fanconi Syndrome) and ESRD (Besouw and Levtchenko, 
2014). Therefore, the elimination of these conjugates could have important implications 
at the nephroprotection level. 
 
As so, the level of interaction between the drug and the mercapturate pathway might have 
an influence on the temporal changes observed regarding the detoxification of CysSSX. 
While the different renal handling of CISP and G might induce changes on the time of 
uNAC decrease, the common tubular toxic effects induced by both drugs could be the 
reason why both models have decreased levels of uNAC and increased levels of uCys. 
 
II.5. Conclusions 
In summary, uNAC might represent an early biomarker of drug induced-AKI, particularly 
for drugs undergoing the mercapturate pathway, such as CISP. Nevertheless, both drugs 
might inhibit the activity of NAT8 through their nephrotoxic effects. As so, CysSSX 
acetylation might represent the primary and early mechanism of detoxification upon acute 
insult.  
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In the future, considering the unavailability of genetic models neither selective inhibitors 
of NAT8, more studies are required to further investigate: 1) early points, especially day 
or even hours after injury, that we believe that will increase uNAC in the maximum levels 
of CysSSX in the tubular cell; 2) evaluate the change of NAT8 expression and CysSSX 
levels in kidney in a time-dependent manner, the effect of GGT inhibitors, administrations 
of NAC and comparison with other markers of tubular dysfunction; 3) measurement of 
other endogenous CysSCX and their mercapturates and also the effect of administration 
of exogenous CysSCX; and 4) assess this pathway in other acute models of renal disease 
such as ischemia/reperfusion and other tubular nephrotoxicants that undergo the 
mercapturate pathway (e.g. paracetamol) or not (e,g. tenofovir, TDF) (Gorgulho et al., 
2018).
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER III 
Factors for uNAC inter-individual variability and uNAC as 
an indicator of kidney disease progression in HIV-infection 
 

Chapter III 
 93 
CHAPTER III 
Factors for uNAC inter-individual variability and uNAC as an indicator of kidney 
disease progression in HIV-infection 
 
III.1. Rationale & Objectives  
Based on the previous data, we decided to determine the factors that would influence the 
inter-individual variability of uNAC in HIV-infected patients. The choice of this 
population is related with the fact that kidney disease is one of the major causes of 
morbidity and mortality in this condition (Wyatt, 2017; Swanepoel et al., 2018). 
 
Kidney disease prevalence, which keeps increasing and is predicted to rise even further 
(Palau et al., 2018), might be linked not only to residual viremia, immunosuppression and 
chronic inflammation, well known traits of HIV-infection, but also to the contribution of 
the sub-toxic chronic effects of antiretroviral (ARVs) drugs (Campos, Ortiz and Soto, 
2016). These factors might lead to chronic low-grade kidney insults (oxidative stress, 
DNA damage and mitochondrial injury) on the tubular epithelium, increasing epithelial 
cell sensitivity to new insults, maladaptive repair and progression to CKD (Ferenbach and 
Bonventre, 2015).  
 
Thus, we have investigated the inter-individual variability of the excretion of 
mercapturates of CysSSX, through uNAC measurement, in a cross-sectional analysis of 
a HIV-infected population. Also, the relation of CysSSX formation through CysSSP was 
also measured in serum. As LTE4 is the best well known endogenous Cys-S-conjugate 
that is substrate of NAT8, the urinary levels of LTE4 (uLTE4) were also quantified and 
their association with uNAC was performed. Additionally, a prospective evaluation of 
uNAC changes with the progression of kidney disease was performed in this population. 
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III.2. Patients & Methods 
III.2.1. Study population 
As part of a prospective study of a cohort of HIV-infected patients, a cross-sectional 
analysis was performed in patients included in a consecutive manner. Pregnancy and age 
under 18 years old were set as exclusion criteria. Anthropometric and clinical data were 
recorded at study admission. The study was approved by the Hospital Prof. Dr. Fernando 
da Fonseca, EPE ethics committee and conducted in accordance with the Declaration of 
Helsinki. All patients gave their written informed consent. 
 
III.2.1.1. Interventions 
Urine and blood samples were collected after outpatient consult and immediately 
processed (in the case of the blood to obtain serum) and frozen at -80 °C until further 
analysis. Anthropometric, combined antiretroviral therapy (cART)-related and clinical 
data were collected and registered on a database. Laboratory data gathered included sCr, 
sCys C, HIV viral load (VL) and T-cells. 
 
III.2.1.2. Definitions 
eGFR was calculated by the Chronic Kidney Disease-Epidemiology Collaboration 
(CKD-EPI) equation using sCr, sCys C or both (sCr – sCys C) and the equation of the 
Modification of Diet in Renal Disease (MDRD) with sCr (Levey et al., 2007, 2009; Inker 
et al., 2012), presented as mL/min/1.73m2. 
 
III.2.2. Inter-individual variability of uNAC 
To assess its inter-individual variability, uNAC was quantified in first morning urine of 
patients included consecutively, as previously described (Chapter I). Inter-individual 
variability was assessed through the calculation of the CV of uNAC quantified in all 
included patients.  
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III.2.2.1. Influence of kidney function on the levels of uNAC 
To assess the association between uNAC and kidney function, we performed correlations 
between the levels of uNAC and the above mentioned eGFR equations in section III.2.1.2. 
 
III.2.2.2. Effect of anthropometric factors in the levels of uNAC 
Whenever applicable, correlations or group comparisons were performed with 
anthropometric factors that could potentially influence the inter-individual variability of 
uNAC. The analysis was performed with several factors including age, sex, race, body 
weight and BMI. 
 
III.2.2.3. Impact of cART in uNAC 
To understand the effect of cART-related data in the levels of uNAC, correlations or 
group comparisons were performed. Factors included on this analysis were the 
pharmacological control of the infection (patients under cART versus patients without 
cART), the time of cART initiation, cART scheme and the use of each ARV. 
 
III.2.3. Variability of serum CysSSP and its association with uNAC 
To obtain the CysSSP fraction of Cys in serum, the levels of total and free total Cys were 
quantified, as previously described. Serum CysSSP levels were obtained by subtracting 
was quantified as previously described (Grilo et al., 2017). Both fractions were quantified 
using an initial volume of 50 µL of serum for each fraction. In brief, to obtain the total 
fraction, after reduction of sulfhydryl groups with 100g/L TCEP (30 min, RT), proteins 
were removed by precipitation with 100 g/L TCA containing 1 mM EDTA followed by 
centrifugation (13000 g, 10 min, 4°C). Afterwards, the supernatant was collected to a new 
tube containing 1.55 M NaOH, 125 mM Na2B4O7, (pH 9.5) with 4 mM EDTA and 1g/L 
SBD-F in Na2B4O7 buffer. The final mixture was vortexed and incubated in the dark, at 
60 ºC for 1 h, to complete the derivatization of the free sulfhydryl groups. The free total 
fraction of Cys was obtained by first submitting the sample to protein precipitation with 
TCA followed by centrifugation (13000 g, 10 min, at 4ºC). Then, samples were reduced 
with TCEP (30 min, RT) and the protocol described above for derivatization was 
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followed. The CysSSP fraction was then obtained by subtracting the free total to the total 
values of Cys. 
 
III.2.4. Association of uNAC with uLTE4 
uLTE4 was measured in urine samples by ELISA (E-El-H1037, Elabscience), according 
with manufacturer’s instructions. Briefly, 50 µL of serum was added to each well of the 
96-well microplate pre-coated with human LTE4, upon which 50 µL of biotinylated 
detection antibody was immediately added. Then, after an incubation period of 45 min at 
37 °C, the wells were washed and 100 µL of HRP conjugate was added to each well and 
incubated for 30 min at 37 °C. The microplate was once again washed and 90 µL of 
substrate reagent was added. A new incubation period of 15 min at 37 °C was performed 
where upon 50 µL of stop solution was used to stop the reaction. The levels of uLTE4 
were immediately measured spectrophotometrically at 450 nm and expressed as pg/mL. 
 
III.2.5. Variability of uNAC with the progression of kidney disease after one year of 
follow-up 
We performed a one-year prospective study on patients that were included on the cross-
sectional analysis. Only patients with samples collected at T0 and T12 months were 
included on this study. Patients were stratified according to their baseline eGFR values 
using CKD-EPI equation with sCr: normal controls (NC), with eGFR equal or higher than 
90 mL/min/1.73m2; early kidney disease (EKD), with eGFR values lower to 90 and equal 
or higher to 60 mL/min/1.73m2 and CKD, with eGFR below 60 mL/min/1.73m2. 
Additionally, eGFR evolution throughout study time was used for stratification: non-
progression (NP), for those patients with stable kidney function (no GFR changes, 
increased or decreased lower than 10% of baseline over 1-year of follow-up); and 
progression (P), for patients with decreased kidney function equal or higher to 10% 
(KDIGO CKD Work Group, 2013) from baseline values. uNAC quantified in samples 
from the T12 visit is presented as the % of the values attained at baseline (T0 visit). 
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III.2.6. Statistical analysis 
Statistical analysis was performed using GraphPad Prism® version 7.0 (GraphPad 
Software Inc., San Diego, CA, USA) and Statistical Package for Social Sciences (SPSS) 
software version 23 (IBM Corp., Armonk, NY, USA). Data was presented in percentage, 
mean ± SEM or mean ± SD or median ± IQR, whenever applicable. Variability among 
data was expressed in CV (%). Non-normal continuous variables were analyzed with 
Kruskal-Wallis test with Dunn’s multiple comparisons test, or Mann-Whitney test, while 
for normal variables One-way ANOVA with Bonferroni’s multiple comparisons test, 
Unpaired t-test or Paired t-test analysis were performed. A step-wise multivariable 
regression models were performed to identify factors influencing the levels of uNAC. 
Two-way ANOVA with Bonferroni’s multiple comparisons test was used when both 
baseline eGFR values and progression to kidney disease were analyzed. Statistical 
significance for all tests was set at p < 0.05. 
 
III.3. Results 
III.3.1. Anthropometric and clinical data 
Table III.1. presents the anthropometric and clinical data of the 242 included patients. 
Table III.1 – Anthropometric and clinical data of the included patients. 
Men (%) 64 
Black (%) 26 
Age (years old) a 51 [44-58] 
Body weight (Kg) a 70 [60-80] 
BMI (Kg/m2) a 24 [22-28] 
HIV type-1 (%) 96 
Time of HIV diagnosis (years) a 8 [4-13] 
Undetectable VL (%) 69 
CD4+ T-cells (cells/µL) a 486 [332-693] 
CD3+ T-cells (cells/µL) a 1421 [1016-1859] 
CD8+ T-cells (cells/µL) a 868 [588-1175] 
Patients on cART (%) 78 
Time on cART (years) a 7 [3-12] 
Patients on TDF (%) 49 
cART scheme (%) 2N(t)RTI+NNRTI: 52; 2N(t)RTI+PI/r: 21; Other: 27 
eGFR CKD-EPI sCr a, c 89 [76-101] 
eGFR MDRD a, c 81 [69-96] 
eGFR CKD-EPI sCr – sCys C a, c 94 [73-105] 
eGFR CKD-EPI sCys C a, c 96 [68-109] 
a Median [IQR]; b mg/g of uCr; c mL/min/1.73m2 
BMI: body mass index; cART: combined antiretroviral therapy; CD: cluster of differentiation; CKD-EPI: Chronic Kidney Disease-
Epidemiology Collaboration; eGFR: estimated glomerular filtration rate; HIV: human-immunodeficiency virus; MDRD: Modification 
of Diet in Renal Disease; NNRTI: non-nucleoside reverse transcriptase inhibitor; N(t)RTI: nucleoside/nucleotide reverse transcriptase 
inhibitor; PI/r: ritonavir-boosted protease inhibitor; sCr: serum creatinine; sCys C: serum cystatin C; TDF: tenofovir; VL: viral load. 
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III.3.2. Inter-individual variability of uNAC 
Our first approach consisted in investigating the inter-individual variability of uNAC. 
This was assessed by the calculation of the CV of the 242 uNAC values measured (Figure 
III.1). The median [IQR] values of obtained were 51 [31-72] µM. The levels of uNAC 
were highly variable, with > 30x differences between the lowest and the highest values 
(Figure III.1). 
 
Figure III.1 – uNAC inter-individual variability among 242 included HIV-infected patients. Median [IQR] levels 
of uNAC were 51 [31-73] µM, varying between 7 µM and 231 µM, with a coefficient of variation of 59%.  
uNAC: urinary surrogate of the mercapturates from cysteine-disulfides. 
 
III.3.2.1. Influence of kidney function on the levels of uNAC 
We further analyzed the contribution of renal function for uNAC’s inter-individual 
variability. For this, kidney function, was evaluated through eGFR using the most applied 
equations in human diagnostic (Levey et al., 2007, 2009; Inker et al., 2012). Our results 
showed that patients with higher eGFR present higher uNAC levels, regardless of the 
used equation (Spearman r = 0.183, p = 0.004 for CKD-EPI with sCr – Figure III.2A; 
Spearman r = 0.175, p = 0.006 for MDRD – Figure III.2B; Spearman r = 0.165, p = 
0.016 for CKD-EPI with both sCr and sCys C – Figure III.2C; and Spearman r = 0.146, 
p = 0.034 for CKD-EPI with sCys C – Figure III.2D).  
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Figure III.2 – uNAC and eGFR. Higher levels of uNAC were observed in patients with increased GFR estimated 
using CKD-EPI with sCr (Spearman r = 0.183, p = 0.004 – A), MDRD (Spearman r = 0.175, p = 0.006 – B), CKD-EPI 
with sCr and sCys C (Spearman r = 0.165, p = 0.016 – C) and CKD-EPI with sCys C (Spearman r = 0.146, p = 0.034 
– D) (n = 242 for CKD-EPI with sCr and MDRD and n = 212 for CKD-EPI with sCr and sCys C and CKD-EPI with 
sCys C). 
CKD-EPI: chronic kidney disease-epidemiology collaboration; eGFR: estimated glomerular filtration rate; MDRD: modification of 
diet in renal disease; sCys C: serum cystatin C; sCr: serum creatinine; uNAC: urinary surrogate of the mercapturates from cysteine-
disulfides. 
 
III.3.2.2. Effect of anthropometric factors in the levels of uNAC 
Next, we investigated other factors that could influence the levels of uNAC rather than 
eGFR. We observed that uNAC was influenced by sex, race and BMI (Figure III.3). 
Specifically, the levels of uNAC were lower in women (44 [26-66] µM) and Black 
patients (44 [26-60] µM), in comparison with men (59 [35-78] µM) and non-Black 
patients (57 [33-83] µM), respectively (p = 0.011 for sex – Figure III.3A; and p = 0.001 
for race – Figure III.3B). Additionally, higher BMI was associated with decreased uNAC 
(Spearman r = -0.136, p = 0.042) (Figure III.3C), while no effect of age and body weight 
was observed. 
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Figure III.3 – Influence of sex, race and BMI on the levels of uNAC. Female sex (A) and Black race (B) influenced 
negatively the levels of uNAC. On the other hand, higher BMI was associated with lower levels of uNAC (Spearman 
r = -0.136, p = 0.042 – C) (n = 154 men, 88 women, 180 non-Black, 62 Black and 226 for BMI). 
* or *** Mann-Whitney test; BMI: body mass index; uNAC: urinary surrogate of the mercapturates from cysteine-disulfides; * p < 
0.05; *** p < 0.001. 
 
In a multivariable analysis including these anthropometric factors, the levels of uNAC 
were only influenced by Black race (B: -17.0, 95% CI [-26.7 – 7.2], p = 0.001). However, 
when eGFR was added to the model, uNAC levels were influenced both by Black race 
(B: -17.6, 95% CI [-27.2; -8.0], p < 0.001) and eGFR (B: 0.281, 95% CI [0.102 – 0.459], 
p = 0.002). 
 
III.3.2.3. Impact of cART in uNAC   
In order to assess if the pharmacological control of HIV-infection influenced uNAC, we 
compared uNAC levels in patients that were receiving cART with non-treated HIV-
infected patients. The levels of uNAC were similar between patients receiving cART and 
patients without cART (Figure III.4A).  
Then, we evaluated if the time on cART affected uNAC, but no association was found as 
well as no association was found between uNAC and time on cART. 
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Next, the influence on uNAC of the main cART schemes, i.e. combination of two 
nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTIs) with one non-
nucleoside reverse transcriptase inhibitor (NNRTI) (2N(t)RTIs + NNRTI) or one protease 
inhibitors boosted with ritonavir (PI/r) (2(N(t)RTIs + PI/r) was assessed. No significant 
differences were found (Figure III.4B). Similarly, no differences were found when 
patients were stratified according to each of the NNRTI (Figure III.4C) or PI/r on the 
scheme (Figure III.4D). 
Afterwards, the role of each N(t)RTI on the levels of uNAC was evaluated. Higher levels 
of uNAC were found in patients receiving cART with TDF (57 [37-77] µM and 46 [27-
70] µM respectively for TDF and no-TDF) (p = 0.043) (Figure III.4E). In the opposite 
direction, uNAC levels were lower in patients on lamivudine (3TC)-containing cART (38 
[26-58] µM and 56 [35-80] µM respectively for 3TC and no-3TC) (p < 0.001) (Figure 
III.4F) and abacavir (ABC)-containing cART (45 [26-61] µM and 55 [26-61] µM 
respectively for ABC and no-ABC) (p = 0.027) (Figure III.4G). Nevertheless, the 
differences found for emtricitabine (FTC) did not reach statistical significance (p = 0.060) 
(Figure III.4H). Similarly, no differences were found for raltegravir, nevirapine (NVP), 
etravirine (ETV), efavirenz (EFV), lopinavir (LPV), darunavir (DRV) and atazanavir 
(ATV). 
Finally, we compared the eGFR in each N(t)RTI and observed that lower eGFR was found 
in patients under 3TC (90 [78-105] mL/min/1.73m2 and 81 [59-93] mL/min/1.73m2, 
respectively for no-3TC and 3TC) (p < 0.001) (Figure III.5A) and ABC (90 [79-105] 
mL/min/1.73m2 and 85 [59-94] mL/min/1.73m2, respectively for no-ABC and ABC) (p 
< 0.001) (Figure III.5B), while TDF and FTC use had no effect. 
In a multivariable analysis where uNAC was the dependent variable, the levels of uNAC 
were influenced by Black race (B: -16.8, 95% CI [-26.1; -7.5], p < 0.001) and use of 3TC 
(B: -15.3, 95% CI [-25.3; -5.2], p = 0.003). 
Secondly, the analysis was performed by including the four N(t)RTIs and eGFR. Both 
3TC use and eGFR influenced uNAC in opposite ways (B: -13.1, 95% CI [-23.6; -2.7], p 
= 0.015 and B: 0.190, 95% CI [0.007; 0.373], p = 0.042, respectively for 3TC use and 
eGFR). 
Lastly, the factors that influenced uNAC in the previous 2 models (3TC, race and eGFR) 
were included on a third multivariable analysis. All factors appeared to influence the 
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levels of uNAC. In fact, Black race was the most prominent influencer (B: -17.5, 95% CI 
[-26.8; -8.3], p < 0.001), followed by for 3TC use (B: -12.2, 95% CI [-22.5; 2.0], p = 
0.019) and finally eGFR (B: 0.213, 95% CI [0.035; 0.392], p = 0.020). 
 
Figure III.4 – uNAC stratification by antiretroviral use. No differences were found on the levels of uNAC between 
patients under-cART or without cART (A) neither between the two different cART schemes (B) or different NNRTI 
(C) or PI/r used (D). While TDF use increased the levels of uNAC (E), the opposite was found for 3TC and ABC (F 
and G, respectively for 3TC and ABC). No differences were found for FTC use (H) (n = 54 no-cART, 188 cART, 97 
2N(t)RTI + NNRTI, 36 2N(t)RTI + PI/r, 43 NVP, 45 EFV, 9 ETV, 9 ATV/r, 17 DRV/r, 8 LPV/r, 118 TDF, 124 no-
TDF, 50 3TC, 192 no-3TC, 66 ABC and 176 no-ABC, 99 FTC and 143 no-FTC). 
* or *** Mann-Whitney test; 3TC: lamivudine; ABC: abacavir; ATV: atazanavir; cART: combined antiretroviral therapy; DRV: 
darunavir; EFV: efavirenz; ETV: etravirine; FTC: emtricitabine; LPV: lopinavir; NNRTI: non-nucleoside reverse transcriptase 
inhibitor; N(t)RTI: nucleoside/nucleotide reverse transcriptase inhibitor; NVP: nevirapine; PI/r: protease inhibitor boosted with 
ritonavir; TDF: tenofovir; uNAC: urinary surrogate of the mercapturates from cysteine-disulfides; * p < 0.05; *** p < 0.001. 
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Figure III.5 – Influence of 3TC and ABC use on eGFR. Lower eGFR was found in patients under cART-containing 
3TC (A) and ABC (B) (n = 50 3TC, 192 no-3TC, 66 ABC and 176 no-ABC).  
*** Mann-Whitney test; 3TC: lamivudine; ABC: abacavir; eGFR CKD-EPI sCr: estimated glomerular filtration rate obtained by 
chronic kidney disease-epidemiology collaboration using serum creatinine; *** p < 0.001. 
 
III.3.3. Variability of serum CysSSP and its association with uNAC 
Serum levels of CysSSP were assessed due to its previously established relation with 
kidney disease (Regazzoni et al., 2013; Nagumo et al., 2014). Furthermore, cysteinylated 
proteins have been reported as one of the major sources of Cys and CysSSX for the 
proximal tubular cells (Thoene and Lemons, 1980; Sumayao, Newsholme and 
McMorrow, 2018). Median IQR levels of CysSSP were 174 [150-197] µM, with a CV of 
22% (Figure III.6). An indirect association between CysSSP and kidney function was 
observed (Spearman r = -0.278, p < 0.001) (Figure III.7A) and we were unable to find 
an association between CysSSP and uNAC (Figure III.7B). 
 
 
Figure III.6 – Serum CysSSP inter-individual variability among 242 included HIV-infected patients. Median 
[IQR] levels of serum CysSSP were 174 [150-197] µM, varying between 52 µM and 314 µM, with a coefficient of 
variation of 22%.  
CysSSP: protein cysteinylation. 
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Figure III.7 – Serum CysSSP and its association with kidney function and uNAC. While patients with higher 
CysSSP had lower eGFR (Spearman r = -0.278, p < 0.001)  (A), no association was found between CysSSP and uNAC 
(B).  
CysSSP: protein cysteinylation; eGFR CKD-EPI sCr: estimated glomerular filtration rate obtained by chronic kidney disease-
epidemiology collaboration using serum creatinine; uNAC: urinary surrogate of the mercapturates from cysteine-disulfides. 
 
III.3.4. Association of uNAC with uLTE4 
Since LTE4 is the most widely studied substrate of NAT8 (Veiga-da-Cunha et al., 2010; 
Deol, 2015; Deol and Josephy, 2017), its urinary levels were quantified and related with 
uNAC in a subpopulation of the study (n = 40, median [IQR] age of 50 [44-60], 68% 
men, 25% Black). Whereas no association with eGFR was observed (Figure III8.A), 
uLTE4 levels were related with the levels of uNAC (Spearman r = 0.379, p = 0.016) 
(Figure III8.B). 
 
Figure III.8 – uLTE4 and its association with kidney function and uNAC. uLTE4 was not related with eGFR (A), 
whereas it was directly associated with the levels of uNAC (Spearman r = 0.379, p = 0.016) (B).  
eGFR CKD-EPI sCr: estimated glomerular filtration rate obtained by chronic kidney disease-epidemiology collaboration using serum 
creatinine; uLTE4: urinary leukotriene 4; uNAC: urinary surrogate of the mercapturates from cysteine-disulfides. 
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III.3.5. Variability of uNAC with the progression of kidney disease after one year of 
follow-up 
III.3.5.1. Patient’s baseline (T0) status 
A total of 118 HIV-infected patients fulfilled the criteria for inclusion on the one-year 
follow-up (samples collected at baseline, T0, and 12 months after, T12). Of them, 69% 
were men and 25% were Black. The median age of all patients included was 52 [42-60] 
years old and 96% were infected with HIV-type 1 virus. 
At baseline, 90% of patients were on cART and cART schemes was distributed as 
follows: 52% with 2N(t)RTI+NNRTI, 19% with 2N(t)RTI+PI/r, 7% with PI/r+N(t)RTI 
and 22% with others cART schemes. A total of 63% of patients were on TDF-containing 
cART. Regarding baseline kidney function, 52 patients were NC, 51 were EKD and 15 
were CKD. Of all, 52% showed progression of kidney disease, as shown by eGFR CKD-
EPI obtained with serum creatinine. Anthropometric and clinical data at baseline for each 
group are presented in Table III.2. 
Chi-square analysis showed significant differences among groups in what regards the 
number of patients under TDF-containing cART (p = 0.001) and on cART scheme (p = 
0.003). No differences were found for anthropometric and hepatic function, with the 
exception of high density lipoprotein levels, which median levels were 52 [45-65] mg/dL 
for NC-NP, 58 [47-71 mg/dL for NC-P, 50 [38-55] mg/dL for EKD-NP, 48 [37-66] 
mg/dL for EKD-P, 68 [34-81] mg/dL for CKD-NP and 68 [58-74] for CKD-P (p = 0.011, 
data not shown). Concerning kidney function, baseline eGFR levels were similar between 
NP and P groups with the same baseline kidney function stratification. As patients were 
stratified according to baseline levels of eGFR, significant differences regarding this 
parameter were found, as expected (p < 0.001). Differences were also found for serum 
urea levels, urinary protein-to-creatinine ratio (uPCR), as well as the fractional excretions 
of sodium, potassium and phosphorus (p < 0.001 except for FePi, which was p = 0.001). 
Nevertheless, the fractional excretion of uric acid was similar among groups and there 
was not enough data regarding baseline urinary ACR (uACR). However, published 
guidelines for CKD screening in HIV-infected patients states that kidney function should 
be assessed by estimating eGFR and measuring proteinuria (Gupta et al., 2005), as herein 
presented.  
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III.3.5.2. Patient’s one-year of follow-up (T12) status 
III.3.5.2.1 Clinical status at T12 
We evaluated the patient’s clinical status after one-year of follow-up regarding renal, 
hepatic and immunological function. Kidney function was assessed by eGFR CKD-EPI 
with sCr (Figure III.9). In comparison with NP groups, all P groups had decreased eGFR 
at T12 (median [IQR] of 84 [75-88], 83 [75-89] and 81 [72-86] % of T0, respectively for 
NC-P, EKD-P and CKD-P groups) (p < 0.001). On the other hand, EKD-NP patients had 
an increase in eGFR at T12 (107 [100-112] % of T0) than the remaining NP groups (98 
[95-102] and 98 [93-117] % of T0, respectively for NC-NP and CKD-NP groups) (p = 
0.002).  
Liver function was assessed through transaminases levels. Alkaline phosphatase was 
increased in CKD-P group (110 [99-120] % of T0) in comparison with CKD-NP group 
(102 [71-245] % of T0) (p = 0.016, data not shown). On the other hand, lactate 
dehydrogenase was increased in EKD-NP group (107 [96-122] % of T0) compared to 
EKD-P group (99 [89-105] % of T0) (p = 0.019, data not shown). No further differences 
were found for the remaining parameters previously analyzed on baseline. 
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Table III.2 – Anthropometric and clinical data at baseline. 
Parameter 
(Unit) 
NC-NP 
(n = 25) 
NC-P 
(n = 27) 
EKD-NP 
(n = 27) 
EKD-P 
(n = 24) 
CKD-NP 
(n = 5) 
CKD-P 
(n = 10) 
p 
value 
Men 
(%) 
76 56 70 79 40 80 ns 
Black 
(%) 24 26 33 17 20 30 ns 
Age 
(years old) a 51 [43-56] 47 [44-58] 50 [42-56] 56 [49-63] 58 [44-66] 58 [50-83] ns 
Undetectable VL 
(%) 
96 67 81 71 80 90 ns 
CD4+ T-cells 
(cells/µL) a 
483 [339-771] 460 [207-636] 620 [380-783] 543 [388-648] 416 [356-1107] 448 [348-720] ns 
Patients on cART 
(%) 92 93 81 88 100 100 ns 
Patients on TDF 
(%) 70 68 77 71 0 20 0.001 
b 
cART scheme (%) 
2N(t)RTI+NNRTI 
2N(t)RTI+PI/r 
PI/r+N(t)RTI 
Other 
 
83 
0 
0 
17 
 
68 
12 
4 
16 
 
37 
27 
18 
18 
 
33 
24 
14 
29 
 
20 
20 
0 
60 
 
30 
50 
0 
20 
0.003 b 
eGFR CKD-EPI sCr 
(mL/min/1.73m2) a 104 [94-109] 98 [93-110] 78 [75-86] 
***, ###  80 [72-85] ***, ### 44 [22-58] ***, ### 47 [22-58] ***, ### < 0.001 c 
Serum Urea 
(mg/dL) a 30 [26-34] 31 [25-36] 36 [30-40] 38 [35-49]
 **, # 56 [42-190] **, # 62 [44-109] ***, ###, §  < 0.001 c 
uPCR 
(mg/g of uCr) a 138 [99-193] 123 [105-205] 138 [108-194] 203 [125-344] 310 [97-2230] 677 [431-1315] 
***, ###, §§§ < 0.001 c 
FeNa 
(%) a 0.5 [0.3-0.8] 0.6 [0.4-0.9] 0.7 [0.4-1.1] 0.9 [0.7-1.5] 
* 1.2 [0.7-4.0] 1.7 [0.7-2.6] **, # < 0.001 c 
FeK 
(%) a  5.8 [4.0-8.2] 4.9 [3.7-7.3] 6.9 [4.3-12.7] 7.8 [5.1-12.1] 17 [13-18]
 *, ## 16 [11-18] **, ### < 0.001 c 
FePi 
(%) a 17 [11-22] 16 [10-21] 18 [13-22] 20 [15-25] 25 [21-54] 31 [19-39] 
*, ## 0.001 c 
a Levels presented as median [IQR]; b Chi-square test; c Kruskal-Wallis test; *, **, ***, #, ##, ###, § or §§§ Kruskal-Wallis test with Dunn’s multiple comparisons test (* versus NC-NP group; # versus NC-P group and § 
versus EKD-NP group); cART: combined antiretroviral therapy; CD: cluster of differentiation; CKD: chronic kidney disease; eGFR CKD-EPI sCr: estimated glomerular filtration rate with Chronic Kidney Disease-
Epidemiology Collaboration equation using serum creatinine; EKD: early kidney disease; FeK: fractional excretion of potassium; FeNa: fractional excretion of sodium; FePi: fractional excretion of phosphate; NC: normal 
control; NNRTI: non-nucleoside reverse transcriptase inhibitor; NP: non-progression; N(t)RTI: nucleoside/nucleotide reverse transcriptase inhibitor; P: progression; PI/r: ritonavir-boosted protease inhibitor; 
TDF: tenofovir ; uPCR: urinary protein-to-creatinine ratio; VL: viral load; *, # or § p < 0.05; ** or ## p < 0.01; ***, ### or §§§ p < 0.001.
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Figure III.9 – Variation of eGFR at T12. Patients from P groups showed a decrease in eGFR in comparison with NP 
groups. EKD-NP patients had an increase in eGFR in comparison with the other NP groups (n = 25 for NC-NP, 27 for 
NC-P, 27 for EKD-NP, 24 for EKD-P, 5 for CKD-NP and 10 for CKD-P). 
eGFR presented as % of values attained at baseline; *** Two-way ANOVA with Bonferroni’s multiple comparisons test (versus NP 
group); ## Kruskal-Wallis test, with Dunn’s multiple comparisons test (versus NC-NP group); CKD: chronic kidney disease; eGFR: 
estimated glomerular filtration rate; EKD: early kidney disease; NC: normal control; NP: non-progression; P: progression; *** p < 
0.001; ## p < 0.01. 
 
III.3.5.2.2. uNAC at T12 
Although the variation of uNAC at T12 was similar in NC groups (73 [56-131] and 73 
[44-98] % of T0 respectively for NC-NP and NC-P groups), we found striking differences 
for the EKD and CKD groups (Figure III.10). Particularly, uNAC decreased significantly 
in the EKD-P group (56 [41-88] % of T0) comparatively to EKD-NP group (80 [65-119] 
% of T0) (p = 0.009). An even higher difference was found between CKD groups, with 
CKD-NP presenting a uNAC variation of 152 [123-188] % of T0 and while CKD-P group 
had 62 [56-80] % of T0 (p < 0.001). Furthermore, CKD-NP group had increased uNAC, 
relatively to the remaining NP groups (p = 0.016). 
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Figure III.10 – Variation of uNAC at T12. uNAC decreased in P groups in comparison with NP groups, particularly 
for EKD and CKD groups. Among NP groups, CKD patients had increased in uNAC (n = 25 for NC-NP, 27 for NC-
P, 27 for EKD-NP, 24 for EKD-P, 5 for CKD-NP and 10 for CKD-P).  
uNAC presented as % of values attained at baseline; ** or *** Two-way ANOVA with Bonferroni’s multiple comparisons test (versus 
NP group); # Kruskal-Wallis test, with Dunn’s multiple comparisons test (versus CKD-NP group); CKD: chronic kidney disease; 
EKD: early kidney disease; NC: normal control; NP: non-progression; P: progression; uNAC: urinary surrogate of the mercapturates 
from cysteine-disulfides; ** p < 0.01; *** p < 0.001; # p < 0.05. 
 
In accordance with the results obtained in the cross-sectional study, Spearman correlation 
showed an association between the variation of uNAC and eGFR at T12 (Spearman r = 
0.298, p = 0.001) (Figure III.11).  
 
Figure III.11 – uNAC and eGFR at T12. The variation of uNAC was positively associated with eGFR (Spearman r 
= 0.298, p = 0.001) (n = 118). 
Presented as % of values attained at baseline; eGFR CKD-EPI sCr: estimated glomerular filtration rate with Chronic Kidney Disease-
Epidemiology Collaboration equation using serum creatinine; uNAC: urinary surrogate of the mercapturates from cysteine-disulfides. 
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III.4. Discussion 
The present study showed that eGFR use of 3TC as well as Black race are factors that 
independently contribute for the high inter-individual variability found in uNAC levels. 
Notably, through a prospective analysis, we found that uNAC can discriminate patients 
with kidney disease progression from those that remain with stable kidney function, 
independently of their baseline eGFR values.  
We found a high inter-individual variability on the capacity to detoxify CysSSX. While 
HIV-infected patients have a high prevalence of kidney disease, evidence for delineating 
the best therapeutic strategy in susceptible patients is limited by several factors. This 
include, for instance, the absence of accurate markers of kidney tubular function and the 
absence of long-term follow-up studies regarding the effects of chronic exposure to ARVs 
in a population affected by residual viremia and inflammation, immunosuppression and 
low antioxidant defenses (Swanepoel et al., 2018). 
While CysSSX might undergo glomerular filtration and tubular secretion (Crawhall et al., 
1967; Griffith, 1981; Commandeur, Stijntjes and Vermeulen, 1995), the detected uNAC, 
accordingly to our hypothesis and our results might be exclusively formed in tubular cells 
upon CysSSX acetylation by NAT8. This would explain the nephroprotective effect of 
NAT8 which has been reported mainly through genetic association studies (Juhanson et 
al., 2008; Chambers et al., 2010; Köttgen et al., 2010; Tin et al., 2013). Thus, changes in 
the levels of uNAC may reflect alterations solely happening in the proximal tubule. This 
might have important implications in the early detection of injury, since the proximal 
tubule has been identified as the primary sensor and effector in the progression of renal 
disease (Chevalier, 2016).  
The widespread use of cART can be interpreted as a double-edged sword. Whereas cART 
has significantly reduced the incidence of the classic kidney disease associated with HIV-
infection, HIV-associated nephropathy, it has also led to a concomitant increase in the 
prevalence of other kidney diseases (Swanepoel et al., 2018). Additionally, as cART is 
chronically administrated throughout the patient’s life (Cihlar and Fordyce, 2016), it is 
plausible to assume that cART could potentially induce or even exacerbate kidney injury 
at any time (Swanepoel et al., 2018).  
Oxidative stress has been increasingly implicated in HIV-associated kidney injury (Rai 
et al., 2013) and several mechanisms have been reported for generating ARV-induced 
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oxidative stress. For instance, NRTIs are able to inhibit DNA polymerase gamma, further 
inhibiting mitochondrial DNA synthesis (Day and Lewis, 2004). On the other hand, 
decreased levels of oxidized glutathione (GSSG) were associated with the toxic effects 
of TDF (Morello et al., 2018), which might indicate a decrease in GSH synthesis 
(Santangelo et al., 2004; Shang et al., 2016) or an increase in the conjugation of 
electrophiles with GSH (Wang and Ballatori, 1998). Additionally, protease inhibitors 
(PIs) trigger the increased production of reactive oxygen species, with downstream 
consequences that include impaired mitochondrial function and ubiquitin proteasome 
system dysregulation, and eventually cell death (Reyskens and Essop, 2014). ARVs were 
also reported to inhibit drug transporters and reduce tubular secretion of sCr (Yombi et 
al., 2014). This might increase sCr and reduce eGFR although in the absence of change 
in the real GFR. For instance, TDF, 3TC, FTC, EFV and NVP are known inhibitors of 
multidrug-resistance-associated protein (MRPs) transporters, namely MRP1, MRP2 and 
MRP3 (Weiss et al., 2007). ABC also inhibits MRP1 and MRP2 but has no effect on 
MRP3 (Weiss et al., 2007). Therefore, both the inhibition of MRP2 and the GSH-
conjugation of ARVs might influence the elimination of CysSSX. On the other hand, the 
cystinuria-related plasma membrane protein rBAT/SLC3A1, together with 
b0,+AT/SLC7A9 (S1 segment) or AGT1/SLC7A13 (S3 segment) is responsible for 
CysSSCys reabsorption in the renal proximal tubules (Calonge et al., 1995; Feliubadaló 
et al., 1999; Nagamori et al., 2016). The interaction between these transporters, as far as 
we know, remains to be investigated. The NNRTIs rilpivirine (Pereira et al., 2012), EFV 
(Pereira et al., 2012), NVP (Srivastava et al., 2010) and ETV (Godinho et al., 2018) are 
known to form reactive metabolites that are eliminated as mercapturates. The toxicity of 
these drugs is mostly associated with the liver, where they are mainly biotransformed 
(Pereira et al., 2012). In fact, in the liver, GSH-conjugates are substrates of MRP2 
(Keppler, 2005). Nevertheless, the susceptibility of this organ to this toxic mechanism is 
lower compared to the kidney, due to its increased capacity to produce GSH and to 
metabolize Cys, with consequent lower Cys/GSH ratio and hence lower susceptibility to 
oxidation (States, Foreman and Segal, 1987).  
We observed that TDF use increased the levels of uNAC. This result was unexpected, as 
TDF has been associated with nephrotoxic events (Herlitz et al., 2010; Scherzer et al., 
2012; Gupta et al., 2014; Jotwani et al., 2016), which includes Fanconi syndrome, 
characterized by an accumulation of CysSSCys (Cherqui and Courtoy, 2017). However, 
it is recommended this drug avoidance with eGFR bellow 60 mL/min/1.73m2 or to stop 
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its prescription if eGFR drops 25% of baseline eGFR and to a level bellow 60 
mL/min/1.73m2 (Lucas et al., 2014). This fact could explain the absence of differences in 
eGFR between patients receiving TDF and patients not receiving this drug. It can also 
explain the similar results obtained for FTC, since all patients from this group also had 
TDF on their cART scheme. 
TDF is excreted by the kidneys through a combination of glomerular filtration and active 
tubular secretion (Barditch-Crovo et al., 2001; Gutiérrez et al., 2014) and is eliminated 
as an unchanged drug in urine since there is no hepatic biotransformation (Kearney et al., 
2006). Specifically, the basolateral uptake of TDF by proximal tubular cells is mediated 
by OAT1 and OAT3 while its efflux from tubular cells is mediated essentially by MRP4 
(Kohler et al., 2011). Evidence from both in vitro and in vivo models show that Cys-S-
conjugates also enter the proximal tubular cells through OATs in both basolateral and 
brush border membranes (Lash and Anders, 1989; Commandeur, Stijntjes and 
Vermeulen, 1995; Groves et al., 2003). As such, TDF and Cys-S-conjugates may compete 
for their basolateral uptake, which could explain the increased levels of uNAC in patients 
under TDF-containing cART. Another plausible explanation for this increase might be an 
adaptation to a nephrotoxic agent that leads to an over-production of CysSSX and/or 
acetylation of CysSSX to avoid injury. The transport of mercapturates for elimination still 
remains a debating issue, and there are only reports for the involvement of OATs, 
specifically OAT1, in the basolateral uptake when mercapturates are administered 
intravenously (Inoue, Okajima and Morino, 1981; Pombrio et al., 2001), although the 
exact mechanism of transport across the brush border membrane is yet to be elucidated. 
Notably, TDF has higher affinity for OAT1 than OAT3 (approximately 20x more) 
although the expression of OAT3 in the proximal tubule is greater than OAT1 (Kohler et 
al., 2011), which might also contribute for the results herein described. 
On the other hand, ABC is extensively metabolized in liver, only with less than 2% being 
eliminated as an unchanged drug in urine. The major metabolites found in urine are 
inactive (a glucuronide and a carboxylate). The remaining percentage is divided between 
minor metabolites in urine and also faecal elimination (Yuen, Weller and Pakes, 2008). 
No differences were found on the pharmacokinetics of ABC in HIV-infected patients with 
kidney dysfunction from the profile observed in healthy adults (Izzedine et al., 2001),  
which is consistent with the kidney’s minor route of ABC elimination. Still, both ABC 
and 3TC have been implicated in case reports of Fanconi syndrome and nephrogenic 
diabetes insipidus (Ahmad, 2006; Nelson et al., 2008). Moreover, 65% of ABC-patients 
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were treated with a combination containing 3TC, which was the only drug that 
independently influenced the levels of uNAC in this study. As so, the effect observed for 
ABC might be due to the simultaneous use of 3TC. Contrarily to ABC, renal clearance is 
the major route of elimination of 3TC. Indeed, about 70% of the unchanged drug is found 
in urine, being only 5 to 10% metabolized in liver to form a trans-sulfoxide metabolite 
which is then excreted by the kidney (Johnson et al., 1998). Significant effects have been 
reported on the pharmacokinetics of 3TC with renal impairment (increase on peak 
concentration and half-life), and dose adjustment (dose reduction or lengthening of the 
dosing interval) is sometimes encouraged (Heald et al., 1996). Moreover, the amount of 
the trans-sulfoxide metabolite excreted increases with decreasing renal function (Johnson 
et al., 1998). The clinical relevance of these findings remains to be elucidated, since, as 
far as the author’s knowledge, no toxicity studies have been reported for this metabolite. 
Our results showed that Black race was the most important factor that independently 
determined the levels of uNAC, in a negative way. As a contributor to the calculation of 
eGFR (Levey et al., 2009), racial differences are clearly evidenced regarding kidney 
disease. For instance, ESRD is disproportionately prevalent in Black people, its risk 
appears early in the course of kidney disease and is not explained by the survival 
advantage of Black people (Choi et al., 2009). Specifically for HIV-infection, Black race 
is a traditional risk factor for the development of kidney disease (Winston et al., 2008) 
and increases the risk of microalbuminuria and proteinuria by at least 2-fold (Szczech et 
al., 2002, 2007).  
A different, and yet very interesting explanation for the low uNAC in the Black race might 
be related with melanin. The formation of pheomelanin which is responsible for lighter 
colours (in opposition to eumelanin, responsible for darker colours) requires Cys. In fact, 
pheomelanogenesis has been proposed as a mechanism that contributes to the removal of 
excess Cys  from the endogenous pool (Galván, Ghanem and Møller, 2012) potentially 
avoiding Cys oxidation in susceptible organs, as it is kidney. 
The kidney is prone to receive a large quantity of CysSSX, owing to the high expression 
of its transporters (Calonge et al., 1995; Feliubadaló et al., 1999; Nagamori et al., 2016). 
Moreover, the kidney is also susceptible to oxidation due to its dependence on oxidative 
phosphorylation to produce energy (Simmons, Bogusky and Humes, 1980; Basile, 
Anderson and Sutton, 2012; Chevalier, 2016). In fact, cysteinylated proteins are the major 
source of Cys and CysSSX for the proximal tubular cells (Thoene and Lemons, 1980; 
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Sumayao, Newsholme and McMorrow, 2018) and serum levels of CysSSP increase with 
the presence of kidney disease (Regazzoni et al., 2013; Nagumo et al., 2014). Our results 
are concordant with this, though no relation with uNAC was observed. This might suggest 
that CysSSX detoxification is somehow independent of CysSSP regulation and that 
uNAC do not allow to predict CysSSP. For instance, part of the lysosomal CysSSCys 
pool has been shown to be originated upon the uptake of extracellular CysSSCys mediated 
by the previous mentioned transporters (rBAT/SLC3A1, b0,+AT/SLC7A9, 
AGT1/SLC7A13) (Calonge et al., 1995; Feliubadaló et al., 1999; Nagamori et al., 2016). 
The efflux of CysSSCys into the cytosol is mediated by cystinosin. Under non-oxidative 
conditions, CysSSCys is reduced to Cys by the cytosolic reducing systems which leads 
to the formation of GSSG (Sumayao, Newsholme and McMorrow, 2018). An impairment 
in this system might lead to an accumulation of CysSSCys with consequent overload of 
NAT8 that is trying to detoxify these compounds. On the other hand, NAT8 function 
might also be overloaded due to the formation of other Cys-S-conjugates rather than 
CysSSX, such the case of LTE4. In fact, increased formation of mercapturates from 
CysSSX was associated with an increase in uLTE4 levels, probably suggesting that NAT8 
is acetylating CysSSX rather than LTE4. Nevertheless, these results should be analyzed 
with caution. Besides the reduced sample size (n = 40 patients), the method herein used 
to measure LTE4 levels is limited by existing techniques. The manufacture state that cross 
reaction may still exist, as it is impossible to complete the cross-reactivity detection 
between human LTE4 and all the analogues (LTC4 and LTD4). Moreover, ideally, N-
acetyl-LTE4 would be measured and the cross-reactivity with this compound is unknown. 
Regarding the prospective analysis of the population, we observed that uNAC decreased 
with the progression of kidney disease, a result that was independent of the baseline 
eGFR, particularly for EKD and CKD patients. CKD-NP patients were the ones that had 
higher increases in uNAC for one year, suggesting that despite their lower kidney 
function, they are able to eliminate CysSSX and maintain stable their function even if it 
is low. This might also indicate that the decrease in uNAC levels observed is not due to 
lower activity of drug transporters, as CKD-NP patients have increased uNAC. As so, 
uNAC might represent a marker of tubular dysfunction, due to the predominance of the 
mercapturate pathway in the tubular cell (Chambers et al., 2010; Veiga-da-Cunha et al., 
2010). Having into account the fact that the proximal tubule is the primary sensor and 
effector on the progression of kidney disease (Chevalier, 2016), this might have important 
implications for the early management and detection of kidney dysfunction. In this 
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scenario, patients with lower ability to detoxify CysSSX might be at a higher risk for the 
development and progression of kidney disease, a condition that could be further 
increased with the presence of factors like the exposure to nephrotoxic drugs. 
 
III.5. Conclusions 
In conclusion, our data shows that uNAC has a high person to person variability and that 
nucleosides backbone of cART, particularly 3TC, race and eGFR are factors for the high 
inter-individual variability observed. uNAC is able to identify patients that are 
progressing in their kidney disease related to a lower detoxification of CysSSX products. 
Moreover, it reveals that uNAC might be a candidate for a new biomarker for diagnosis 
of early events of tubulopathy and for theranostic purposes on this setting. 
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CHAPTER IV 
Cysteine-disulfides dynamics in kidney tubule differs between  
models of pre-diabetes 
 
IV.1. Rationale & Objectives 
Based on the data obtained in the previous chapter (Chapter III), we questioned how the 
dynamics of CysSSX will occur in the progression to CKD. For this purpose, as 
tubulointerstitial inflammation and oxidative stress have been described as events 
underlying it, we selected models of pre-diabetes. Growing evidence is now supporting 
the concept of diabetic tubulopathy as an underlying cause of DKD (Zeni et al., 2017). 
The tubulocentric-concept of DKD links tubulointerstitial inflammation, oxidative stress, 
hypoxia and fibrosis with kidney dysfunction (Vallon, 2011), understanding the 
mechanisms underlying the progression of diabetic tubulopathy is in its infancy. As 
proximal tubule underlies the initiation and progression of the early pathogenesis of the 
diabetic kidney (Zeni et al., 2017), we considered that Cys-S-conjugates dynamics and 
NAT8 are relevant players to be investigated (Dias et al, 2018).  
As previously mentioned, the kidney is rich in Cys (States, Foreman and Segal, 1987; 
Guan et al., 2003) and an organ highly susceptible to oxidation under inflammatory 
conditions (Simmons, Bogusky and Humes, 1980; Basile, Anderson and Sutton, 2012; 
Chevalier, 2016). Cys has a lower reductant capacity than GSH and is a first target for 
oxidative conditions (Jones et al., 2000; Grunwell et al., 2015). The total net content of 
Cys can dynamically exchange between distinct pools, which are influenced by the redox 
status of the tissue involved. The free Cys pool includes the free reduced (CysSH) and 
oxidized (when Cys forms a disulfide bond with other LMW thiol-containing molecule, 
CysSSX) fractions. The latter one contains symmetric disulfides (CysSSCys) and 
asymmetric disulfides such as CysSSG, CysSSCoA and CysSSHCys (Moreno et al., 
2014; Coelho et al., 2018). Additionally, CysSSP is generated when a disulfide bond is 
formed between a free reduced Cys and a Cys protein residue (Rossi et al., 2009).  
Although the impact of these changes for kidney redox homeostasis and tubular disease 
progression is still to be fully understood, we hypothesized that the redox couple 
CysSH/CysSSX controls the rapid response to tubular injury and that the formation of 
disulfides is a protective mechanism, especially for the regulation of proteins. 
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Nevertheless, the formation of LWM disulfides might induce an opposite reaction and 
should be eliminated through acetylation. As so, the early events of injury should be an 
increase in CysSSX (and consequently uNAC) and CysSSP as an adaptive response. 
Besides the toxic profile elicited by CysSSX (Vina et al., 1983; Munday, 1989; Moreno 
et al., 2014; Poole, 2015; Sumayao et al., 2016; Coelho et al., 2018), plasma Cys has been 
pointed out as one of the top uremic toxins (Duranton et al., 2012). CysSSX might be 
detoxified through the action of NAT8, an enzyme that has been associated with the 
control of both blood pressure and kidney function (Juhanson et al., 2008) and can be 
followed by uNAC elimination (Chapter I). 
Herein, we studied the temporal variation of uNAC in two models of pre-diabetes, namely 
high-fructose (HFruct) and hypercaloric (HFat) diets and its association with renal NAT8 
expression, Cys dynamics and kidney dysfunction. We hypothesize that changes in 
tubular CysSSX dynamics underlies the pathogenesis of diabetes-induced renal disease 
and that the monitoring of uNAC can be used as a marker of disease progression. 
 
IV.2. Animals & Methods 
IV.2.1 Animal models and study design 
Experiments were performed using male C57BL/6 mice obtained from the NOVA 
Medical School rodent facility. Animals were housed in polycarbonate cages with wire 
lids and maintained under standard laboratory conditions as follows: artificial 12 h 
light/dark cycles at RT, with ad libitum access to food and water. Animals were specific-
pathogen-free according to FELASA recommendations (Mähler et al., 2014). All 
applicable institutional and governmental regulations concerning the ethical use of 
animals were followed, according to the NIH Principles of Laboratory Animal Care (NIH 
Publication 85 23, revised 1985), the European guidelines for the protection of animals 
used for scientific purposes (European Union Directive 2016/63/EU) and the Portuguese 
Law nº 113/2013. The experimental procedures received prior approval by the Portuguese 
Directorate-General for Food and Veterinary that regulates the animal care and use in 
research (protocol nº 0421/000/000/2017). 
Animals were divided into three groups, each one exposed to a different type of diet. The 
mice were given ab libitum access to a normal diet containing 3.6 g/Kg of methionine 
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and 3.5 g/Kg of CysSSCys (Chow Group) (SDS diet RM3, Special Diets Services) or a 
high-fructose diet with 35% m/v of fructose (FRUC-00T-500, Enzymatic) in drinking 
water (HFruct group) or a hypercaloric diet with 58% fat by kcal, 175 g/Kg of sucrose 
and 2 g/Kg of DL-methionine (HFat group) (D12331, Research Diet, Inc.) for 15 weeks.  
Animal’s weight was weekly recorded, and food and water intake were recorded during 
the first six weeks of diet and caloric intake was obtained. Blood from tail tip and urine 
samples were collected throughout study-time. At the end of the experiments, animals 
were euthanized, and both kidneys were collected, weighed and stored until further 
analysis. The time at each sample was collected as well as the recording of data and 
performance of experiences is shown in Figure IV.1.  
 
Figure IV.1 – Study design. The “x” represents the time at each sample was collected and/or the experiment was 
performed.  
Cys: cysteine; IPGTT: intra-peritoneal glucose tolerance test; ITT: insulin tolerance test; qPCR: quantitative real-time polymerase 
chain reaction; uACR: urinary albumin-to-creatinine ratio; uCr: urinary creatinine; uNAC: urinary surrogate of the mercapturates from 
cysteine-disulfides. 
 
 
 
Week of study 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Sample 
collection
Weight x x x x x x x x x x x x x x x x
Food intake x x x x x x x
Water intake x x x x x x x
Caloric intake x x x x x x x
IPGTT x x
Baseline insulin x
Kidney histology x
Kidney weight x
Kidney qPCR x
uCr x x x x x x
uACR x x x
Kidney Cys x
uNAC x x x
Urine collection Blood collection Kidney collection
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IV.2.2. Assessment of glucose tolerance and insulin resistance 
Glucose tolerance was assessed by intra-peritoneal glucose tolerance test (IPGTT), 
performed at 6 and 12 weeks of diet in overnight-fasted conscious animals. Blood glucose 
was measured using a standard glucometer in samples collected from a small incision 
made at the tip of the tail immediately before glucose administration (2 g/Kg of body 
weight; G8270, Sigma-Aldrich) and 15, 30, 60, 90 and 120 afterwards. The area under 
the curve (AUC) describing blood glucose levels was then calculated. Insulin levels were 
measured at the baseline at 12 weeks of diet. The homeostasis model assessment of insulin 
resistance (HOMA-IR) was calculated using the formula: HOMA-IR = fasting insulin x 
fasting glucose / 22.5 to assess insulin resistance. 
 
IV.2.3. Kidney parameters 
IV.2.3.1. Weight and histology 
After collection, both kidneys were weighted, and histological analysis was performed in 
10% formaldehyde-fixed paraffin embedded left kidney. Sections from 3 mice per group 
were stained with H&E. 
 
IV.2.3.2. Urinary creatinine (uCr) 
The levels of uCr were quantified by a methodology adapted from George and 
collaborators (2006) (George et al., 2006). Briefly, after centrifugation (800g, 5 min, 4 
°C), urine samples were diluted (1:20 to 1:40) in reverse osmosis water. A total volume 
of 20 µL was analyzed by high-performance liquid chromatography with ultraviolet 
detection (HPLC-UV) on an Agilent 1100 Series equipment (Agilent Technologies), 
using a reversed-phase Luna C18 (250 mm x 4.6 mm; 5 µm; 100 Å; Phenomenex), at 25 
°C. The mobile phase was a 10 mM potassium dihydrogen phosphate solution (pH 4.7) 
(104877, Merck). Cr (retention time 4.3 min) was separated in an isocratic elution mode, 
with a flow rate of 1 mL/min and UV detection at 220 nm. The concentration of Cr from 
urine samples was extrapolated from calibration curves constructed with standards with 
known concentrations of Cr (C4255-10G, Sigma-Aldrich) that were submitted to the same 
procedure described for urine samples. 
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IV.2.3.3. uACR 
Albuminuria levels were measured using the Bromocresol Green Albumin (BCG) Assay 
Kit (MAK124, Sigma-Aldrich). The assay was performed in duplicate following the 
manufacturer’s instructions in a 96-well flat bottom plate. First, 5 µL of urine sample or 
standards were transferred into each well followed by the addition of 200 µL of BCG 
reagent. After an incubation period of 5 min at RT, the absorbance was measured at 620 
nm in a microplate reader (Biotrack II plate reader, Amersham Biosciences). Then, uACR 
was obtained by dividing albumin by uCr levels. 
 
IV.2.3.4. Gene expression 
Right kidney tissue was collected and homogenized in Trizol® (T9424, Sigma-Aldrich) 
using a tissue homogenizer (Heidolph DIAX 900). Total RNA extraction was performed 
according to the Trizol® manufacturer’s instructions. The RNA concentration was 
determined prior to cDNA synthesis by measuring the absorbance at 260 nm on a 
Nanodrop 2000 (Thermo Scientific). cDNA was synthesized from 1 μg of RNA, 
according to manufacturer’s instructions (MB12501, nzytech). Mouse specific primers 
were used for the housekeeping gene (Hprt) as wells as for the target genes. The selected 
genes and the primer sequences are shown in Table IV.1.  
The experiments were performed using LightCycler® 480 SYBR Green I Master Mix 
(04887352001, Roche), according to manufacturer's protocol. Quantitative real-time PCR 
(qPCR) was performed on a LightCycler® 480 II real-time PCR system (Roche). 
Experiments were performed in biological triplicates. The relative quantification was 
performed using the comparative CT method (2 - ΔΔCt) with LightCycler® 480 Software 
release 1.5.0 SP4. 
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Table IV.1 - Primer sequences of housekeeping gene and target genes. 
Gene Forward 5’-3’ Reverse 5’-3’ 
Hprt GGACTGATTATGGACAGACTGG GTAATCCAGCAGGTCAGCAAAG 
Nat8 CAGAACTGTCCTCCAGTTTGC GTATGTCCACGAAGGATTCACC 
Fn TGACTGGCCTTACCAGAGGG CATCTGTAGGCTGGTTCAGGC 
Col1a2 GGTCCCCGAGGCAGAGAT CCATTAAACCCATTGGTCCAGG 
Tgfb1  GAAGAACTGCTGTGTGCGGC CTCCACCTTGGGCTTGCGA 
Vim CCGAGGAATGGTACAAGTCCA CTCTTCCATCTCACGCATCTG 
Hspa5 GTCTTCTCAGCATCAAGCAAGG CCAACACTTTCTGGACAGGCT 
Ccl2 TAGGCTGGAGAGCTACAAGAGGAT AGACCTCTCTCTTGAGCTTGGTGA 
Tnfa GGGTGATCGGTCCCCAAAG TTGAGATCCATGCCGTTGGC 
Fbpase AGCCTTCTGAGAAGGATGCTC GTCCAGCATGAAGCAGTTGAC 
Chrebp CTGGGGACCTAAACAGGAGC GAAGCCACCCTATAGCTCCC 
Srebp1a GGCCGAGATGTGCGAACT TTGTTGATGAGCTGGAGCA TGT 
Elovl2 CCTGCTCTCGATATGGCTGG AAGAAGTGTGATTGCGAGGTTAT 
Glut2 TTTCTTTGCCCTGACTTCCT GGCTAATTTCAGGACTGGTT 
Sglt2 TAGAGGCACAGTTGGTGGCTA CGAGGAGCAGCACCACGA 
Ccl2: chemokine (C-C motif) ligand 2; Chrebp: carbohydrate-responsive element-binding protein; Col1a2: collagen, type I, alfa 2; 
Elovl2: elongation of very long chain fatty acids like 2; Fbpase: fructose 1,6 biphosphatase; Fn: fibronectin; Glut2: glucose transporter 
2; Hprt: hypoxanthine guanine phosphoribosyl transferase; Hspa5: heat shock protein 5; Nat8: N-acetyltransferase 8; Sglt2: 
sodium/glucose co-transporter 2; Srebp1a: sterol regulatory element binding protein; Tgfb1: transforming growth factor, beta 1; Tnfa: 
tumor necrosis factor, alfa; Vim: vimentin; 
 
IV.2.4. CysSSX and related metabolites 
IV.2.4.1. Quantification of Cys fractions in kidney 
Renal total and free total fractions of Cys were quantified using a fourth (between 30 to 
60 mg) of the right kidney. The tissue was homogenized in 400 µL of iced PBS 1x 
(P4417-100TAB, Sigma-Aldrich) in a tissue homogenizer (Heidolph DIAX 900). The 
quantification was performed by an HPLC-FD method, as previously reported (Grilo et 
al., 2017; Coelho et al., 2018) (Chapter III).  
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IV.2.4.2. Quantification of uNAC, uCys and uCysGly  
The levels of uNAC, uCys (as a measure of CysSSX filtration and reabsorption) and 
uCysGly (as a measure of GSH turnover) were quantified in urine by HPLC-FD (Chapter 
I) (Grilo et al., 2017; Coelho et al., 2018). 
 
IV.2.5. Statistical analysis 
Statistical analysis was performed using GraphPad Prism® version 7.0 (GraphPad 
Software Inc., San Diego, CA, USA). Data are presented in % of effect or as mean ± SD. 
Whenever applicable, data was analysed through, Unpaired t-test, One-way ANOVA 
with Dunnett’s multiple comparisons test or Two-way ANOVA with Bonferroni’s 
multiple comparisons test. Statistical significance for all tests was set at the level of p < 
0.05. 
 
IV.3. Results 
IV.3.1. Animals 
At the beginning of the experiments, animals (n = 6 animals per group) were age-matched 
(6 weeks of age) and no differences were found regarding total body weight (mean ± SD 
BW of 16 ± 3 g, 18 ± 2 g and 18 ± 4 g, respectively for Chow, HFruct and HFat groups). 
However, the HFat group gained significantly more weight throughout study time in 
comparison with the remaining groups (Figure IV.2). Specifically, the HFat group 
presented higher weight variation than the Chow group right after 4 weeks of diet (p < 
0.023), further increasing until the end of the study. A similar result was obtained between 
HFat and HFruct groups (p < 0.001) (Figure IV.2). 
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Figure IV.2 – Weight variation throughout study time. After 4 weeks of diet, the HFat group gained significantly 
more weight than the Chow group, a difference that further increased until the end of the experiment. This difference 
was also observed between the HFat and the HFruct group (n = 6 animals per group).  
Body weight was normalized by the values attained at week 0 and is presented as percentage of effect from Chow group; *** Two-
way ANOVA with Bonferroni’s multiple comparisons test, versus HFruct group of the same week; +, ++ or +++ Unpaired t-test, 
versus Chow group of the same week; HFat: hypercaloric diet group; HFruct: high-fructose diet group.; + p < 0.05; ++ p < 0.01; +++ 
or *** p < 0.001. 
 
Daily records during the first six weeks of diet showed that both models had a decrease 
in ingestion of food and water in comparison with the Chow group (p < 0.001 for food 
and p = 0.003 for water intake) (Figure IV.3A and IV.3B). Additionally, HFruct animals 
presented lower ingestion of food than the HFat model (p < 0.001).  
However, this decrease was not translated in a decrease on caloric intake (Figure IV.3C). 
In fact, a tendency for an increase in caloric intake in the HFat group was observed after 
5 weeks of diet. 
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Figure IV.3 – Daily food and water intake and caloric intake during the first six weeks of diet. HFat and HFruct 
groups had lower ingestion of food (A) and water (B) than the Chow group during the first six weeks of diet. However, 
for caloric intake a tendency for an increase was observed after 5 weeks of diet (C) (n = 6 animals per group).  
Values presented as mean ± SD; *, **, *** or +++ One-way ANOVA with Bonferroni’s multiple comparisons test (*, ** or *** 
versus Chow group and +++ versus HFruct group); HFat: hypercaloric diet group; HFruct: high-fructose diet group; * p < 0.05; ** p 
< 0.01; *** or +++ p < 0.001. 
 
IV.3.2. Assessment of glucose tolerance and insulin resistance 
To assess glucose tolerance of these animals, we performed the IPGTT in two different 
time-points. At 6 weeks, blood glucose curve was significantly different after 60 min for 
HFat and after 90 min for HFruct groups (p < 0.001) (Figure IV.4A). However, the AUC 
parameter was not different among groups (Figure IV.4B). In contrast, 12 weeks of diet 
induced changes in the blood glucose curve of the HFat group after 30 min of injection 
(p = 0.02 for 30 min, p = 0.002 for 60 min, p < 0.001 for 90 min and p = 0.001 for 120 
min) (Figure IV.4C) that was translated in an impaired glucose tolerance in comparison 
with both the Chow and HFruct diets, as evidenced by the increased AUC for glucose (p 
< 0.001) (Figure IV.4D). Furthermore, we also assessed insulin resistance at 12 weeks 
of diet through the calculation of HOMA-IR (Figure IV.5). Similarly, the HFat group 
presented higher HOMA-IR in comparison with the Chow group (p = 0.035) as well as 
with the HFruct group (p = 0.049), compatible with the presence of insulin resistance in 
these animals. 
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Figure IV.4 – Intra-peritoneal glucose tolerance test. Glucose tolerance was similar between groups at 6 weeks of 
diet (A and B). However, at 12 weeks, mice from HFat group were intolerant to glucose, as shown by the increase on 
the area under the curve (C and D) (n = 3 to 6 animals per group).  
Values presented as mean ± SD; *, **, ***, +, ++ One-way ANOVA with Bonferroni’s multiple comparisons test (*, **, *** versus 
Chow group, where black symbols are for HFat and grey symbols are for HFruct group; and + or ++ versus HFruct group); AUC: area 
under the curve; HFat: hypercaloric diet group; HFruct: high-fructose diet group; * or + p < 0.05; **, ++ p < 0.01; *** p < 0.001. 
 
 
Figure IV.5 – Insulin resistance test. At 12 weeks of diet, the HFat group presented higher HOMA-IR in relation to 
both the Chow and the HFruct groups, characteristic of a phenotype of insulin resistance (n = 3 to 4 animals per group).  
Values presented as mean ± SD; * or + Unpaired t-test (* versus Chow group and + versus HFruct group); HFat: hypercaloric diet 
group; HFruct: high-fructose diet group; HOMA-IR: homeostasis model assessment of insulin resistance; * or + p < 0.05. 
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IV.3.3. Kidney parameters 
IV.3.3.1. Weight and histology 
The weights of both kidneys were assessed as additional reflections of diet on kidney 
status. The HFat group showed higher kidney weights in comparison with the remaining 
groups (p < 0.001) (Figure IV.6A and IV.6B). On the other hand, H&E staining-
histological analysis revealed a normal architecture with no clear pathology on the left 
kidney of all animals examined (Figure IV.7). 
 
Figure IV.6 – Left and right kidney weights. The HFat group presented higher weight of both kidneys (A for left 
kidney and B for right kidney) (n = 6 animals per group).  
*** One-way ANOVA with Bonferroni’s multiple comparisons test, versus Chow and HFruct groups; HFat: hypercaloric diet group; 
HFruct: high-fructose diet group; *** p < 0.001. 
 
 
Figure IV.7 – Left kidney histology. No histological changes were observed (n = 3 animals per group). 
Staining was performed in 10% formaldehyde-fixed paraffin embedded left kidney sections using H&E; Magnification: 10x; HFat: 
hypercaloric diet group; HFruct: high-fructose diet group. 
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IV.3.3.2. uCr 
uCr was quantified in order to normalize albuminuria as well as the urinary concentration 
of metabolites herein described (uCys, uNAC, uCysGly) (Figure IV.8). An increase on 
creatinuria was observed in the HFat model right after 2 weeks of diet and until the end 
of the study in comparison with the Chow group (p = 0.006 for weeks 2 and 4 and p < 
0.001 for weeks 8 and 15 of diet). As for the HFruct group, changes in uCr levels were 
only visible at 8 weeks of diet (p = 0.009). 
 
 
Figure IV.8 – uCr levels. While an increase in creatinuria was observed right after 2 weeks of HFat diet, mice from 
the HFruct group presented increased creatinuria only at 8 weeks of diet (n = 3 to 6 animals per group).  
**, ***, +, ++, +++ Two-way ANOVA with Bonferroni’s multiple comparisons test (** or *** versus Chow group and +, ++ or +++ 
versus HFruct group); HFat: hypercaloric diet group; HFruct: high-fructose diet group; uCr: urinary creatinine; + p < 0.05; ** or ++ 
p < 0.01; *** or +++ p < 0.001. 
 
IV.3.3.3. uACR 
The temporal variation of uACR (Figure IV.9) was evaluated as a measure of kidney 
function. uACR was stable throughout study time in the Chow group (872 ± 355 mg/g of 
uCr, 953 ± 276 mg/g of uCr and 914 ± 418 mg/g of uCr, respectively for weeks 0, 8 and 
15 of diet). We were able to observe increases in uACR in both HFruct and HFat groups 
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after 8 and 15 weeks of diet. This increase was significantly higher for the HFat group in 
both time-points (p < 0.001 for week 8 and p = 0.001 for week 15) (Figure IV.9). 
 
Figure IV.9 – uACR variation at 8 and 15 weeks of diet. Although not statistically significant, HFruct and HFat 
diets increased uACR throughout study time, an increase that was more pronounced for the HFat group (n = 3 to 6 per 
group, per week). 
uACR was normalized by the values attained at week 0 and is presented as percentage of effect from Chow group; ** or *** Two-
way ANOVA with Bonferroni’s multiple comparisons test, versus HFruct group of the same week; HFat: hypercaloric diet group; 
HFruct: high-fructose diet group; uACR: urinary albumin-to-creatinine ratio; ** p < 0.01; *** p < 0.001. 
 
IV.3.3.4. Gene expression  
The renal expression of several genes involved in different processes that might influence 
kidney status was also quantified and the results are depicted in Figure IV.10. We first 
analyzed the expression of Nat8, as the enzyme responsible for the detoxification of 
CysSSX, and observed an increase in its expression for the HFat group (p = 0.001) 
(Figure IV.10A). As this enzyme is expressed in the ER, we have also evaluated a 
markers of ER stress as heat shock protein 5 (Hspa5, also known as Grp78) was 
quantified and was increased in both pre-diabetic models (p < 0.001) (Figure IV.10A). 
 
Secondly, we wanted to assess the renal expression of genes related with inflammation, 
fibrosis and epithelial to mesenchymal transition (EMT) (Figure IV.10B). We analyzed 
the expression of chemokine (C-C motif) ligand 2 (Ccl2, also known as Mcp1) and tumor 
necrosis factor alfa (Tnfa), observing increases in both HFruct and HFat diets (p < 0.001 
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and p = 0.002, respectively for Ccl2 and Tnfa). A marked increased in the expression of 
fibronectin (Fn), collagen type 1 alfa 2 (Col1a2) and Tgfb1 was found in the HFat group, 
whilst the levels of vimentin (Vim) were increased in both HFruct and HFat (p < 0.001 
for Fn and Col1a2; p = 0.007 for Tgfb1 and Vim) (Figure IV.10B).  
 
Finally, we evaluated markers of glucose and lipid metabolism and dynamics (Figure 
IV.10C) revealing an increase in the of expression of fructose 1,6 biphosphatase (Fbpase) 
in the kidney of HFat mice (p < 0.001). Additionally, the HFat group also presented higher 
expression of sterol regulatory element binding protein (Srebp1a) and elongation of very 
long chain fatty acids like 2 (Elovl2) (p = 0.029 and p = 0.020, respectively for Srebp1a 
and Elovl2). Both HFruct and HFat diets induced higher expression of carbohydrate-
responsive element-binding protein (Chrebp) (p < 0.001). We also assessed the 
expression of glucose transporter 2 (Glut2) and sodium/glucose co-transporter 2 (Sglt2), 
the later was increased mice fed with HFruct diet (p = 0.019) (Figure IV.10C). 
 
IV.3.4. CysSSX and related metabolites 
IV.3.4.1. Quantification of Cys fractions in kidney 
To investigate the status of CysSSX availability and dynamics in pre-diabetes, Cys 
fractions were quantified in kidney homogenates upon exposure to the different diets. 
Animals from the Chow group presented a Cys total net of 14 ± 1 µM/mg of tissue. The 
free Cys pool (containing both the reduced and oxidized fractions of Cys) represented the 
major fraction of Cys in this tissue (11 ± 1 µM/mg of tissue) whereas a small proportion 
(about 21%) of Cys levels were found bound to proteins (3 ± 1 µM/mg of tissue). 
Exposure to the pre-diabetic-inducing diets lead to different outcomes (p < 0.001 for all 
fractions in both diets) (Figure IV.11). While an increase in all fractions was found for 
the HFruct group in comparison with the Chow diet (p = 0.046, p = 0.045 and p = 0.017, 
respectively for total, free total and CysSSP fractions), the HFat diet decreased all 
fractions (p = 0.028, p = 0.065 and p = 0.049, respectively for total, free total and CysSSP 
fractions) (Figure IV.11)
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Figure IV.10 – Renal gene expression at 15 weeks of diet. The HFat group presented increased renal expression of Nat8, Ccl2, Tnfa, Fn, Col1a2, Tgfb1, Vim, Hspa5, Fbpase, Chrebp, Srebp1a 
and Elovl2. On the hand the HFruct group has increased expression of Vim, Hspa5, Ccl2, Tnfa, Chrebp and Sglt2 (n = 6 animals per group) 
Gene expression was normalized by Hprt; *, **, ***, +, ++ or +++ One-way ANOVA with Bonferroni’s multiple comparisons test (*, ** or *** versus Chow group and +, ++ or +++ versus HFruct group); Ccl2: 
chemokine (C-C motif) ligand 2; Chrebp: carbohydrate-responsive element-binding protein; Col1a2: collagen, type I, alfa 2; Elovl2: elongation of very long chain fatty acids like 2; Fbpase: fructose 1,6 biphosphatase; 
Fn: fibronectin; Glut2: glucose transporter 2; HFat: hypercaloric diet; HFruct: high-fructose diet; Hspa5: heat shock protein 5; Nat8: N-acetyltransferase 8; Sglt2: sodium/glucose co-transporter 2; Srebp1a: sterol regulatory 
element binding protein; Tgfb1: transforming growth factor, beta 1; Tnfa: tumor necrosis factor, alfa; Vim: vimentin; * or + p < 0.05; ** or ++ p < 0.01; *** or +++ p < 0.001. 
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Figure IV.11 – Cys fractions in kidney homogenates after 15 weeks of diet. HFruct group presented increases in all 
fractions, while the HFat diet induced decreases (n = 4 animals per group).  
Cys fractions were normalized by tissue weight and are presented as the percentage of effect from Chow group; *** Two-way ANOVA 
with Bonferroni’s multiple comparisons test, versus HFruct group; + Unpaired t-test, versus Chow group; Cys: cysteine; CysSSP: 
cysteine protein-bound fraction; HFat: hypercaloric diet; HFruct: high-fructose diet; + p < 0.05; *** p < 0.001. 
 
IV.3.4.2. Quantification of uNAC, uCys and uCysGly 
The levels of uNAC were evaluated in order to explore the effect of diets on the 
detoxification of CysSSX. uNAC levels were similar among weeks 0, 1, 2, 4, 8 and 15 
for the Chow group, with mean values varying between 7.5 to 9.4 µM/mg of uCr.  
The temporal variation of uNAC in the pre-diabetic models is shown in Figure IV.12. 
uNAC varied significantly between the pre-diabetic models (p < 0.001). Regarding the 
HFruct group, a small increase in uNAC elimination was observed in the first week, 
which was abolished with the chronicity of exposure to this diet (p < 0.001). As for the 
HFat, this effect was not observed, which by the end of week 1 had already a reduction 
of more than 20% of uNAC elimination that further decreased along study time (p < 
0.001). Overall, both pre-diabetic diets induced significant reductions in uNAC 
elimination, reaching a difference of -17 for HFruct and -47% for HFat after 15 weeks of 
diet. However, comparing to the Chow group, these differences were only significant for 
the HFat group at weeks 8 and 15 of diet (p = 0.016 and p = 0.005, respectively for week 
8 and 15).  
Total Cys Free Total Cys CysSSP
-60
-40
-20
0
20
40
60
Δ
 C
ys
 (%
)
HFruct HFat
*** ***
***
+
+ +
+
+
+
Chapter IV 
 135 
 
Figure IV.12 – Temporal variation of uNAC in HFruct and HFat groups. Both pre-diabetic models induced 
significant reductions in uNAC elimination (n = 3 to 6 animals per group, per week).  
uNAC was normalized by uCr and the values attained at week 0 and is presented as percentage of effect from Chow group; *** Two-
way ANOVA with Bonferroni’s multiple comparisons test, versus HFruct group; §§§ One-way ANOVA with Bonferroni’s multiple 
comparisons test, versus week 1; + or ++ Unpaired t-test, versus Chow group of the same week; HFat: hypercaloric diet; HFruct: high-
fructose diet; uNAC: urinary surrogate of mercapturates of cysteine-disulfides; + p < 0.05; ++ p < 0.01; *** or §§§ p < 0.001. 
 
IV.3.4.3. Quantification of uCys and uCysGly 
The effect of pre-diabetic diets on the urinary levels of CysSSX was assessed through the 
quantification of uCys (Figure IV.13). The levels of uCys were stable in the Chow group 
throughout study time, with mean values of each week ranging from 6.2 to 11.5 µM/mg 
of uCr.  
The levels of uCys were significantly different between HFat and HFruct groups in the 
time-course performed (p <0.001). After 1 week of diet, both HFruct and HFat groups 
presented lower uCys in comparison with the Chow group, (p = 0.020 and p = 0.003, 
respectively for HFruct and HFat groups). With the chronicity of diet uCys was similar 
to Chow in HFruct and lower than Chow in the HFat group with tendency to increase.  
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Figure IV.13 – Temporal variation of uCys in in HFruct and HFat groups. uCys initial decreases in week 1 in both 
groups. With the chronicity of diet uCys was similar to Chow in HFruct and lower than Chow in the HFat group with 
tendency to increase. 
uCys was normalized by uCr and the values attained at week 0 and is presented as percentage of effect from Chow group; *** Two-
way ANOVA with Bonferroni’s multiple comparisons test, versus HFruct group; §§§ One-way ANOVA with Bonferroni’s multiple 
comparisons test, versus week 1; + or ++ Unpaired t-test, versus Chow group of the same week; HFat: hypercaloric diet; HFruct: high-
fructose diet; uCys: urinary cysteine; + p < 0.05; ++ p < 0.01; *** or §§§ p < 0.001. 
 
We also assessed changes in GSH turnover by measuring the levels of uCysGly (Figure 
IV.14). As for the uCysGly, the mean levels in the Chow group varied between 3.9 and 
7.7 µM/mg of uCr, with differences observed between week 0 (3.9 ± 1.4 µM/mg of uCr) 
and weeks 1 (7.7 ± 2.5) and 4 (7.0 ± 0.7 µM/mg of uCr) (p = 0.007). Similar to uCys, the 
variation on the levels of uCysGly was different between pre-diabetic models (p <0.001). 
Nevertheless, no differences were found between pre-diabetic and chow diets. There was 
a progressive increment on the levels of uCysGly in urine for the HFat model in 
comparison with week 1 (p < 0.001) while the differences found in the HFruct group were 
linear, although significantly different from the values attained at week 1 (p < 0.001). 
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Figure IV.14 – Temporal variation of uCysGly in in HFruct and HFat groups. uCysGly varied widely between 
pre-diabetic diets, although no significant differences were found in comparison with the Chow group (n = 3 to 6 
animals per group, per week).  
uCysGly was normalized by uCr and the values attained at week 0 and is presented as percentage of effect from Chow group; *** 
Two-way ANOVA with Bonferroni’s multiple comparisons test, versus HFruct group; §§§ One-way ANOVA with Bonferroni’s 
multiple comparisons test, versus week 1; HFat: hypercaloric diet; HFruct: high-fructose diet; uCysGly: urinary cysteine-glycine; *** 
or §§§ p < 0.001. 
 
Tables IV.2 and IV.3 summarizes the overall results obtained. 
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Table IV.2 – Summary of findings of the study at week 15 for kidney function and CysSSX dynamics. 
 Body Weight 
Kidney 
weight 
Renal 
histology uACR 
Total 
Cys 
Free total  
Cys CysSSP uNAC uCys uCysGly 
HFruct = = =  ­ ­ ­    
HFat ­ ­ =  ¯ ¯ ¯ ¯   
­ or ¯ represents increase or decrease relatively to Chow group; grey color represents increase relatively to the other pre-diabetic diet; Cys: cysteine; CysSSP: protein-bound cysteine fraction; HFat: hypercaloric diet; 
HFruct: high fructose diet; uACR: urinary albumin to creatinine ratio; uCys: urinary cysteine; uCysGly: urinary cysteine-glycine; uNAC: urinary surrogate of the mercapturates of cysteine-disulfides. 
 
Table IV.3 – Summary of findings of the study at week 15 for gene expression in kidney. 
 Nat8 Hspa5 Ccl2 Tnfa Fn Col1a2 Tgfb1 Vim Fbpase Srebp1a Elovl2 Chrebp Sglt2 
HFruct  ­ ­ ­    ­    ­ ­ 
HFat ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­  
­ represents increase relatively to Chow group; grey color represents increase relatively to the other pre-diabetic diet; Ccl2: chemokine (C-C motif) ligand 2; Chrebp: carbohydrate-responsive element-binding protein; 
Col1a2: collagen, type I, alfa 2; Elovl2: elongation of very long chain fatty acids like 2; Fbpase: fructose 1,6 biphosphatase; Fn: fibronectin; HFat: hypercaloric diet; HFruct: high-fructose diet; Hspa5: heat shock protein 
5; Nat8: N-acetyltransferase 8; Sglt2: sodium/glucose co-transporter 2; Srebp1a: sterol regulatory element binding protein; Tgfb1: transforming growth factor, beta 1; Tnfa: tumor necrosis factor, alfa; Vim: vimentin 
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IV.4. Discussion 
We herein investigated changes in CysSSX dynamics with chronicity of exposure to pre-
diabetic diets and how these changes were related to kidney dysfunction and to our marker 
uNAC. Using uNAC as a surrogate of the mercapturates derived from CysSSX, we 
demonstrate that pre-diabetic states are characterized by lower mercapturates of CysSSX 
in urine that might indicate a decrease on the formation or on the detoxification of 
CysSSX, a condition that aggravates with the progressive exposure to the pre-diabetic 
diets. This fact was particularly evident for the HFat diet. 
Differently from HFruct diet, after 15 weeks of diet, the HFat group has an increase in 
NAT8 expression and decreased uNAC. Additionally, while no histological changes were 
observed, there was an increase in the expression of fibrotic markers.  
A recent work by Guo and co-authors (2017) showed that C57BL/6 mice fed with a HFat 
diet for 3 weeks have a slight, yet not significant, increase in NAT8 expression in liver 
(Guo et al., 2017), that might indicate that NAT8 increases with a reduced exposure to 
the diet. The increase observed in our study suggest that these mice are on an initial stage 
of kidney injury, as suggested by the increased uACR. Nevertheless, the elimination of 
CysSSX is already impaired, further supporting that uNAC might be an indicator of 
kidney disease progression. This decrease could also mean that although NAT8 
expression is increased, its function could be overloaded by other Cys-S-conjugates that 
can compete with CysSSX. In fact, the production of CysLTs is increased in adipocytes 
of HFat mice (Mothe-Satney et al., 2012). Furthermore, the elimination of Cys-S-
conjugates in diabetic conditions has been reported. For instance, the urinary excretion of 
LTE4 is increased in streptozotocin-induced diabetic rats (Hardy et al., 2001) and also in 
patients with type 1 diabetes (Hardy et al., 2005). Cys is also able to form a stable and 
irreversible conjugate with glucose (Glucose-Cys), a reaction reported to be much faster 
than the one between GSH and glucose. Interestingly, urinary Glucose-Cys levels were 
increased in patients with diabetes (Szwergold, 2006). 
Also, NAT8 action can be counteracted by the action of sirtuin 1 (SIRT1), a deacetylase 
that suppresses gluconeogenesis in proximal tubular cells (Sasaki et al., 2017). To date, 
no studies have been reported regarding the ability of NAT8 to acetylate Cys residues of 
proteins. 
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As NAT8 is a microsomal enzyme, we investigated the expression of a markers of ER 
stress, Hspa5, which was increased in both pre-diabetic groups. ER stress, oxidative stress 
and oxidative DNA are all factors that have been associated with kidney dysfunction 
(Ozbek, 2012; Cao and Kaufman, 2014). Moreover, ER stress activates CysLTs pathway, 
the best well known endogenous substrate that undergoes the mercapturate pathway, 
mediating ER stress-triggered kidney damage, apoptosis, oxidative DNA damage and 
morbidity in vivo (Dvash et al., 2015). 
On the other hand, a remarkable difference in Cys dynamics was observed for both pre-
diabetic groups. The HFruct model, that does not present insulin resistance at week 12, 
has an increase in renal Cys availability, both in the free and CysSSP forms, and lower 
uACR while the HFat model, with marked increase in insulin resistance and glucose 
intolerance, displayed exactly an opposite profile, with worse kidney markers. These 
results might indicate that changes in Cys redox homeostasis in kidney that course with 
the increase in CysSSP might have a protective role.  
In accordance, cysteinylation of SOD1 has reported to protect it from oxidation under 
conditions of oxidative stress (Auclair, Brodkin, et al., 2013). On the other hand, it is 
known that albumin cysteinylation in ESRD patients is greatly increased in respect to 
healthy subjects, consequently hindering the protective functions of albumin, particularly 
its antioxidant activity (Regazzoni et al., 2013). The cysteinylation of the only free Cys 
residue of albumin (Cys34) correlates with oxidative stress related pathological 
conditions, namely chronic liver disease, CKD and diabetes mellitus (Nagumo et al., 
2014). Furthermore, CysSSP increases with age (Rossi et al., 2009), this increase might 
be related to protection of reactive Cys in albumin but also because it can represent an 
important source of Cys to the proximal tubular cell. 
In fact, a major source of cytosolic Cys is the lysosomal CysSSCys pool, normally 
generated inside the lysosomes via endoproteolysis of disulphide-containing proteins 
(Thoene and Lemons, 1980). The proximal tubular cells are responsible for almost all of 
the protein reabsorption in kidney via receptor-mediated endocytosis from the brush 
border membrane. Afterwards, vesicles are fused with the lysosomes, allowing lysosomal 
internalization of CysSSCys-containing proteins. These proteins undergo cathepsin-
catalyzed degradation, leading to the formation of CysSSCys, which is then effluxed into 
the cytosol, a process mediated by cystinosin. Under non-oxidative conditions, CysSSCys 
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is reduced to Cys by the cytosolic reducing systems which leads to the formation of GSSG 
(Sumayao, Newsholme and McMorrow, 2018). 
On the other hand, part of the lysosomal CysSSCys pool has been shown to be originated 
upon the uptake of extracellular CysSSCys, which in proximal tubular cells is mediated 
by the plasma membrane protein rBAT/SLC3A1, together with b0,+AT/SLC7A9 (S1 
segment) or AGT1/SLC7A13 (S3 segment) (Calonge et al., 1995; Feliubadaló et al., 
1999; Fernández et al., 2002; Nagamori et al., 2016). Importantly, mutations in these 
genes are associated with a cystinuria phenotype, characterized by excessive wasting of 
CySSCys into the urine (Feliubadaló et al., 1999; Fernández et al., 2002). In addition, 
cystinosin-LKG has been recently identified (Bellomo et al., 2016).  
Both thiol availability and redox status were shown to influence the expression of 
cystinosin (Bellomo et al., 2010). In specific, reduced intracellular Cys and GSH was 
followed by a concomitant increase in reactive oxygen species production was observed 
in HK-2 cells under thiol-free conditions. Moreover, these authors observed a shift 
towards a more oxidized status of Cys and GSH with progressive increase in the mRNA 
levels of cystinosin gene (Bellomo et al., 2010). Thus, it would be interesting to 
understand how these targets change Cys dynamics in order to maintain cellular redox 
homeostasis in kidney and its impact in kidney disease progression and uNAC. 
The healthy human kidney cortex has only about 8% of Cys represented as CysSSCys 
(Crawhall and Segal, 1967). Uremia-triggered oxidative stress affects the reduction of 
CysSSCys and correlated with increased pCr. Furthermore, the accumulation of 
CysSSCys is a hallmark of cystinosis and leads to loss of renal function (Gahl, Thoene 
and Schneider, 2002). This dysfunction elicited by Cys accumulation is associated with 
increased intracellular H2O2, reduced GSSG/total GSH ratio, catalase activity and ATP 
production and impairment in GSH synthesis (Wilmer et al., 2007; Bellomo et al., 2010; 
Sansanwal et al., 2010). 
The HFat model seems to have a more pronounced kidney dysfunction comparatively to 
the HFruct model. In addition to the decreased uNAC elimination and renal cysteine 
availability, HFat animals also have increased kidney weight, higher renal fibrosis 
(showed by increase expression of Fn, Col1a2 and Tgfb1) and higher expression of 
enzymes involved in the glucose and lipid metabolism and dynamics than the HFruct 
group.  
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Nevertheless, increased CysSSP observed in the HFrcut animals might contribute for 
kidney dysfunction, as cysteinylated proteins are transported to the lysosomes of tubular 
epithelial cells where undergo proteolysis, generating CysSSCys (Sumayao, Newsholme 
and McMorrow, 2018). If there is a defect on the transport of CysSSCys, its consequent 
accumulation in the lysosome will elicit toxic effects, including elevated intracellular 
reactive oxygen species production, reduced antioxidant capacity, induction of redox-
sensitive proteins, altered mitochondrial integrity and augmented cell death (Sumayao et 
al., 2016). While the cellular pathways required for protein cysteinylation are not fully 
elucidated, evidence shows that cystathionine beta-synthase (CBS) might have a relevant 
role on this setting since no cysteinylated albumin was detected in CBS deficient mouse 
(Bar-Or et al., 2004). In fact, renal expression of CBS in HFat mice is decreased (Liu et 
al., 2018), hence probably explaining the decrease in CysSSP observed in this group. 
Kidney glutamate/cystine antiporter (xCT, responsible for uptake of CysSSX) protein 
expression is decreased in diabetic mice induced by streptozotocin. In addition, mice 
models of type II diabetes have increased expression of renal GST, the enzyme 
responsible for the formation of GSH-S-conjugates (Fujita et al., 2001).  
It is important to highlight the relative resistance to kidney dysfunction presented by the 
C57BL/6 mice. Albuminuria and renal pathological changes are less commonly observed 
in diabetic C57BL/6 animals (Brosius et al., 2009; Soler, Riera and Batlle, 2012; Kitada, 
Ogura and Koya, 2016). These facts might justify the results herein obtained.  
The detection of mercapturates in urine can be used for biomonitoring of disease 
progression (Mathias and Bhymer, 2016; Dias et al., 2017). In fact, an increase on the 
levels of mercapturates derived from acrolein were found in patients with diabetes 
(Daimon et al., 2003) whereas the mercapturates from 4-hydroxynonenal were lower in 
patients with impaired glucose tolerance (Ntimbane et al., 2008). Our results are in 
accordance with this last aforementioned report.  
 
IV.5. Conclusions 
The present study shows an impaired elimination of mercapturates derived from CysSSX 
with the progression of disease, as denoted by a decrease on the elimination of uNAC in 
urine throughout study time. This is, for the extent of our knowledge, the first study 
reporting an association between DKD progression and the detoxification of CysSSX. 
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This effect seems to more pronounced in the HFat group, a model associated with weight 
gain and a higher degree of kidney dysfunction. The results support the involvement of 
CysSSX and the mercapturate pathway on the early events of tubulopathy in DKD.  
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CHAPTER V 
Cysteine-disulfides in an animal model of hypertension-induced  
by chronic intermittent hypoxia 
 
V.1. Rationale & Objectives 
As the elimination of CysSSX seems to be through their acetylation by the activity of 
NAT8 (Chapter I), which has been associated not only with the mercapturate pathway 
(Veiga-da-Cunha et al., 2010) but also with the regulation of blood pressure (Juhanson et 
al., 2008), both processes mostly dependent on the kidney, we aimed to test our 
hypothesis in a model of hypertension associated with increased oxidative stress and 
inflammation. We have previously described that CysSSX formation increases at rat 
kidney upon exposition to chronic intermittent hypoxia (CIH) (Coelho et al., 2018), a 
model of model of hypertension associated to sleep apnea (Diogo et al, 2015), 
characterized by increased oxidative stress and inflammation, contributing to damage of 
various tissue and organs (May and Mehra, 2014; Lavie, 2015).  
 
The specific aims in this chapter were to measure the temporal variation of uNAC in this 
model and its association with the establishment of hypertension and changes in kidney 
function. Moreover, uNAC variation was also related with CysSSX formation at the 
kidney. 
 
V.2. Animals & Methods 
V.2.1. Animals 
Experiments were performed using male Wistar rats Crl:WI (Han) obtained from the 
NOVA Medical School rodent facility. Animals (two per cage) were housed in 
polycarbonate cages with wire lids (Tecniplast) under 12h light/dark cycles (8am-8pm), 
at room temperature (22 ± 2 °C) and a relative humidity of 60 ± 10%. Rats were 
maintained on a standard laboratory diet (SDS diets RM1, Special Diets Services) and 
reverse osmosis water, which was provided ab libitum. Corncob bedding (Probiológica) 
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was used and changed every week. Animals were specific-pathogen-free according to 
FELASA recommendations (Mähler et al., 2014). 
All applicable institutional and governmental regulations concerning the ethical use of 
animals were followed, according to the NIH Principles of Laboratory Animal Care (NIH 
Publication 85 23, revised 1985), the European guidelines for the protection of animals 
used for scientific purposes (European Union Directive 2016/63/EU) and the Portuguese 
Law nº 113/2013. The experimental procedures received prior approval by the 
Institutional Ethics Committee of the NOVA Medical School for animal care and use in 
research (protocol nº 15/2017/CEFCM). 
 
V.2.1.1. Experimental design 
The experimental design is outlined in Figure V.1. Rats were randomly assigned and 
divided into different groups, which were exposed to CIH during 1, 7, 14, 21 and 60 days. 
Four different control groups of animals were kept in the same room under normoxic (Nx) 
conditions (21% O2 and 79% N2) for 7 (control of both 1 and 7 days of exposure to CIH), 
14, 21, and 60 days. All animals were weighed at baseline and once a week during the 
entire study. Water and food intake were also recorded every week. Additionally, urine 
samples were collected at day 0, 1, 7, 14, 21, 28, 35, 42, 49, 56 and 60 at approximately 
9:00-10:00 am. 
At day 1, 7, 14, 21 and 60 of each group, rats were anaesthetised by intraperitoneal 
injection with medetomidine (0.5 mg/kg body weight; Domitor®, Pfizer Animal Health) 
and ketamine (75 mg/kg body weight; Imalgene 1000®, Mérial). Cardiac puncture was 
performed for blood sampling, obtaining plasma that was stored at -80 °C until use. Renal 
sections, namely renal cortex (RC) and renal medulla (RM) were rapidly collected and a 
part was stored in Trizol® (Life Technologies) until further use. 
The 3Rs police was employed to minimize the number of animals used in the experiments, 
meaning that the same rat was used for almost all experiments.  
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Figure V.1 – Study design. The “x” represents the time at each sample was collected and/or the experiment was 
performed. 
Cys: cysteine; qPCR: quantitative real-time polymerase chain reaction; uACR: urinary albumin-to-creatinine ratio; uCr: urinary 
creatinine; uNAC: urinary surrogate of the mercapturates from cysteine-disulfides; uPCR: urinary protein-to-creatinine ratio. 
 
V.2.1.2. CIH exposure 
CIH-exposure was performed as previously published (Diogo et al., 2015; Coelho et al., 
2018). Rats were kept in a eucapnic atmosphere inside medium A-chambers (76 x 51 x 
51 cm3, A-60274-p, Biospherix Ltd). The chambers were equipped with gas injectors and 
O2 and CO2 sensors levels to ensure the accuracy of CIH cycles. Accumulation of CO2 
was prevented by the continuous flow and circulation of the gases inside the chambers 
using vents and self-indicating soda lime (AnalaR Normapur®, VWR), which absorbs 
expired CO2. Carbon dioxide levels inside the chamber never exceed 1%. Excess water 
was absorbed by a silica gel container (Chameleon® C 2-6 mm, VWR) that was also placed 
inside the chambers. Oxygen concentration inside the chambers was regulated by 
electronically regulated solenoid switches that controlled 100% N2 and 100% O2 gas input 
in a three-channel gas mixer and gradually lowered the oxygen in the chamber from 21% 
Days of exposure 0 1 7 14 21 28 35 42 49 56 60
Sample collection
Weight x x x x x x x x x x
Food intake x x x x x x x x x x
Water intake x x x x x x x x x x
Kidney histology x
Kidney/liver qPCR x x x x x
uCr x x x x x x x x x x x
uACR x x x x x x x
Plasma/kidney/liver
Cys fractions x x x x x 
uNAC x x x x x x x x x x x
Urine collection Blood collection Liver/kidney collection
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to 5% O2 (OxyCycler AT series, Biospherix Ltd). The chambers were infused with 100% 
N2 for 3.5 min to briefly reduce the O2 concentration to 5%; afterwards, the chambers 
were infused with 100% O2 for 7 min to restore O2 to ambient levels of 21% until the start 
of the next CIH cycle. Each CIH cycle had a duration of 10.5 min (5.6 CIH cycles/h) and 
the exposure period was during the rat’s sleep period (light phase of light/dark cycle), 
corresponding to 10.5 h/day. During the remaining hours of the day, the chambers were 
ventilated with a constant flow of room air to maintain oxygen levels at 21%. Oxygen 
was purchased as regular bottles (Gasin), while N2 was generated from the air by pressure 
swing absorption technology using a high-output nitrogen generator (Nitrogen 15 Plus, 
PSA Technology, Sysadvance). 
 
V.2.2. Kidney parameters 
V.2.2.1. Renal histology 
Histological analysis was performed in 10% formaldehyde-fixed paraffin embedded left 
kidney from rats exposed to 60 days of CIH or Nx. Sections from 3 rats per group were 
stained with H&E. 
 
V.2.2.2. uCr 
The levels of uCr were quantified as previously described (Chapter IV). 
 
V.2.2.3. uACR 
Albuminuria levels were measured as described in Chapter IV. uACR was obtained by 
dividing albumin by uCr levels. 
 
V.2.2.4. Gene expression 
Right kidney cortex and medulla tissue were collected and homogenized in Trizol® 
(T9424, Sigma-Aldrich) using a tissue homogenizer (Heidolph DIAX 900). Total RNA 
extraction was performed according to the Trizol® manufacturer’s instructions. The RNA 
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concentration was determined prior to cDNA synthesis by measuring the absorbance at 
260 nm on a Nanodrop 2000 (Thermo Scientific). cDNA was synthesized from 1 μg of 
RNA, according to manufacturer’s instructions (MB12501, nzytech). Rat specific primers 
were used for the housekeeping gene (b-actin) as wells as for the target gene Nat8 and 
are shown in Table V.1. 
The experiments were performed using LightCycler® 480 SYBR Green I Master Mix 
(04887352001, Roche), according to manufacturer's protocol. qPCR was performed on a 
LightCycler® 480 II real-time PCR system (Roche). Experiments were performed in 
biological triplicates. The relative quantification was performed using the comparative 
CT method (2 - ΔΔCt) with LightCycler® 480 Software release 1.5.0 SP4. 
 
Table V.1 - Primer sequences of housekeeping gene (b-actin) and target gene (Nat8). 
Gene Forward 5’-3’ Reverse 5’-3’ 
b-actin AAGTCCCTCACCCTCCCAAAAG AAGCAATGCTGTCACCTTCCC 
Nat8 CATCTGCGAGTACCAAGACAG GATGCATACAACAGCCAGCAG 
Nat8: N-acetyltransferase 8 
 
V.2.3. CysSSX and related metabolites 
V.2.3.1. Quantification of Cys fractions  
Fractions of Cys were quantified in right kidney cortex and medulla sections as previously 
described (Chapter IV) (Grilo et al., 2017; Coelho et al., 2018). For this quantification, 
approximately 50 mg of each tissue was homogenized in 400 µL of iced phosphate 
buffered saline 1x (PBS1x) (P4417-100TAB, Sigma-Aldrich) in a tissue homogenizer 
(Heidolph DIAX 900). As for the free reduced fraction of Cys, the protocol employed for 
the quantification of the free fraction was used although samples were incubated with 
reverse osmosis water instead of TCEP in order to obtain the naturally reduced fraction. 
The free oxidized fraction was obtained by subtracting the free reduced to the total free 
fraction. 
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V.2.3.2. Quantification of uNAC, uCys and uCysGly  
The levels of uNAC, uCys (as a measure of CysSSX filtration and reabsorption) uCysGly 
(as a measure of GSH turnover) were quantified in urine by HPLC-FD (Chapter I) (Grilo 
et al., 2017; Coelho et al., 2018). 
 
V.2.4. Statistical analysis 
Statistical analysis was performed using GraphPad Prism® version 7.0 (GraphPad 
Software Inc., San Diego, CA, USA). Data are presented in % of effect or as mean ± 
SEM. Whenever applicable, data was analysed through Unpaired t-test, One-way 
ANOVA with Dunnett’s multiple comparisons test or Two-way ANOVA with 
Bonferroni’s multiple comparisons test. Statistical significance for all tests was set at the 
level of p < 0.05. 
 
V.3. Results 
V.3.1. Animals 
We have followed the changes in animal weight in both groups (n = 5-6 rats per group) 
that were age-matched (median [IQR] age of 12 [10-13] weeks) and had no differences 
regarding their total body weight at the baseline (mean ± SD BW of 293 ± 44 g). However, 
the curve of body weight variation throughout exposure time showed significantly less 
weight gain in animals exposed to CIH in comparison with Nx animals (Figure V.2). 
This was evident right after 14 days of exposure (p = 0.033), increasing over time (p = 
0.001 from day 21 to 35 and p < 0.001 from day 42 until the end of the experiment). 
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Figure V.2 – Body weight curves for rats exposed to Nx or CIH conditions. Animals exposed to CIH had 
significantly lower body weight gain in comparison with Nx animals. This difference was evident right after 14 days 
of exposure to CIH, increasing until the end of experiments (n= 5-6 animals per group).  
Body weight was normalized as % of day 0 values and presented as mean ± SEM; *, ** or ***Unpaired t-test Nx versus CIH of the 
same day; ## or ### One-way ANOVA with Dunnett’s multiple comparisons test, versus day 0; CIH: chronic intermittent hypoxia; 
Nx: normoxic; * p < 0.050; ** or ## p < 0.010; *** or ### p < 0.001. 
 
The analysis of weekly records of food intake showed that CIH animals ingested lower 
amounts of food in comparison with the Nx group, a difference that was significant after 
49 days of CIH exposure until the end of experiments (p = 0.025 and p = 0.028, 
respectively for days 49 and 56 of CIH exposure) (Figure V.3A). However, whereas CIH 
animals ingested a higher quantity of water on the first week of exposure comparatively 
to Nx animals, an opposite effect was found after 49 days of study (p = 0.002 for both 
days 7 and 49 and p = 0.038 for day 56) (Figure V.3B). Furthermore, Nx animals 
progressively ingested more water, while an inverse result was observed in the CIH group 
(p < 0.001 for Nx and p = 0.010 for CIH groups) (Figure V.3B). 
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Figure V.3 - Food and water intake. By the end of the study period, CIH animals ingested lower amounts of both 
food (A) and water (B). Also, there was an increase in water intake throughout study time for the Nx group, while CIH 
animals decreased its consumption (B) (n = 5-6 animals per group).  
Data presented as mean ± SEM; * or ** Two-way ANOVA with Bonferroni’s multiple comparisons test, Nx versus CIH of the same 
day; # or ## One-way ANOVA with Dunnett’s multiple comparisons test, versus day 7; CIH: chronic intermittent hypoxia; Nx: 
normoxic; * or # p < 0.05; ** or ## p < 0.01. 
 
V.3.2. Renal parameters 
V.3.2.1. Histology 
Histological analysis through H&E staining revealed a normal architecture with no clear 
pathology on the left kidney of all animals examined after 60 days of study time (Figure 
V.4). 
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Figure V.4 – Left kidney histology. No histological changes were observed for the left kidney of all groups (n = 3 
animals per group). 
Staining was performed in 10% formaldehyde-fixed paraffin embedded left kidney sections using H&E; Magnification: 10x; CIH: 
chronic intermittent hypoxia; Nx: normoxic. 
 
V.3.2.2. uCr 
uCr was quantified in order to normalize albuminuria and proteinuria as well as the 
urinary concentration of metabolites herein described (uCys, uNAC, uCysGly). There 
were no differences for uCr levels throughout the study in both groups of animals (Figure 
V.5).  
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V.3.2.3. uACR  
To evaluate kidney function, we quantified the temporal variation of uACR (Figure V.6). 
Although not reaching statistical meaning, CIH animals presented higher uACR in the 
majority of the analyzed time-points. 
 
 
Figure V.5 – uCr levels. No differences were observed regarding the temporal variation of uCr in both groups (n = 5-
6 animals per group, per week).  
Data presented as mean ± SEM; CIH: chronic intermittent hypoxia; Nx: normoxic; uCr: urinary creatinine. 
 
 
Figure V.6 – Temporal variation of uACR. Although without reaching statistical significance, the CIH group 
presented higher uACR in most time-points.  
Data presented as mean ± SEM; CIH: chronic intermittent hypoxia; Nx: normoxic; uACR: urinary albumin-to-creatinine ratio. 
 
V.3.2.4. Gene expression 
In order to address the effect of chronicity of CIH in NAT8, its mRNA expression was 
evaluated in kidney sections, namely RC and RM. We observed differences between Nx 
and CIH groups in a time- and tissue-dependent manner (Figure V.7). Specifically, after 
1 day of exposure, CIH animals presented lower NAT8 in comparison with Nx group (p 
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= 0.006 for RC and p = 0.041 for RM), a difference that remained similar after 7 days of 
study time (p = 0.021 for RC and p = 0.024 for RM). However, while no differences were 
found between Nx and CIH animals after 14 days of exposure, a significant increase in 
this expression was observed only in RC of CIH animals at 21 days (p = 0.007). By the 
end of the study, CIH animals presented lower expression of NAT8 in comparison with 
Nx groups in both renal sections (p = 0.037 for RC and p = 0.024 for RM). On the other 
hand, when the temporal expression of NAT8 was compared with the values attained after 
1 day of study time, we observed an increase at days 14 and 21 for RC and RM (p < 0.001 
for both days and both sections), while a slight decrease was observed in RM after 7 days 
of study time (p < 0.001).  
 
 
Figure V.7 – Temporal variation of NAT8 mRNA expression. The expression of NAT8 varied in a temporal- and 
tissue-dependent manner. Specifically, we observed that right after 1 day of exposure, CIH animals presented lower 
expression in both RC and RM. A similar result was obtained after 7 days of study time. However, by the 21st day of 
exposure, these animals presented higher expression in RC comparatively to Nx animals though only in RC. By the 
end of the study, NAT8 expression was once again reduced in the CIH group in both kidney sections. Notably, in 
comparison with day 1, the expression of NAT8 increased at days 14 and 21 in RC and RM sections while a slight, yet 
significant reduction was observed at 7 days of study time in RM (n = 5-6 animals per group).  
Gene expression was normalized with b-actin. Data presented as the ratio of CIH by Nx groups; *** Two-way ANOVA with 
Bonferroni’s multiple comparisons test, versus day 1 of each tissue; # or ## Unpaired t-test, Nx versus CIH of the same day; CIH: 
chronic intermittent hypoxia; D: day; NAT8: N-acetyltransferase 8; Nx: normoxic; RC: renal cortex; RM: renal medulla; # p < 0.05; 
## p < 0.01; *** p < 0.001. 
 
V.3.3. CysSSX and related metabolites 
V.3.3.1. Quantification of Cys fractions  
The influence of CIH in Cys availability and dynamics was investigated through the 
quantification of Cys fractions in RC and RM tissue (Figure V.8). At 1 day of study time, 
the total net content of Cys (i.e free plus protein-bound fraction) in CIH animals in both 
sections was similar to Nx (Figure V.8A). However, a significant increase was observed 
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after 7 days of exposure (p = 0.003 and p = 0.001, respectively for RC and RM). 
Afterwards, Cys availability decreased in both sections until the end of the experiment (p 
< 0.001).  
In a similar manner, we observed increased CysSSP at day 7 in CIH animals in both RC 
and RM (p = 0.041 and p = 0.028, respectively for RC and RM) that progressively 
decreased throughout study time (p < 0.001) (Figure V.8B). 
On the other hand, we also assessed the oxidative status of Cys through its redox couple, 
given by the ratio of CysSH divided by free oxidized Cys (i.e. cysteine disulfides, 
CysSSX) (Figure V.8C). A higher ratio was observed at day 7 in both sections (p = 0.008 
and p = 0.017, respectively for RC and RM). However, Cys rapidly shift towards a more 
oxidized status, as shown by a lower ratio at days 14 and 21 (p < 0.001), returning to 
values closer to the ones attained in Nx conditions at 60 days of CIH exposure. 
 
V.3.3.2. Quantification of uNAC 
To explore the effect of CIH on the elimination of CysSSX, the levels of uNAC were 
quantified throughout study time (Figure V.9). After an increase of almost 100% on the 
elimination of uNAC after 1 day of exposure to CIH, a progressive decrease was observed 
in CIH animals until the end of the study (p < 0.001). However, differences between Nx 
and CIH groups were only significant at day 21 and then from day 42 until the end of the 
experiments (p = 0.010, p = 0.005, p = 0.034, p = 0.032 and p = 0.042, respectively for 
day 21, 42, 49, 56 and 60). 
 
V.3.3.3. Quantification of uCys and uCysGly 
We have evaluated the contribution of CysSSX trough the quantification of uCys (Figure 
V.10) and GSH turnover through uCysGly (Figure V.11). Both uCys and uCysGly were 
generally lower in CIH than in Nx. 
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Figure V.8 – Cysteine availability and dynamics throughout study time. At 7 days of exposure to CIH, we observed 
an increase in both kidney fractions in total Cys (A) and CysSSP (B), decreasing with the increment on the temporal 
exposure to CIH. A significant increase was also observed in CysSH/CysSSX (C) at day 7, indicative of a more reduced 
state of Cys, decreasing from day 14 to 21 and returning to values closer to control conditions by the end of the 
experiment (n= 5-6 animals per group).  
Cys fractions were normalized by tissue weight and are presented as the as percentage of effect from Nx group; *** Two-way ANOVA 
with Bonferroni’s multiple comparisons test, versus day 1 of each tissue; # , ## or ### Unpaired t-test, versus Nx group of the same 
day; Cys: cysteine; CysSH: free reduced cysteine; CysSSP: cysteine protein-bound fraction; CysSSX: cysteine disulfides; D: day; RC: 
renal cortex; RM: renal medulla; # p < 0.05; ## p < 0.01; *** or ### p < 0.001. 
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Figure V.9 – Temporal variation of uNAC. CIH rats presented increased elimination of uNAC after 1 day of exposure 
to CIH. Afterwards, this elimination progressively decreased throughout study time. Nevertheless, differences between 
Nx and CIH groups was only significant at day 21 and then from day 42 until the end of the study period (n = 5-6 
animals per group per week).  
uNAC was normalized by uCr and the values attained at day 0 and is presented as percentage of effect from Nx group; *** One-way 
ANOVA with Bonferroni’s multiple comparisons test, versus day 1; # or ## Unpaired t-test, versus Nx group of the same day; uNAC: 
urinary surrogate of mercapturates of cysteine-disulfides; # p < 0.05; ## p < 0.01; *** p < 0.001 
 
 
 
Figure V.10 – Temporal variation of uCys. uCys varied widely throughout study time in CIH animals, but was 
generally lower in this group in relation with Nx animals (n = 5-6 animals per group per week).  
uCys was normalized by uCr and the values attained at day 0 and is presented as percentage of effect from Nx group; *** One-way 
ANOVA with Bonferroni’s multiple comparisons test, versus day 1; # or ## Unpaired t-test, versus Nx group of the same day; uCys: 
urinary cysteine; # p < 0.05; ## p < 0.01; *** p < 0.001 
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Figure V.11 – Temporal variation of uCysGly. The variation of uCysGly in the CIH group relatively to the Nx group 
exhibited a similar pattern to the one obtained for uCys (n = 5-6 animals per group per week).  
uCysGly was normalized by uCr and the values attained at day 0 and is presented as percentage of effect from Nx group; *** One-
way ANOVA with Bonferroni’s multiple comparisons test, versus day 1; # or ### Unpaired t-test, versus Nx group of the same day; 
uCysGly: urinary cysteine-glycine; # p < 0.05; *** or ### p < 0.001. 
 
V.4. Discussion 
The present study shows that the progression of kidney dysfunction associated with 
hypertension-induced by CIH is accompanied by lower detoxification of CysSSX through 
the formation of their mercapturates. The decreased in the elimination of uNAC was 
accompanied by changes in renal Cys availability and dynamics as well as CysSSX 
filtration/reabsorption and GSH turnover. Herein, we observed an increase in the 
elimination of uNAC after acute exposure to CIH (1 day), indicative of an adaptive 
response to injury that is lost with the chronicity of exposure to CIH.  
 
The model herein used mimics several co-morbidities of OSA, the most common sleep 
related breathing disorder (Foldvary-Schaefer and Waters, 2017). Features of the model 
employed include hypertension, insulin resistance and kidney dysfunction (Diogo et al., 
2015; Sacramento et al., 2016; Coelho et al., 2018). However, the paradigm of CIH 
employed does not induce obesity, allowing us to separate the mechanical and 
hypercapnic components of the obstruction, which is associated with obesity, from the 
effects of IH (O’donnell et al., 1999; Schwartz et al., 2008; Zammit et al., 2010; Diogo 
et al., 2015; Shetty and Parthasarathy, 2015). The absence of increase in weight observed 
in CIH animals is consistent with previous reports (Fenik et al., 2012; Diogo et al., 2015) 
and is not related with the decrease in food consumption, which only happened nearly at 
the end of the study. Instead, it seems to be associated with a significantly higher 
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metabolism and energy expenditure due to the increased work of breathing required in 
the CIH animals (Fenik et al., 2012).  
The association of sleep apnea and kidney dysfunction has been studied (Iseki et al., 2008; 
Ahmed et al., 2011; Chou et al., 2011; Kanbay et al., 2012; Nicholl et al., 2012). For 
instance, CKD is highly prevalent in patients with sleep-related breathing disorders (Iseki 
et al., 2008; Chou et al., 2011). Moreover, a progressive decline in eGFR was detected as 
the severity of OSA increased (Kanbay et al., 2012) and OSA patients with nocturnal 
hypoxia were at significant risk for accelerated loss of kidney function (Ahmed et al., 
2011). Still, this association is not a one-way street, as sleep apnea is also considered a 
relevant co-morbidity in CKD patients (Nicholl et al., 2012; Aziz and Chaudhary, 2017). 
Although the contribution of OSA per se or other confounding factors (e.g. obesity, 
hypertension, diabetes) for kidney injury remains unclear (Calvin et al., 2009; X. I. A. 
Wang et al., 2013; X. Wang et al., 2013; Abuyassin et al., 2015; Badran et al., 2015; 
Rajan and Greenberg, 2015), OSA induces alterations known to stimulate functional and 
structural kidney damage such as increased activities of renin angiotensin-aldosterone 
system and sympathetic nervous system as well as the generation of systemic and local 
reactive oxygen species (Somers et al., 1995; Carpagnano et al., 2003; Adeseun and 
Rosas, 2010; Parati et al., 2014). 
A recent study revealed the presence of kidney injury in a mouse model of OSA-induced 
by IH that was characterized by glomerular hypertrophy, expansion of the glomerular 
mesangial matrix, increased expression of growth factors, renal cellular apoptosis and 
albuminuria (Abuyassin et al., 2018). Our model seems to be a less severe form of kidney 
dysfunction, as no histological changes were observed neither significant increases uACR 
at the end of the study, probably due to the absence of glomerular hypertrophy (Cravedi 
and Remuzzi, 2013). However, rats exposed to our paradigm of CIH have increased renal 
expression of fibronectin (Coelho et al., 2018) as well as inflammatory and EMT markers 
(unpublished data), further showing alterations at the kidney level. Moreover, these 
differences on the magnitudes of kidney dysfunction between both models might be due 
to the fact that the model employed by Abuyassin and co-authors is a more severe form 
of IH, with 60 cycels/h for 12 h/day (Abuyassin et al., 2018), in comparison with the 5.6 
cycles/h for 10.5/day obtained with our model (Diogo et al., 2015; Coelho et al., 2018). 
In fact, our paradigm of CIH approximates the impact of sleep apnea lasting for more 
than 2 years in humans and matches the clinical practice of OSA diagnosis (Diogo et al., 
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2015). A AHI higher than 5 per hour is usually sufficient to consider someone as having 
OSA (Aziz and Chaudhary, 2017), although falling bellow the AHI cut-offs for moderate 
OSA in humans (> 15 events/h of sleep) (Berry et al., 2012) even after correction for the 
higher metabolic activity in animlas (Germack et al., 2002).  
On the other hand, the effects of IH in the kidney seems to be time-dependent. Whereas 
short-term IH induces a protective response against renal oxidative damage, long-term IH 
induces damage to the kidneys (Sun et al., 2013). This time-dependency of IH effects on 
the kidney are consistent with the initial increase in the elimination of uNAC observed in 
the present study as well as with the increase on free reduced Cys (increased 
CysSH/CysSSX) that precedes the increase in Cys oxidation (decreased 
CysSH/CysSSX). Interestingly, the increase in blood pressure denoted after 14 days of 
CIH exposure coincides with the time-point of changes on the elimination of uNAC. In 
fact, at this time-point, uNAC, uCys and uCysGly levels are similar among CIH and Nx 
animals. It is also at this time that a shift on the renal expression of NAT8 occurs, as 
shown by an increase in its expression mainly at the RC after 21 days of CIH exposure, 
coinciding also with an increase in renal fibronectin (Coelho et al., 2018) and vimentin 
expression (unpublished data). This is probably due to the increase in Cys oxidation, that, 
under oxidative conditions is not able to be reduced to its free reduced formed, promoting 
toxicity. On the other hand, this can also be related with the increase on the oxidation of 
GSH in an attempt to reduce CysSSX. The increase in NAT8 mRNA expression is 
probably a mechanism to eliminate CysSSX and/or other Cys-S-conjugates. Alternative 
hypothesis might be related with NAT8’s association with autophagy (Peng and Puglielli, 
2016) and the possible acetylation of CysSSP, which has not been proven though there is 
evidence of its in vitro ability to acetylate protein lysine residues (Ko and Puglielli, 2009; 
Mak et al., 2014). However, the activity might be reduced, as there is a progressive 
decline in the elimination of uNAC, reaching a difference of -80% in CIH than Nx 
animals by the end of the study, that also coincides with the decrease in NAT8 expression 
in kidney. This can also be explained by the action of the deacetylase SIRT1 (Sasaki et 
al., 2017) or the fact that since Cys-S-conjugates are increased in inflammatory conditions 
(as reviewed in the Introduction) they might also compete with CysSSX for acetylation 
by NAT8, further contributing to the decrease elimination of uNAC. In a way, it seems 
that the increment on blood pressure underlies alterations in the mercapturate pathway 
and on CysSSX handling by the kidney. This fact is not surprising as NAT8 has been 
suggested as a positional candidate for blood pressure and renal regulation through a 
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resequencing, association and in silico study (Juhanson et al., 2008). Specifically, the 
authors suggested a contribution of highly variable NAT8 promoter polymorphisms in 
determination of systolic blood pressure and eGFR, with minor alleles of these 
polymorphisms revealing a significant protective effect against elevated systolic blood 
pressure as well as kidney failure in hypertensive patients (Juhanson et al., 2008). 
 
V.5. Conclusions 
The initial increase of uNAC upon short-term injury might be indicative of an adaptation 
response. However, with the chronicity of exposure to an inflammatory injury, the 
adaptation capacity is lost. This occurrence suggests the participation of CysSSX and the 
mercapturate pathway in the pathophysiological mechanism of kidney disease. 
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FINAL CONSIDERATIONS 
The starting point of this project was to discover a bioindicator of progression of kidney 
disease. The relevance of this work is related with huge global impact of kidney disease 
merged with the fact that there are no reliable markers to early predict and manage the 
progression of kidney disease. This was a hypothesis-oriented investigation, where it was 
aimed to implicate NAT8 activity into kidney disease progression by controlling the 
balance of Cys-S-conjugates and kidney redox homeostasis. 
 
As so, the general aim was to discover a bioindicator of progression of tubular kidney 
disease and contribute to the knowledge of NAT8 function in the mechanisms underlying 
kidney tubular dysfunction with different etiologies.  
 
Herein, the final considerations of this study are presented, divided into four different 
sections. First, the relevant findings and contributions of each chapter are summarized. 
The added value of this work is described in the second section, followed by its main 
limitations. Finally, future perspectives are presented. Due to this stratification, there is a 
possibility that some content herein presented overlaps with points stated in the discussion 
section of each chapter. 
 
1. TOP 3 findings 
The work herein presented contributes to the knowledge on the impact of renal cysteine 
disulfides renal dynamics and NAT8 activity in the development and progression of 
kidney dysfunction.  
 
Development and validation of a non-invasive method to quantify uNAC that 
might be an indicator of Cys redox status in the kidney and evidence of a high 
person to person variability in the levels of uNAC 
  
Final Considerations 
 168
Using a mechanistic-based approach to kidney, we first developed a method to non-
invasively measure tubular Cys redox status (cysteine disulfide stress) in kidney. This 
ability to measure uNAC was one of the major achievements of the present work. 
Thereby, we developed a method to quantify the mercapturates of CysSSX, using a 
surrogate that we named uNAC. In fact, this was the first report aiming at the 
quantification of uNAC as a surrogate of the urinary mercapturates derived from CysSSX 
and that provides first-hand evidence that its formation occurs in the kidney. 
We also provide evidence on person-to-person variation in uNAC and factors associated 
to this variation, at least in the HIV-infected population. This high variability justifies that 
there are differences in patients in the way they eliminate CysSSX and it is relevant to 
understand these differences and its underlying consequence.  
 
In fact, the study the temporal variation of uNAC along the progression of kidney 
dysfunction in animal models associated with metabolic inflammation, namely two pre-
diabetic mice models and a rat model of hypertension and insulin resistance induced by 
CIH also contributed to this knowledge. In two of the three models, we observed an initial 
increase in uNAC, that might be indicative of an adaptive response, that was lost with the 
chronicity of exposure to injury. This decrease had different magnitudes and relations to 
CysSSP but was common to the three animal models. This provided evidence that it might 
exist particularities related to the etiology in the involvement of disulfide stress and 
cysteine disulfides dynamics in the pathophysiological mechanism of kidney disease and 
that uNAC might have a place in precision medicine of tubulopathy. Additionally, uNAC 
variation showed differences in CISP (that undergoes the mercapturate pathway) and G 
(that do not undergo mercapturate pathway) AKI-induced models, suggesting that there 
are mechanisms dependent on the mercapturate pathway and others that do not point in 
the same direction of the remaining models.  
 
Evidence that uNAC might represent an early indicator of tubulopathy and is able 
to distinguish those at higher risk of disease progression regardless of the grade of 
kidney dysfunction progression 
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Using different models of kidney disease that course with tubulointerstitial oxidative 
stress and inflammation we evaluated temporal variations of uNAC. This was performed 
in acute and chronic models with different harmful stimulus (diet, CIH, infection, 
nephrotoxic drugs) in an attempt to approach as high as possible the relation of uNAC 
with tubular disease. The decrease in uNAC was consistent in all models used, and the 
more pronounced progression of kidney disease, the more uNAC decreases followed by 
a decrease in renal CysSSP.  
As so, our translational approach shows a progressive decrease in the elimination of 
uNAC with the increment in kidney dysfunction. This is a concept that has never been 
addressed and that is common to all presented models, both in the clinical and in the in 
vivo setting. The limitations of pCr as a marker of kidney function have been discussed 
priorly (Waikar, Betensky and Bonventre, 2009; Ferguson and Waikar, 2012) and our 
results points towards the identification of uNAC as a valid early indicator of acute injury-
induced by nephrotoxic drugs. 
 
A remarkable evidence that was provided in the prospective study of the HIV-infected 
population was that uNAC allowed to discriminate patients with kidney disease 
progression from those that maintained a stable renal function throughout one-year of 
follow-up. This result suggests that uNAC is a strong candidate for a urinary biomarker 
for early diagnosis and theranostic purposes in kidney disease, particularly for tubular 
dysfunction. 
 
Changes in cysteine disulfides dynamics and availability might underlie early 
events in kidney disease, promoting its progression, which might differ depending 
on the etiology 
 
Our study shows that there are changes in Cys handling by the kidney in response to 
injury stimulus. Also, in animal models, it seems that renal CysSSP decreases in more 
pronounced stages of kidney disease progression. On the other hand, serum CysSSP 
increases with decreased renal function in our cross-sectional analysis of the HIV-
infected population. 
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2. What is the added value and the impact of the present work to the field? 
Notwithstanding the significant research in the field, there is still a lack of a valid reliable 
and accurate marker of kidney disease progression. Still, this scenario is far from reality, 
and several questions need to be addressed. 
 
Tubular markers: a problem in the field 
A major concern in the nephrology field is the lack of markers of proximal tubular cell 
function, since the proximal tubule has been recognized as the primary effector and sensor 
in kidney disease progression (Chevalier, 2016). Hence, our approach was to select a 
metabolic that was mainly expressed in proximal tubular cells, supported by association 
studies (Juhanson et al., 2008; Chambers et al., 2010; Köttgen et al., 2010; Tin et al., 
2013), the mercapturate pathway. As far as the author knowledge, this is the first time 
that this concept has been employed to identify a tubular marker. This might be related 
with the fact that NAT8 has only been identified as the enzyme that acetylates Cys-S-
conjugates in 2010 (Veiga-da-Cunha et al., 2010), reflecting the low number of 
publications associated with the enzyme (only 18 publications in PubMed). 
Herein, a hypothesis-driven method to quantify urinary mercapturates of CysSSX was 
developed and validated. The major advantage is the fact that this enables a non-invasive 
quantification, a relevant fact not only for its clinical application but also for the study of 
its temporal variation, minimizing the number of animals used. 
 
Contribution for the knowledge of disulfide stress and CysSSP in renal tubule 
While the study of renal disulfide stress and CysSSP are still in its early stages, the results 
herein presented pave the way for future studies in this field. Overall, disulfide stress and 
CysSSP are relevant players not only for metabolic inflammation mas but also on the 
interplay with environmental/food toxins and drugs, with potential to detect new 
mechanisms of action and adverse drug reactions. 
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Contribution for the understanding of the non-albuminuric phenotype in diabetic kidney 
disease 
Classically, the progression of DKD is followed by a progressive increase in albuminuria 
and proteinuria with consequent decrease in GFR (Haneda et al., 2014). Nevertheless, 
there is now growing evidence that this traditional pathway of DKD does not always 
happens, as reported in several clinical studies showing the regression or unchanged 
status of albuminuria upon decreases in GFR (Caramori, Fioretto and Mauer, 2003; 
Perkins et al., 2010), the so called “non-albuminuric phenotype” (Viazzi et al., 2017). As 
so, the concept of initial diabetic glomerular disease has now a direct competitor, diabetic 
tubulopathy, that has been stimulating research for better markers of prediction and 
management of DKD. Herein, we showed that the progression of kidney disease in pre-
diabetic states is not directly related with increases in albuminuria. This shows the 
necessity of the identification of new biomarkers and also suggests that there are still 
mechanisms of kidney dysfunction that remain to be identified. 
 
Contribution for the tubulocentric theory of inflammatory diseases 
We have previously suggested that the formation of Cys-S-conjugates is associated with 
inflammatory conditions rather than kidney disease (Gonçalves-Dias et al., 2019). The 
present study also contributes for this theory, as changes in uNAC were identified in HIV-
infection, pre-diabetic and hypertensive conditions, all associated with inflammation 
(Deeks, Tracy and Douek, 2013; De Miguel et al., 2015; Brahimaj et al., 2017). 
Moreover, all Cys-S-conjugates have in common the detoxification by the proximal 
tubular cells as mercapturates, motivating a tubulocentric perspective for other 
inflammatory conditions.  
 
A literature review was performed regarding the endogenous Cys-S-conjugates involved 
in inflammatory conditions. The mercapturate pathway is widely studied in the toxicology 
field to evaluate the exogenous exposure (Mathias and Bhymer, 2016). With this work, 
with cross the borders in an attempt to use this toxicology tools to evaluate the 
endogenous exposure and unravel the role of this tubular pathway in kidney disease and 
identify new markers of tubular dysfunction that are currently lacking in the clinical 
practice. Furthermore, a relation between renal metabolic inflammation and the 
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mercapturate pathway was established, where the Cys redox dynamics, the fibrotic 
mechanism and the identification of new therapeutic targets was included. 
 
uNAC is an early marker of kidney tubular dysfunction 
uNAC reflects mercapturates that are probably formed exclusively in proximal tubular 
cells through the acetylation of CysSSX provided by NAT8 activity, an enzyme that is 
almost exclusively expressed in kidney cortex (Chambers et al., 2010). Furthermore, 
other enzymes that are involved in the mercapturate pathway are highly expressed at the 
brush border of proximal tubular cells (Hughey et al., 1978; Griffith, 1981; Hanigan, 
1998; De Carvalho et al., 2011). Having into account that the proximal tubule is the 
primary effect and sensor of kidney disease progression (Chevalier, 2016) and that the 
mercapturate pathway is an almost exclusive feature of proximal tubular cells, the results 
herein obtain regarding uNAC variation might have tremendous impact in the clinical 
setting of both nephrotoxic and disease-associated kidney dysfunction. 
 
Contribution for the development of strategies to minimize tubular dysfunction  
Give the important role of proximal tubular cells in the progression of kidney disease, 
strategies aimed to minimize tubular dysfunction might contribute for prevention and/or 
management of kidney disease. We believe that targeting vital steps in the mercapturate 
pathway could be a relevant strategy to achieve this goal. For instance, studying patient’s 
susceptibility to drugs undergoing the mercapturate pathway could be a valid option. This 
could be achieved through NAT8 genotyping. Although several SNPs in NAT8 coding 
sequence have been identified that could affect the activity of the enzyme, there is 
contradictory evidence. For instance, SNP rs13538 induces a non-synonymous amino 
acid change (F143S) that is likely to impact on the binding of acetyl-coA, the donor of 
the acetyl moiety of the mercapturates, and hence NAT8 function (Chambers et al., 2010). 
However, in the same year of this report, Veiga-da-Cunha and co-authors performed a 
functional study and reported that the mutated F143S NAT8 had a similar enzymatic 
activity to the that of the wild-type protein (Veiga-da-Cunha et al., 2010). A year later, 
Nicholson et al., showed that the mutation was associated with increased urinary 
concentrations of mercapturates, consistent with an increase in NAT8 efficiency 
(Nicholson et al., 2011). However, whereas another rather frequent non-synonymous 
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amino acid change (E104K) does not influence the activity of the enzyme, a suppression 
on the activity was induced by the R149K mutation, that replaces an extremely conserved 
arginine (Veiga-da-Cunha et al., 2010).  
 
On the other hand, the stratification of patients through the levels of uNAC could also 
allow the identification of patients at higher risk for kidney disease progression. In this 
setting, the treatment choice will be focused solely on the individual’s features, a concept 
associated with personalized medicine. 
 
3. Which were the main limitations of this work? 
As with all research projects, we are conscious regarding the limitations associated with 
this study.  
 
Lack of sustained evidence that NAT8 acetylates CysSSX 
The difficulty in developing NAT8 knockout rats (Fu et al., 2014) and absence of tools 
to pharmacologically address NAT8 hinders to get hard evidence not only on the 
nephroprotective role of this enzyme, but also on the function of NAT8 to acetylate 
CysSSX. Nevertheless, our data points to the direction that, similarly to other Cys-S-
conjugates, NAT8 is also able to acetylate CysSSX.  
In an attempt to overcome this limitation, we tried to establish an in vitro model, an 
approach that is still ongoing. The main results obtained are displayed in attachment 
(Attachment I).  
 
Lack of a gold standard measurement of kidney function 
A major limitation of our clinical study is the lack of a gold standard measurement of true 
GFR rather than the use of eGFR equations with sCr, whose production is dependent on 
muscle mass and decreases in the presence of liver disease (Cocchetto, Tschanz and 
Bjornsson, 1983; Perrone, Madias and Levey, 1992), conditions associated with HIV-
infection. Since establishing the true GFR is difficult due to the simultaneous occurrence 
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of the filtration process in all glomeruli, GFR can be measured by exogenous substances 
that are freely filtered at the glomeruli, with no associated secretion or reabsorption by 
the renal tubules, such the case of inulin (Mandel et al., 1953; Rahn, Heidenreich and 
Brückner, 1999). However, the need for continuous infusion, multiple blood samples and 
urine collection, make it cumbersome and expensive to measure (Lopez-Giacoman and 
Madero, 2015). On the other hand, renal biopsy is also a useful tool for the clinical 
management of kidney disease (Dhaun et al., 2014). Besides being an invasive procedure, 
its performance in this setting would not give enough information to stage the patients 
according the level of kidney function.  
Having this into account, we believe that our choice for evaluation of kidney function 
was the best that we could perform in order to minimize the use of invasive and 
uncomfortable procedures in the patients. 
 
Use of animal models and their associated differences 
The use of animal models was unavoidable for our research purposes, mainly due to the 
fact that we needed to induce kidney injury and/or follow the progression of kidney 
disease from a starting point with no confounding factors (e.g. previous disease, 
medications, age, sex, race) that would be utopic to perform in human subjects. While not 
perfect, the respectful use of animal experimentation allows the study of 
pathophysiological mechanisms in an accelerated time frame. In this setting, the use of 
alternative in vitro models would not be suitable and. Nevertheless, the 3Rs policy 
(replacement, reduction and refinement) was always followed during the entire project. 
The number of animals used per experiment was reduced the minimum possible and the 
same biological sample was used for more than one assay, whenever applicable and all 
guidelines were followed. Furthermore, samples from the pre-diabetic and the drug-
induced AKI models were obtained in collaborations with national and international 
laboratories, hence emphasizing the use of the 3Rs policy in this study. 
 
It is noteworthy to state that the results obtained with animal models could be influenced 
by several factors. For instance, while some species complete their nephrogenesis after 
birth (rats, dogs, pigs and rabbits) in others it is ceased pre-natally (mice, monkey, man) 
(Frazier, 2017). Furthermore, we have to consider the fact that renal dysfunction in rats 
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is influenced by both gender and the genetic background of the strain (Baylis and Corman, 
1998; Nogueira, Pires and Oliveira, 2017). Specifically, renal scarring begins earlier and 
becomes more severe in male rats that females and Sprague-Dawley rats are less resistant 
than other rat strains (Nogueira, Pires and Oliveira, 2017). In mice, the genetic 
background also influences the severity of the development of renal disease (Nishino et 
al., 2010). For instance, C57Bl/6 animals harbor one single renin gene while other 
backgrounds have 2 renin genes (Wang et al., 2002; Nishino et al., 2010). This fact has 
important implications, since 2 renin genes induces a ten-fold higher plasma renin 
activity, angiotensin dependent hypertension, increased blood pressure and cardiac and 
renal hypertrophic responses to salt compared with 1 renin gene (Nishino et al., 2010). 
Moreover, the selection of the species could have an influence on the elimination of 
uNAC and hence impact the mercapturate pathway. In fact, rat livers dosed with l-chloro-
2,4-dinitrobenzen excreted lower amounts of its mercapturate and higher quantity of the 
GSH-conjugate in bile whereas the opposite was found in guinea pig livers (Hinchman et 
al., 1991). On the other hand, the metabolism of acrylamide in humans is apparently more 
prone for GSH conjugation rather than conversion to glycidamide when compared with 
rats and mice (Li et al., 2016). Differences on the expression of the enzymes of the 
mercapturate pathway have also been reported. Rats and mice have very low hepatic but 
very high renal activities of GGT in comparison with guinea pig, pig, macaque monkey 
and man (Hinchman and Ballatori, 1990). Species differences were also found for 
dipeptidases activity, although in a lower magnitude than the one observed for GGT 
(Hinchman and Ballatori, 1990). 
 
Lack of evaluation of changes in other endogenous Cys-S-conjugates and their 
mercapturates 
We cannot exclude the hypothesis that the levels of other Cys-S-conjugates and their 
corresponding mercapturates might be changed in all models presented. In fact, evidence 
points to this fact (Gonçalves-Dias et al., 2019). Unfortunately, we were not able to 
develop tools allowing their quantification, though we hope that in a near future this 
limitation will be overpassed. 
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Several parameters are still lacking in the animal models 
Although we generated a substantially higher amount of data, some parameters were still 
no available for quantification in each one of the animal models used. Regarding the drug-
induced AKI models, as we only had access to urine samples, it was not possible to 
quantify changes in renal NAT8 and CysSSX for the time being. We were also not able 
to quantify the protein levels of NAT8 in either one of the remaining models. This 
limitation was due to problems regarding the isolation of NAT8 for western blot analysis 
and the background noise observed in immunofluorescence/immunohistochemistry of 
histological cuts. Nevertheless, the techniques for its quantification are currently being 
developed and validated. Similarly, we had methodological problems on the 
quantification of pCr in the pre-diabetics and CIH models related with matrix 
interference. Lastly, the quantification of CysSH/CysSSX was also not possible for the 
pre-diabetic models since we only had access to frozen tissue. The quantification of 
CysSH requires the use of freshly collected samples, in order to avoid their spontaneous 
oxidation to CysSSX (McMenamin, Himmelfarb and Nolin, 2009). 
 
Furthermore, other factors that might be lacking in this approach is the comparison of 
uNAC with other published markers and also the lack of mechanistic studies. 
 
4. What is still unknown and should be addressed? 
The knowledge on NAT8 actions has been hampered by its late association to both kidney 
disease and the mercapturate pathway (Juhanson et al., 2008; Chambers et al., 2010; 
Veiga-da-Cunha et al., 2010). Furthermore, the unavailability of pharmacological tools 
and the plausible non-viable genetic animal models also contributes substantially for this 
gap in the knowledge (Ozaki et al., 1998; Fu et al., 2014). 
Considering this, future studies should focus on assessing: 
1. early changes in uNAC and renal CysSSX, specially right after injury; 
2. changes of other endogenous Cys-S-conjugates rather than disulfides as well as 
their mercapturates in the progression of kidney disease 
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3. the mechanism of NAT8 regulation and the effect of exogenous Cys-S-
conjugates in proximal tubular cells; 
4. the mercapturate pathway in other acute models of renal disease such as 
ischemia/reperfusion, other tubular nephrotoxicants that undergo the mercapturate 
pathway (e.g. paracetamol) or not (e,g. tenofovir) (Gorgulho et al., 2018) as well as in 
other diseases associated with kidney dysfunction; 
5. the prospective evaluation in type II diabetic and OSA patients of uNAC and 
CysSSP, the identification of a pattern of mercapturates and NAT8 polymorphisms to 
evaluate the risk of kidney disease progression; 
6. the evaluation of uNAC performance in drug-induced AKI or contrast-induced 
AKI in the clinical setting; 
7. the identification of which specific proteins are cysteinylated; 
8. if NAT8 regulated the effect of insulin and glucose in the proximal tubular cell. 
 
Additionally, another fact that requires further elucidation is the possible role of NAT8 
for the acetylation of protein Cys residues. Recently, NAT8 has been reported as a player 
in the acetylation of lysine residues of cargo proteins at the ER, controlling the 
homeostatic balance between quality control and autophagy (Peng and Puglielli, 2016). 
This acetylation is only performed in correctly folded polypeptides whereas non-
acetylated polypeptides are prevented from leaving the ER and are disposed of. Moreover, 
autophagy is also controlled through acetylation. Specifically, acetylated ATG9A 
prevents the induction of autophagy while non-acetylated ATG9A stimulates it (Peng and 
Puglielli, 2016). Moreover, CD133 and BACE1 proteins have been suggested to be 
acetylated by NAT8 at lysine residues (Ko and Puglielli, 2009; Mak et al., 2014). 
However, Veiga-da-Cunha and co-authors (2010) found that the catalytic efficiency of 
NAT8 to acetylate L-lysine residues and protein-bound lysine was 20-fold lower than for 
cys-S-conjugates (Veiga-da-Cunha et al., 2010). Additionally, the mentioned reports of 
lysine acetylation by NAT8 were either in vitro (Ko and Puglielli, 2009) or in a line of 
human epithelial colorectal adenocarcinoma (Mak et al., 2014), both context very apart 
from the proximal tubular cells where NAT8 is physiologically expressed to the greatest 
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extent. Therefore, this protein acetylation function of NAT8 remains unclear and should 
be further addressed. 
 
Lastly, future work should also target the upstream steps of the mercapturate pathway to 
avoid the accumulation of toxic CysSSX. In fact, increasing GSH synthesis through other 
ways rather that the use of sulfur-containing supplements that may add to the Cys toxicity 
might be a valid long-term solution. There are antagonistic reports regarding the effect of 
N-acetylcysteine supplementation in kidney dysfunction, which further suggests the study 
of alternative approaches to avoid the dampening of endogenous antioxidant defenses in 
situations involving oxidation and inflammation.  
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ATTACHMENT I 
 
AI.1. Comparison of the cytotoxicity of CISP versus Cys-CISP 
To address cytotoxicity of cisplatin versus Cys-CISP, total cell death and its dose-
dependency was evaluated in Mock cells. Cells were also exposed to Cys as a control. It 
was observed that increasing concentrations lead to a decrease in total cell death (p = 
0.010), while the opposite variation was found for CISP (p = 0.004). No differences were 
observed for the three concentrations of Cys-CISP conjugate used that were associated 
with cell death similar to CISP 50 µM.  Nevertheless, at 10 µM and 25 µM, the conjugate 
Cys-CISP was able to induce higher total cell death in comparison with the same 
concentrations of CISP, while the effect was similar between the two compounds at 50 
µM (p = 0.034 and p = 0.022, respectively for 10 µM and 25 µM) (Figure AI.1). 
 
Figure AI.1 – Total cell death in mock cells. A decrease in total cell death was observed with increased concentration 
of Cys, while Cisp elicited an opposite effect. Although no differences were found on the total cell death elicited by 
the three concentrations of CysCisp conjugate, 10 µM and 25 µM of CysCisp were able to induce higher cell death 
then the same concentrations for Cisp. This effect was not served when the CISP 50 µM was used. 
HK-2 cells were transiently transfected with pcDNA 3.1-mock and exposed to CTL (DMEM F-12 media), Cys, CISP 
or Cys-CISP for 24h. Data were normalized by the values observed in CTL condition and presented as mean ± SEM of 3 
independent experiments. * One-way ANOVA with Dunnett’s multiple comparisons test, versus 10 µM of each compound; # Two-
way ANOVA with Bonferroni’s multiple comparisons test, versus Cisp; CTL: control; Cisp: cisplatin; Cys: cysteine; Cys-Cisp: 
cysteine-cisplatin conjugate. 
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AI.2. Effect of NAT8 overexpression in CISP cytotoxicity 
NAT8 overexpression lead to a decrease in total cell death elicited by CISP and Cys-CISP 
in comparison with the results obtained for mock cells, except for wt-NAT8. This is 
demonstrated by normalized values below 100% for most experimental conditions (one-
sample t-test), considering that 100% corresponds to equal % of total cell death obtained 
for NAT8 overexpression in the same mock condition (Figure AI.2). This decrease was 
not so significant for the higher dose of Cys-CISP.  
 
Figure AI.2 – Total cell death in NAT8 overexpressed cells exposed to CISP or Cys-CISP. The mutated forms of 
NAT8 showed significantly lower total cell death relatively to the wt form. In specific, the F143S mutation had lower 
cell death in cells exposed to CISP at 10 µM and 50 µM and Cys-CISP at 10 µM and 25 µM concentrations (Two-way 
ANOVA with Bonferroni’s multiple comparisons test, p = 0.030, p = 0.004, p = 0.010 and p = 0.024, respectively for 
CISP 10 µM, CISP50 µM, Cys-CISP 10 µM and Cys-CISP 25 µM concentrations). Differences in S22P mutation were 
significant for CISP 50 µM, and Cys-CISP conjugate at 10 µM and 25 µM concentrations (Two-way ANOVA with 
Bonferroni’s multiple comparisons test, p = 0.027, p = 0.019 and p = 0.039, respectively for CISP 50 µM, Cys-CISP 
10 µM and Cys-CISP 25 µM concentrations).  
HK-2 cells were transiently transfected with pcDNA 3.1-mock or pcDNA 3.1-NAT8-wt or pcDNA 3.1-NAT8-F143S 
or pcDNA 3.1-NAT8-S22P. Cells were exposed to CTL (DMEM F-12 media), Cys, CISP or Cys-CISP for 24h. Data 
were normalized by the values observed in CTL condition and expressed as the percentage of the values attained at each Mock 
condition. Values are presented as mean ± SEM of 3 independent experiments. # Two-way ANOVA with Bonferroni’s multiple 
comparisons test versus wt; * One sample t-test for differences from 100. 
CTL: control; Cisp: cisplatin; Cys: cysteine; CysCisp: cysteine-cisplatin conjugate; wt: wild-type. 
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